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ABSTRACT 
Curcumin, the active constituent of the rhizome Curcuma longa has been 
extensively studied as an anticancer agent for various types of tumours. However, its 
efficacy as an anticancer agent is constrained due to poor absorption, rapid metabolism, 
degradation in acidic media and consequently, low oral bioavailability. In the present 
study, we aim to formulate a curcumin-containing mucoadhesive nanoparticulate 
delivery system that offers protection to curcumin from the degradative effects of the 
upper digestive tract system but capable of releasing the payload in the colon for the 
localised treatment of colorectal cancer. Such a system should have a good surface 
coverage locally at the tumour site and ideally, capable of traversing the tumour. Thus, 
nanopariculate delivery is most suited to achieve this objective. The latter was 
formulated using chitosan and pectin as polymers due to their biodegradability and non-
toxicity. The objectives of this study were (i) to fabricate, optimize and characterize the 
curcumin-containing delivery system; (ii) to evaluate the mucoadhesive propensity, 
release of curcumin from the carrier, and stability of the formulation in various milieu; 
(iii) to investigate the in vitro antiproliferative efficacy of the formulation as well as the 
cellular uptake profiles; and (iv) to proof the concept of the formulation using animal 
modules. The formulated nanoparticulate system had a z-average of 206.0 nm (± 6.6 
nm), zeta potential of +32.8 mV (±0.5 mV), and encapsulation efficiency of 64%. The 
nanoparticles were more mucoadhesive at alkaline pH compared to acidic pH. 
Furthermore, more than 80% release of curcumin was achieved in simulated colonic 
medium as opposed to negligible release in simulated gastric and intestinal fluids, 
respectively.  The nanoparticles were taken-up by HT-29 colorectal cancer cells which 
ultimately resulted in a tremendous reduction in cell propagation. This anti-proliferative 
effect of the encapsulated curcumin was similar to that of free curcumin at equivalent 
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doses which confirms that the encapsulation process did not affect the anticancer 
efficacy of curcumin.  The bioavailability of curcumin from the nanoparticles was 
enhanced by 4-folds after oral administration after 6 hr of treatment. Moreover, the half-
life, Cmax, and AUC of curcumin were significantly improved. A lower elimination rate 
was observed from the formulation compared to equivalent doses of free curcumin. 
These findings are a strong indication of the potential of the studied formulation for the 
possible treatment of colon cancer via oral administration.  
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Chapter 1 
Introduction 
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1 Introduction 
1.1 General Overview 
According to the World Health Organization (WHO) media centre key facts, 
8.2 million deaths occurred worldwide in 2012 because of cancer, making it the leading 
cause of death among diseases. Unfortunately, the annual cancer cases are expected to 
jump up to 22 million in two decades from 2012 where it was 14 million case in that 
year (WHO media Center, 2014).  
Despite recent advances in cancer therapy, treatment remains a challenging 
task. For example, surgery is associated with high risk of damage to nearby organs and 
tissues, pain, infections and recurrence of the disease  (Bornstein et al., 1991; Cohen et 
al., 2000; Crawford et al., 2005; Gamba et al., 1992). While radiation therapy has 
common side effects like skin changes, fatigue, diarrhoea, nausea and vomiting and 
many others, which may affect the patient's quality of life (Bentzen, 2006; Dearnaley 
et al., 1999; Scholefield & Eng, 2014). Chemotherapy, being one of the most common 
cancer treatment options as neoadjuvant, adjuvant, or the sole therapy given has 
manifests serious side effects, including fatigue, pain, sores in the mouth and throat, 
nausea and vomiting as well as blood disorders (Farrell et al., 2013; Groopman & Itri, 
1999; Molassiotis et al., 2014). 
Plants have been extensively studied as a natural source for cancer treatment 
due to their proved efficacy in treating many types of cancer and the advantage that 
they manifest fewer side effects compared to the chemotherapeutic agents (Bhanot et 
al., 2011; Nirmala et al., 2011; Pezzuto, 1997). 
Curcumin (CUR), commonly known as turmeric, is a natural polyphenol 
derived from rhizome of the plant Curcuma longa is one of the plant agents that has 
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showed anti-cancer activity through researches in the last 50 years (Adams et al., 2004; 
Kanai et al., 2012; Tang et al., 2010). Although CUR has an effective and safe colon 
anticancer activity (Cheng et al., 2013; Howells et al., 2011; Mudduluru et al., 2011), 
its beneficial effects are limited due to low absorption efficacy, rapid metabolism and 
elimination (Anand et al., 2012). Hence, there is the need to enhance the oral 
bioavailability of CUR via appropriate strategies. Using adjuvants like piperine, the 
oral bioavailability and delivery of CUR was improved by piperine inhibiting CUR's 
metabolizing enzymes (Bhutani et al., 2009; Yallapu et al., 2012). Micelles, liposomes 
and phospholipids complexes are other strategies under investigation (Anand et al., 
2007). Recently, nanoparticle technology had a special interest as a drug delivery 
system for therapeutic agents (Yih and Al-Fandi, 2006; Hamidi et al., 2008) and 
explored for CUR as well. Poly(lactide-co-glycolide) (PLGA) based CUR 
nanoformulations were successful (Khalil et al., 2013) as well as chitosan (CS) CUR 
nanoparticles (NPs) (Chuah et al., 2011) and CUR loaded fibrinogen NPs (Sanoj et al., 
2011). 
We believe that delivering CUR in NPs to the colon is a good strategy for 
increasing the bioavailability at that region. In this regard, the delivery system should 
have the ability of protecting CUR from the onslaught acids and enzymes through its 
journey from the mouth to the colon. Since the cancer is restricted to the colon in 
colorectal cancer there is the likelihood of enhanced therapy with such a system. In a 
previous study, CUR-CS NPs were successfully fabricated in which these NPs 
demonstrated good mucoadhesive and anticancer properties (Chuah et al., 2011). In 
that study the effect of acid and enzymatic conditions on the mucoadhesive and 
anticancer properties of the NPs are not ascertained. The aim is to develop a 
nanoparticulate delivery system with enhanced mucoadhesive properties and able to 
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withstand the acidic and enzymatic conditions of the upper gastrointestinal tract (GIT). 
We also aim to prove the concept of the formulation using animal modules.  
1.2 Colon and Colorectal Cancer 
1.2.1 The Human Colon 
The human colon (large intestine) is a muscular, U-shaped tube approximately 
1.5 meters long in an average size adult. The colon is a part of the lower GIT that 
extends from the ilocaecal valve to the rectum.  
The human colon (Figure 1.1) consists of the ascending and transverse 
segments, in which are the posterior segments, which lack mesentery. This is followed 
by the descending and sigmoid segments, which are the anterior and have mesentery. 
The four segments of the colon are sacculated. The caecum is poorly determined and 
continuous within the human colon (Kararli, 1995; Moran & Jackson, 1992) . 
 
Figure 1.1 The structure of the colon (Drawn using Chemdraw® Pro 8.0, 
PerkinElmer). 
The wall of the colon, in cross-section, encompasses of a fine mucosal layer, 
thicker submucosal layer and the muscularis mucosae. The later comprises of two 
distinct layers, the circular and outer longitudinal layer, separated by a thin layer of 
connective tissues. Moreover, the muscularis mucosae is opulent with perirectal fat 
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(Brown, 2007). Compared to the small intestine, the colon luminal surface lacks well-
defined villi, is less closely packed microvilli (if present) and does not differentiate into 
enterocytes (Kararli, 1995).  
The colon develops during the embryological development phase from two 
parts: the ascending colon to the proximal transverse colon develops from the midgut 
while the distal transverse colon to sigmoid colon develops from the hind gut (Snell, 
2008). The development subsists in three rotational phases. In the first phase, also called 
the temporary physiological intestinal herniation, the umbilical loop undergoes counter-
clockwise 90o rotation. This phase occurs in the 8th week of the embryological 
development. Followed by the second phase at the 10th week where a new counter-
clockwise 90o rotation occurs. Finally, the third stage, fixation stage, starts between the 
11th and 12th week and ends with birth (Baud et al., 2008; Engin, 2015).  
The pH values of the colonic fluids are 7.0 ±0.7, 6.6 ±0.8 and 6.4 ±0.6 in the 
left, mid and right colon, respectively. The colon pH depends highly on the type of the 
ingested food (Evans et al., 1988; Kararli, 1995). Transit time of food in the colon varies 
from 8-72 hr (Kararli, 1995).  
The colon has various functions including water and electrolyte absorption, 
storing and evacuating stool, cistern function for bacterial metabolism and fermentation 
and metabolic functions. Approximately 1.5 L of materials passes through the colon 
daily, in which 1.3-1.4 L is absorbed and 0.1-0.2 L stool water is evacuated daily. The 
storage sites of the colon are the ascending and transverse segments while the aqueduct 
function is mainly executed by the descending and sigmoid segments (Kararli, 1995; 
Moran & Jackson, 1992). Within the GIT, the colon has the most abundant number and 
variety of microorganisms, approximating 7-10 log per gram per weight compared to 
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0-5 and 0-7 log per gram per weight in the stomach and small intestine, respectively. 
The colonic normal flora comprises of over 400 different species in which the anaerobic 
predominate, accounting for 99% of the cultivable organisms throughout the GIT. The 
beneficial bacteria in the colon play a major role in producing a variety of B-vitamins, 
folate and sulphur-containing amino acids that are absorbed from the colon. These 
bacteria also produce short chain fatty acids which contribute in the growth of the 
colonic mucosa and contribute in metabolism such as the hydrolysis of glucuronide 
conjugates (Canny & McCormick, 2008; Finegold & Angeles, 1969; Kararli, 1995; 
Moran & Jackson, 1992). 
Colonic dysfunction may be manifested as motility or mucosal diseases. The 
former includes diarrhoea, constipation, irritable bowel syndromes and diverticular 
disease, while the latter includes polyps, inflammatory bowel disease (IBD), colonic 
infestation and carcinoma (Moran & Jackson, 1992). In the next section, I shall present 
salient features related to colorectal cancer and how it relates to the present 
investigation. 
1.2.2 Colorectal cancer 
According to the WHO media center (2014), colorectal cancer was the third 
most common type of cancer amongst men and the second amongst women leading to 
694,000 worldwide deaths for the year 2012. In England, colorectal cancer was the 
fourth most common type of cancer in 2013, accounting for 12.6% and 10.4% of the 
registered cancer cases in males and females, respectively (Cancer registration 
statistics, 2015). In Malaysia, colorectal cancer is the most common type of cancer in 
males whilst it is the second one in females (Veettil et al., 2017). 
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Most colorectal tumours arise from benign adenomatous polyps from the 
mucosa followed by subsequent changes within the cells lining the bowels, eventually, 
leading to a malignant transformation and invasive carcinoma. In rare cases, some types 
of benign and malignant colorectal tumours may arise from other cell types like 
lymphocytes and muscles (Brown, 2007; Irving et al., 2010; Scholefield & Eng, 2014). 
The etiological factors causing colorectal cancer are various including 
environmental, genetic susceptibility and somatic changes during the initiation and 
progression of benign adenomatous polyps from the mucosa. Several studies aimed at 
identifying specific genes causing colorectal cancer have presented two types of 
molecular defects: alterations in several oncogenes (K-ras) and alterations on tumour-
suppressor genes (TSGs) (Brown, 2007). 
Age is a major risk factor in colorectal cancer incidences and death rates. Over 
90% of new colorectal cancer cases occur in patients at 50 years and older. However, 
since the 1990s, new colorectal cancer incidences have occurred in patients younger 
than 50 as well. Worldwide, men are at a greater risk of developing colorectal cancer 
than women. Although specific reasons for differences in incidence rates and mortality 
among gender are not well-understood but could be related to hormonal, genetic and 
environmental interaction (Gao et al., 2008; Scholefield & Eng, 2014). Colorectal 
cancer incidence rates and mortality vary geographically, where the highest rates are 
found in the developed and high-income countries like Australia and Canada, whilst 
presentation is generally lower in the developing countries (Fatima & Robin, 2009; 
Scholefield & Eng, 2014). However, this statistic is bound to change due to affluence 
in some previously categorised ‘low-income’ countries due to affluence or 
modifications in lifestyle. Although family history of colorectal cancer does not 
increase the rate of incidence of colorectal cancer through genetic predisposition, it is 
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nonetheless a major risk factor since it combines genetic and environmental factors to 
trigger manifestation. Having a first-degree relative diagnosed with colorectal cancer 
may double the risk of having the disease (Scholefield & Eng, 2014). Patients with a 
history of adenoma, prior colorectal cancer, prior large polyps, IBD, especially patients 
with history of long duration ulcerative colitis are at increased risk of developing 
colorectal cancer in their lifetime (Eaden et al., 2001; Gupta et al., 2007; Scholefield & 
Eng, 2014). Recent studies (Larsson et al., 2005; Deng et al., 2012; Shikata et al., 2013) 
have strongly supported the association between diabetes mellitus and the increased 
risk of developing colorectal cancer in both men and women. Two mechanisms have 
been proposed: (i) inhibition of insulin-like growth factors (IGF) binding proteins, 
which increases the free and bioavailable IGF-I, and (ii) increased concentrations of 
faecal bile acids (Larsson et al., 2005; Shikata et al., 2013). However, long-term insulin 
therapy has also been associated with increased risk of colorectal cancer as well 
(Larsson et al., 2005; Deng et al., 2012; Shikata et al., 2013). Several modifiable 
lifestyle risk factors immensely increase the incidence rates of colorectal cancer 
including heavy alcohol consumption, smoking, red and processed meat consumption, 
obesity, and low physical activity (Fedirko et al., 2011; Huxley et al., 2009; Kirkegaard 
et al., 2010; Ogino & Stampfer, 2010). 
A third of colorectal cancer cases, especially at the early stages of the disease, 
are asymptomatic. Moreover, other bowel diseases such as ulcerative colitis, 
diverticulosis and irritable bowel syndrome manifest symptoms similar to those with 
colorectal cancer. Some of the symptoms associated with colorectal cancer are 
abdominal pain, change in bowel habit, and rectal bleeding. Moreover, most of the 
patients are diagnosed with anaemia and positive faecal occult blood tests. Other 
symptoms include fatigue, anorexia, diarrhoea, constipation, nausea, vomiting, rectal 
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pain, and the presence of mucus in stools. Studies have shown no association between 
the symptoms of the disease and age or gender of the patient. However, some symptoms 
can be correlated with the location of the disease (Majumdar et al., 1999). The presence 
of anaemia besides any other symptom of fatigue, anorexia, abdominal pain, nausea, or 
vomiting is associated with proximal colorectal cancer. While the presence of altered 
stool consistency, rectal bleeding besides any other symptom of diarrhoea, rectal pain, 
tenesmus, or mucus in stools are associated with distal colorectal cancer (Majumdar et 
al., 1999; Miskovitz & Betancourt, 2005; Adelstein et al., 2011). In some cases, patients 
may have phlebitis and pulmonary embolism because of the breaking and lodging of 
blood clots in one of the vessels feeding the lungs during its migration through the veins 
back to the heart. Disruptions to the immune system before, during, or after colorectal 
cancer diagnosis cause shingles. In advanced stages, the cancer may metastases to the 
other organs in which organ-specific symptoms appear. For example, symptoms of 
cancer spreading to the liver include jaundice, low blood concentration of albumin, 
coagulation disturbances, bleeding, and pain localized in the upper-right part of the 
abdomen, which may radiate to the back or the right shoulder. If the colorectal cancer 
has spread to the lungs, symptoms start as a simple cough that increase in intensity, 
accompanied with blood, shortness of breath, tightness and chest discomfort at later 
stages (Adrouny, 2002). 
Early detection and accurate diagnosis of colorectal cancer are major prognostic 
factors for optimal treatment and higher survival rates. Since colorectal cancer 
symptoms appear at a later stage of the disease, regular population screening is essential 
for early detection of colorectal cancer. However, physical examination, including 
abdomen palpitation and digital rectal exam cannot detect the signs of colorectal cancer. 
Therefore, specific colorectal cancer screening procedures ought to be used (Miskovitz, 
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2010; Steele & McDonald, 2014). Guaiac-based faecal occult blood testing (gFOBT) 
technology has been used for several years. Guaiac is capable of detecting peroxidase 
activity of haem but not the degradation products of haem. Besides, Guaiac does not 
detect dietary haem. The gFOBT technology is more sensitive in detecting bleeding 
lesions in the colon compared to the upper GIT. However, gFOBT has low clinical 
applications due to the low analytical sensitivity and the fact that bleeding is 
intermittent in colorectal cancer cases in general (Scholefield & Eng, 2014). Faecal 
immunochemical testing (FIT) assays the antibodies targeting human haemoglobin. 
Qualitative and quantitative FIT tests are available which are specific for human 
haemoglobin. However, qualitative FIT analytical sensitivity is low and hence, results 
in high false positive rates. Furthermore, haemoglobin quantification has low accuracy 
and varies among different faecal compositions. However, the usage of gFOBT in 
combination with FIT reduces the false positive rates (Scholefield & Eng, 2014). 
Flexible sigmoidoscopy has been proposed as the primary screening method for 
colorectal cancer at the age of 60, along with adenomas removal. A highly specific and 
sensitive screening modality is the colonoscopy, providing visualization of the large 
bowel besides the ability to remove the adenomas. In addition, colonoscopy is highly 
sensitive in polyp detection. However, using colonoscopy in the population screening 
is still controversial. Besides this, both of the flexible sigmoidoscopy and colonoscopy 
are, in some cases, associated with morbidity and mortality (Scholefield & Eng, 2014). 
New promising screening approaches have recently been developed, including, the 
DNA microarray-based tumour gene expression profiles, DNA methylation 
measurements of specific protein panels (Ramaswamy et al., 2001). Others include 
detection of specific RNAs associated with colorectal cancer, using techniques like 
surface-enhanced laser desorption/ ionization - Time of flight (SELDI-TOF) and 
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matrix-assisted laser desorption/ionization - Time of flight (MALDI-TOF), mass 
spectrograph and trained Labrador retriever to detect colorectal cancer by the smell of 
breadth and watery stool (Ramaswamy et al., 2001; Scholefield & Eng, 2014). Once 
invasive colorectal cancer has been diagnosed, pathologists will recommend further 
pathological examinations. Surgical biopsy of the colon and lymph nodes are usually 
recommended for studying the spread and prognosis of the disease (Miskovitz, 2010). 
The stage in the development of colorectal cancer is fundamental in determining 
the optimum treatment plan and prognosis. Dukes et al.,(1932) established the first 
colorectal cancer staging. Dukes’ classification is based on the depth of colorectal 
cancer in the bowel wall, in addition to the embroilment of nearby lymph nodes. 
Colorectal cancer that does not exceed the mucosa is classified as stage A. Stage B 
involves deeper tissues but outside the rectum and without the involvement of the 
lymph nodes whilst stage C involves the lymph nodes. A later modification of Dukes’ 
classification is called the Astler-Coller modification which includes stage D, where 
the colorectal cancer spreads to other organs (Adrouny, 2002). Further modification 
and specifications of Dukes’ classification led to the current staging system, the TNM 
staging system, adopted by the American Joint Committee for Cancer Staging and End 
Results. This staging system is categorized into three junctures. The T stage (T) reflects 
the size and extent of spreading of the cancer to the nearby tissues and organs. Second 
category symbolized (N), reflects the involvement of the nearby lymph nodes. The final 
stage (M), shows the presence or absence of cancer spreading to distant areas of the 
body (Miskovitz, 2010). After determining the TNM category, another staging process, 
called the stage grouping, is further determined. The stage grouping phases are 
summarized in Table 1.1 and illustrated in Figure 1.2 (American Cancer Society, 2004; 
Connell et al., 2004). Regardless of the stage in the colorectal cancer, the location of 
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the tumour is another prognostic determinant. Colon carcinomas might be easier to 
recover compared to rectal carcinoma at the same stage of development. Moreover, 
within the colon itself, the ascending and sigmoid colon carcinomas have better 
recovery outcomes compared to the transverse and descending colon carcinoma at the 
same stage (Miskovitz, 2010).  
Table 1.1 Colorectal cancer stages 
Stage Description 5-year survival 
rate 
Stage 0 Earliest stage of cancer, in which has not exceeded the 
mucosa of the colon or rectum. Also called carcinoma 
in situ or intramucosal carcinoma.  
>90% 
Stage I The cancer has penetrated the mucosa into the 
submucosa or into the muscularis propria yet, has not 
spread to the nearby lymph nodes or distant areas. 
93.2% 
Stage 
IIA 
The cancer has penetrated the wall of the colon or 
rectum into the outermost layers yet, has not spread to 
the nearby lymph nodes or distant areas. 
84.7% 
Stage IIB The cancer has penetrated the wall of the colon or 
rectum into other nearby tissues or organs yet, has not 
spread to the nearby lymph nodes or distant areas. 
72.2% 
Stage 
IIIA 
The cancer has penetrated the mucosa into the 
submucosa or into the muscularis propria and has 
spread to one to three nearby lymph nodes. Distant 
areas are not involved. 
83.4% 
Stage 
IIIB 
The cancer has penetrated the wall of the colon or 
rectum into other nearby tissues or organs and has 
spread to one to three nearby lymph nodes. Distant 
areas are not involved. 
64.1% 
Stage 
IIIC 
The cancer has spread to four or more nearby lymph 
nodes regardless of extent of penetration in the colon 
or rectum. Distant areas are not involved. 
44.3% 
Stage IV The cancer has spread to distant areas like lung, liver, 
ovary or peritoneum regardless the extent of 
penetration in the colon or rectum and nearby lymph 
nodes involvement. 
8.1% 
 
  
13 
 
3  
Figure 1.2 Colorectal cancer stages (Drawn by Chemdraw®Pro 8.0, PerkinElmer and Microsoft paint® 1709) 
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On the basis of the progression of the disease, colorectal cancer treatment and 
prognosis depend on the depth of the tumour, the extent of lymph node’s involvement, 
and the metastases of the disease to other organs (Miskovitz, 2010). The standard 
treatment options for colorectal cancer are surgery, radiofrequency ablation, 
cryosurgery, chemotherapy, radiation therapy and targeted therapy (Solbiati et al., 
2001; Miskovitz, 2010; Berman et al., 2016; Martling et al., 2016). Surgery, is the 
standard treatment option for all stages of colorectal cancer, in addition to liver 
metastasis and recurrent disease cases (Berman et al., 2016). Surgery can be performed 
either as a local excision, colon resection or laparoscopic surgery (Miskovitz, 2010; 
Brown, 2007). Postoperative side effects include pulmonary complications, abnormal 
wound healing, bowel perforation, abscesses, fistula, haemorrhage, infection, and 
sexual dysfunction and urinary retention in men (Milsom et al., 1998; Miskovitz, 2010; 
Scappaticci et al., 2005). Radiation therapy is another local treatment option for stages 
II and III (Table 1.1), however it is usually used as an adjuvant treatment with 
chemotherapy, pre- or post-surgery to decrease the local recurrence and increase 
survival rates (Birgisson et al., 2005; Miskovitz, 2010; Berman et al., 2016). 
Unfortunately, radiation therapy is associated with long-lasting side effects including 
impotency in men and vaginal dryness in women (Miskovitz, 2010). Other side effects 
of radiation therapy include gastrointestinal complications, bowel obstruction, skin 
irritation, fatigue and the occurrence of a secondary primary cancer  (Birgisson et al., 
2005; Martling et al., 2016; Miskovitz, 2010). Chemotherapy has been used for 
colorectal cancer treatment since the 1950s. It is the standard treatment option for stages 
III and IV (Table 1.1), liver metastases and recurrent colorectal cancer and it is usually 
administered as an adjuvant with surgery or radiation therapy (Miskovitz, 2010; 
Berman et al., 2016). Numerous chemotherapeutic agents are used for colorectal cancer 
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either as a mono or combined therapy including 5-fluorouracil (5-FU), irinotecan, 
capecitabine, leucovorin, and oxaliplatin (Cutsem et al., 2015; Miskovitz, 2010). 
Unfortunately, chemotherapy is associated with a long list of debilitating side effects 
including nausea, vomiting, diarrhoea, sore mouth, myelosuppression, 
immunosuppression, hair loss (Coates et al., 1983; Wu et al., 2005),  mucositis (Buhl 
et al., 1999), hepatotoxicity (Rubbia-Brandt et al., 2004), and anemia (Groopman & 
Itri, 1999).  The radio-frequency ablation is an image-guided procedure that includes 
the ablation of the tumour using ion agitation produced by electrodes. Intraperitoneal 
haemorrhage, hepatic abscesses, GIT perforation, and portal hypertension (Livraghi et 
al., 2003; Solbiati et al., 2001; Wood et al., 2000). In cryosurgery, tumours are frozen 
using cryoprobes and left to be reabsorbed. Although this technique sacrifices less 
normal tissues compared to surgery, it cannot be used in multiple metastases cases 
(Onik et al., 1991). Cryosurgery is associated with a phenomenon called “cryoshock 
phenomenon” which includes multi-organ failure, intravascular coagulation and severe 
coagulopathy, besides liver failure, abscess, bile fistula, and wound infection (Seifert 
& Morris, 1998; Seifert et al., 1999). Immunotherapy is a new approach in which 
antibodies are used to help the patient’s immune system fight cancer cells. Side effects 
include flu-like symptoms, nausea, vomiting, diarrhoea, and rash (Miskovitz, 2010). 
Due to the aforementioned side effects associated with chemotherapy, there is an 
interest in discovering alternative agents that are just as effective but manifest fewer 
side effects. It has been proposed that chemotherapeutic agents from plant origin fit this 
requirement because they are natural. In the next section, I would describe in detail 
some of the salient features of one such compound, CUR, that has received significant 
attention in the past decade. 
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1.3 Curcumin 
Turmeric (Figure 1.3), the powdered rhizome of the plant Curcuma longa, has 
been anciently used in the Indian subcontinent as food preservative, dye due to its 
distinctive yellow colour, and as a spice (Aggarwal et al., 2007). Starting from the time 
of Ayurveda (1900 BC), turmeric was therapeutically used as an anti-inflammatory, 
wound healing, scars lightening, in cosmetics (Aggarwal et al., 2007), cure for jaundice, 
digestive enhancer, appetite suppressant, treating stomach and liver problems, and in 
cosmetics (Steinhauser, 2015; Wattenberg et al., 1992). Arab merchants introduced 
turmeric to Europe in the 13th century and was named “Indian saffron” (Aggarwal et 
al., 2007). 
Researchers have found that CUR (diferulovlmethane) (3%) is the active 
ingredient of the spice turmeric and is responsible for its therapeutic activities 
(Steinhauser, 2015). CUR currently a subject of extensive studies due to acclaimed 
variety of therapeutic potential including anti-inflammatory, antiangiogenic, 
chemotherapeutic, antioxidant, hepatoprotective, immunomodulation, treatment of 
arithritis, lung fibrosis, gallstone, cardiovascular disease, among others (Ravindran et 
al., 2007; Braun & Cohen, 2010; Aggarwal et al., 2007). 
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Figure 1.3 Turmeric (adopted from www.authoritynutrition.com) 
 
1.3.1 Chemical Properties of Curcumin 
The chemical profile of turmeric indicates a composition of several 
phytochemicals including CUR, demethoxycurcumin (DMCO), bis-
demethoxycurcumin (BDMC), turmerone, and curlone (Sasikumar, 2012). In addition 
to other nutrients including protein, carbohydrates, phosphorous, and potassium, among 
others (Hegde et al., 2013; Nair, 2013). However, it is believed that the curcuminoid, 
CUR, imparts the distinctive yellow colour to turmeric and is responsible for  the wide 
variety of the therapeutic activities of the spice (Hegde et al., 2013).  
CUR has a bright yellow colour even at very low doses (Boga et al., 2013; Nair, 
2013). It gives red and yellow coloured solutions in basic and acidic media, respectively 
(Bernabé-pineda et al., 2004). It is reported to have a UV-absorption maxima at 420-
430 nm, attributed to its conjugated diaryl heptanoid chromophore (Bernabé-pineda et 
al., 2004; Nair, 2013; Sasikumar, 2012). CUR also exhibits fluorescence under UV 
light, and it has a distinct fluorescent excitation and emission at 435 and 520 nm, 
respectively (Nair, 2013; Park & Lee, 2015; Priyadarsini, 2009). 
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CUR was first isolated and obtained from turmeric in the 19th century (Aggarwal 
et al., 2007) and is estimated to comprise of 2-7% of turmeric constituents (Sasikumar, 
2012). The chemical structure of CUR is 1,7-bis (4-hydroxy-3-methoxy-phenyl)-1,6-
heptadiene-3,5-dione (Figure 1.4) (Sharma et al., 2005; Chen et al., 2006; Maheshwari 
et al., 2006; Sasikumar, 2012).  
 
Figure 1.4 Chemical structure of CUR 
  
The molecular formula of CUR is C21H20O6, its molecular weight is 368.39 Da 
(Hegde et al., 2013; Lin & Lin, 2008). It has a melting point of 183 oC (Aggarwal et 
al., 2006) and pKa values of 7.8, which is attributed to the acetylacetone group, 8.5 and 
9.0 which are attributed to the hydrogen of the phenol groups (Hjorth et al., 2002; 
Bernabé-pineda et al., 2004). It acts as a potent H-atom donor at pH 3-7, whereas it 
mainly acts as an electron donor at pH above 8 (Barzegar, 2012). This therapeutic agent 
is insoluble in water, however, it is easily soluble in ethanol and acetone (Hjorth et al., 
2002; Hegde et al., 2013). Since it is a bis-α,β-unsaturated diketone, it exists in 
equilibrium with the corresponding tautomer in solution. This bis-keto form 
predominates in acidic and neutral conditions, while the enol tautomer predominates at 
pH values above 8 (Aggarwal & Sung, 2008; Anand et al., 2008; Boga et al., 2013). In 
alkali conditions, CUR dissociates forming feruloyl methane, ferulic acid, and vanillin 
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(Hjorth et al., 2002; Nair, 2013). CUR has the ability to dimerise into at least two 
dimeric species (Daniel et al., 2004).  
Stability-wise, CUR is considered unstable and especially pH dependant. It is 
least stable at acidic conditions (Bernabé-pineda et al., 2004; Manju & Sreenivasan, 
2011; Shen & Ji, 2012). In addition, CUR has poor photostability (Hjorth et al., 2002). 
In-vitro studies showed that CUR undergoes degradation in cell culture medium 
containing 10% foetal bovine serum (FBS) (Shen & Ji, 2012). Unfortunately, there are 
not that many studies aimed at studying the stability of CUR. In vivo, however, 
dihydroferulic acid and ferulic acid have been identified in the bile after oral 
administration of CUR which reflects it degradation (Shen & Ji, 2012). Surprisingly, 
some of CUR’s degradation products like ferulic acid and vanillin have higher aqueous 
solubility compared to the parent and hence, similar biological activities (Shen & Ji, 
2012).  
1.3.2 Therapeutic Properties of Curcumin 
Research in recent years have focused on the therapeutic effects of CUR as an 
alternative to several pharmacological activities (Priyadarsini, 2014). Several studies 
have confirmed the efficacy of CUR as an anti-inflammatory, antimalarial, 
antibacterial, antioxidant, and anticancer agent (Biology et al., 2009; Priyadarsini, 
2014; Epstein et al., 2017).  
Available preparations of CUR for research and clinical trials contain three 
major curcuminoids, difruloyl methane commonly known as curcumin (CUR), DMCO, 
and BDMC (Jurenka & Ascp, 2009). Comparative studies have shown different 
therapeutic potencies for the three analogues. For example, Rubya et al.,(1995) found 
that BMDC is the most potent cytotoxic agent amongst the three analogues. Whereas 
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Tamvakopoulos et al.,(2007) found that DMC was the most stable in cultured cells and 
most potent as an anticancer agent when compared to the other two analogues. Wei et 
al.,(2006) found that the three analogues have similar antioxidative activities. In 
contrast, Selvam et al.,(2005) found that CUR was more potent as an antioxidant and 
antiinflammatory agent. Anand et al.,(2008) compared various therapeutic activities of 
the three analogues and found that BDMC is the most potent cytotoxic agent against 
ovarian cancer cells, DMC is the most potent antiproliferative agent against breast 
cancer cells, and BDMC and CUR have similar efficacies in preventing colon 
carcinogenesis. In the next section, I shall give a detailed review of the diverse 
therapeutic activities of CUR. 
1.3.2.1 Antioxidant activity 
Oxygen is an obligatory element for living cells and it is contributed in the 
majority of the crucial biological activities (Sen et al., 2010; Shinde et al., 2012). 
However, during cellular utilization of oxygen, two major types of by-products called 
free radicals are produced, reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) (Sen et al., 2010). ROS includes free radicals and non-radical molecular species 
(like H2O2) (Lushchak, 2014). Free radicals are produced when electrons from the 
reactive enzymes are transferred to molecular oxygen. Therefore, the oxygen molecule 
contains one or more unpaired electrons in the outermost orbital (Halliwell, 2012; 
Kunwar & Priyadarsini, 2011). Besides this, free radicals can be introduced to the body 
by external factors including UV radiation, cigarettes smoking (Shinde et al., 2012), X-
rays, pollutants, interaction with chemicals (Sen et al., 2010), auto-mobile fumes, 
burning of organic matter during cooking, to mention few (Lobo et al., 2010). 
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Free radicals are generally involved in chain reactions and are eventually 
terminated by their destruction (Sen et al., 2010). They are biologically eliminated 
through a complicated antioxidant system that neutralize the excessive levels of free 
radicals (Lushchak, 2014). This system includes enzymes such as catalases, superoxide 
dismutases, and glutathione peroxidases (Sen et al., 2010) in addition to non-enzymatic 
molecules like albumin, ceruloplasmin, ferritin, and lactoferritin (Bayomi et al., 2013). 
Normally, a balance between free radical formation and elimination is preserved, 
however, disturbing this steady state leads to excessive build-up of free radicals leading 
to a condition called oxidative stress. In this state, serious cellular structural changes 
and cellular mutations occur (Shinde et al., 2012). The prolonged state of oxidative 
stress leads to the development of chronic and degenerative diseases such as aging, 
arthritis, cancer, haemorrhage, hypoxia, cardiovascular and neurodegenerative diseases 
(Sen et al., 2010; Shinde et al., 2012; Bayomi et al., 2013; Trujillo et al., 2013).  
CUR shows a distinctive antioxidant activity similar to those of vitamins C, E 
and β-carotene (vitamin A) through several pathways (Akram et al., 2010). The 
phenolic group of CUR scavenge free radicals and hence, prevent lipid peroxidation 
(Lim et al., 2001; Ataie et al., 2010). In addition, CUR acts indirectly through the 
interaction with the reactive species to induce the activity of antioxidants and 
cytoprotective enzymes (Bhullar et al., 2013; Nakmareong et al., 2011; Trujillo et al., 
2013). For instance, Nakmareong et al.,(2011) found that CUR stimulates 
vasorelaxation of the isolated porcine coronary artery in addition to its ability to prevent 
and treat vascular dysfunction in lipopolysaccharide induced endotoxemia. 
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1.3.2.2 Anti-Malarial activity 
Malaria, a disease caused by the plasmodium parasite, is an epidemic and deadly 
disease effecting 300- 500 million individuals every year (Reddy et al., 2005; Mishra 
et al., 2009; Mimche et al., 2011). Quinine and artemisinin are the drugs of choice for 
malaria treatment (Mimche et al., 2011). However, malaria remains a frightening 
worldwide epidemic partially due to the parasite’s resistance to available anti-malarial 
drugs (Cui et al., 2007). Moreover, use of current anti-malarial drugs is restrained due 
to high cost, short half-life, and limited supply (Reddy et al., 2005; Mishra et al., 2011). 
Therefore, there is an urgent need to find alternative treatment regimens or develop 
newer antimalarial drugs and combinational cocktails to overcome drug resistance.  
Recent in vitro and in vivo studies have found that CUR possesses moderate to 
potent anti-malarial activity through several pathways, including the following (Reddy 
et al., 2005; Nandakumar et al., 2006; Cui et al., 2007; Mimche et al., 2011): 
i. Down-regulation of histone acetyltransferase (HAT) and histone deacetylases 
(HDACs), that interferes with histone acetylation and hence, causes DNA damage. 
ii. Generation of ROS in malaria parasite, which induces DNA damage (perooxidant 
activity). 
iii. Binding to the malarial sarco endoplasmic reticulum calcium adenosine 
triphosphatase (ATPase) causing metabolic arrest. 
iv. Immunomodulatory activities. 
v. Anti-protozoan activity. 
Recently, research has been devoted towards using CUR in combination with 
anti-malarial agents not only to overcome the latters’ limited use, due to drug resistance, 
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recrudescence, and high cost, but also to enhance the therapeutic efficacy of both drugs 
and decrease cytotoxicity (Mishra et al., 2009; Reddy et al., 2005). For example, oral 
administration of CUR followed by artemisinin injection prevented retrogression of the 
disease (Nandakumar et al., 2006). In another study, Mishra et al.,(2011) found that 
combination of CUR with andrographolide and artesunate enhanced andrographolide 
anti-malarial effect and decreased the chance of drug resistance without any toxicity.  
1.3.2.3 Anti-inflammatory activity 
Inflammation processes as such are essential for the body. For example, acute 
inflammation helps in pathogens prevention. However, chronic and untreated 
inflammations can eventually lead to cancer and other chronic diseases (Basnet & 
Skalko-basnet, 2011). Normally, pro-inflammatory factors target free radicals, NF-κB, 
TNF-α, and NSAID-activated gene-1 (NAG) which, mediate the inflammation. 
Excessive and uncontrolled exposure to these molecules can lead to chronic diseases 
(Basnet & Skalko-basnet, 2011). Therefore, the use of anti-inflammatory agents such 
as NSAIDs, COX-2 inhibitors, and TNF-α inhibitors is necessary to avoid the 
debilitating effects of uncontrolled inflammation  (Basnet & Skalko-basnet, 2011). In 
the last two decades, CUR has been extensively studied as a natural and potent anti-
inflammatory agent for numerous inflammatory conditions, including pancreatitis, 
postoperative inflammation, rheumatoid arthritis, osteoarthritis (Jurenka & Ascp, 
2009), uveitis, H. Pylori infections, irritable bowel syndrome, and IBD (Jacob et al., 
2007).  
The anti-inflammatory effects of CUR is now established and several 
mechanisms have been proposed as summarized in Figure 1.5 (Chan et al., 1998; 
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Kawamori et al., 1999; Jacob et al., 2007; Jurenka & Ascp, 2009; Basnet & Skalko-
basnet, 2011). 
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Figure 1.5 CUR mechanisms of action as an anti-inflammatory agent 
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1.3.2.4 Anti-bacterial activity 
The world is facing a major challenge in antibiotic resistance. The continuous 
evolution of antibiotic resistance is due to therapeutic use, misuse, and abuse of 
antibiotics (Mun et al., 2013). In addition, ineffectiveness, unfavourable adverse 
effects, non-compliance, and high cost of conventional therapy have changed the path 
of antibacterial research towards developing natural alternatives such as CUR (De et 
al., 2009; Naz et al., 2010).  
Researchers have found that CUR acts as a potent antibacterial agent against 
several gram-positive and gram-negative bacterial strains, such as E-coli, Y. 
enterocolitica, M. tuberculosis, S. aureus, S. epidermidis, Salmonella, P. sudomonas, 
and  H. pylori (Bhullar et al., 2013; Chattopadhyay et al., 2004; Mun et al., 2013; Naz 
et al., 2010; Rai et al., 2008; Vimala et al., 2011). The phenolic groups in CUR form 
H-bonds with the amino/hydroxyl and hydroxyl groups of the bacterial protein and 
cellulose polymers, respectively (Ammayappan & Moses, 2009). Moreover, 
researchers believe that CUR acts as a non-competitive inhibitor of Shikimate 
dehydrogenase (SDH), thus reduction in the synthesis of the bacterial essential 
metabolites (De et al., 2009). Furthermore, CUR binds to tubulin and perturbs 
microtubule polymerization, inhibits the polymerization of the Filamenting 
temperature-sensitive mutant Z (FtsZ) which perturbs its functions and therefore, leads 
to inhibition of bacterial proliferation (Ammayappan & Moses, 2009; Kaur et al., 2010; 
Rai et al., 2008), blocks bacterial respiratory enzymes pathways (Vimala et al., 2011). 
Finally, CUR has phototoxic effects against Salmonella and E.coli (Rai et al., 2008). 
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1.3.2.5 Neuroprotective activity 
Neurodegenerative diseases result in an irreversible loss of functional neurons, 
which results in major mechanical, physiological, and psychological disabilities. 
Therefore, prophylaxis in highly risked patients is vital (Cole et al., 2007). Researchers 
found that CUR acts as a potent neuro- and cytoprotective agent and hence, can be used 
in the prophylaxis and treatment of neurodegenerative diseases such as Alzheimer’s, 
Parkinson's, stroke, head trauma, Huntingtin’s diseases (Thiyagarajan & Sharma, 2004) 
in addition to its protective effects against cerebral, cardiac, and renal ischemia (Jiang 
et al., 2007).  
CUR is believed to possess neuroprotective effects through its anti-oxidant, 
anti-inflammatory, and anti-protein aggregation activities (Rajakrishnan et al., 1999; 
Cole et al., 2007; Yang et al., 2009). It protects the brain from damage through several 
pathways; it regulates the transcription factor (Nrf2) expression (Yang et al., 2009), 
inhibits and reverses lipid peroxidation (Complexes et al., 2003; Bala et al., 2006), 
enhances glutathione content in the brain, and enhances Na+, K+, -ATPase activity 
(Rajakrishnan et al., 1999; Bala et al., 2006). Moreover, it prevents peroxynitrite 
mediated blood-brain barrier disruption (Jiang et al., 2007). Due to its phenolic 
structure, CUR decreases the levels of thiobarbituric acid relative substances (TBARS) 
and reduces the levels of cholesterol, phospholipids, and free fatty acids in the brain 
(Rajakrishnan et al., 1999).  
1.3.2.6 Anti-cancer activity 
Of particular importance to the present research is the anticancer activity of 
CUR. Apoptosis is an essential morphological programed cell death that plays a critical 
role in the development and tissue homeostasis (Elmore, 2007). It is characterized by 
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cell shrinkage, membrane blistering and chromatic condensation that eventually, results 
in cell fragmentation (Hockenbery et al., 1993). Apoptosis is a sophisticated 
autonomous- genetic program for cell death that requires energy and involves the 
activation of “caspases”. Caspases are cysteine proteases that are involved in complex 
events responsible for linking the initiating stimuli to the final vanishing of cells 
(Hockenbery et al., 1993; Elmore, 2007). Essentially, two major pathways drive 
apoptosis: the extrinsic and intrinsic (mitochondrial) pathways (Adams & Cory, 2007). 
The former pathway activates caspase-8 whereas the later activate caspase-9. 
Subsequently, caspase-8 and -9 activate effector caspases (3,7,6) that mediate cellular 
destruction. On the other hand, the B-cell lymphoma 2 (Bcl-2) protein controls the 
intrinsic pathway. Disruption of apoptosis in either pathway results in autoimmune and 
malignant diseases (Adams & Cory, 2007; Mulik et al., 2010a) .  
Research in the last 60 years has found that CUR has potential antitumor effects 
via suppression of tumour initiation, progression, metastasis of several tumour cells 
such as colon, epidermis, breast tumours, among others (Johnson et al., 2009). In 
addition, CUR can sensitize and overcome resistance against several agents that induce 
apoptosis (Tamvakopoulos et al., 2007). Several researchers reported that CUR 
significantly inhibits colon tumorigenesis in the initiation and post-initiation stages 
(Anderson, 2003; Maheshwari et al., 2006). Moreover, Mulik et al.,(2010) found that 
the oral administration of synthetic CUR immensely inhibited the incidence of 
adenocarcinoma in the progression stage. 
The exact mechanism of the anti-tumour effects of CUR is not fully understood, 
however, various mechanisms have been proposed. CUR suppresses proliferation 
induced by cancer growth factors and modulate various cell-signalling pathways such 
as Nrf2, cyclooxygenases, and mitogen-activated protein kinase (Maheshwari et al., 
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2006; Mulik et al., 2010). Furthermore, CUR induces apoptosis through both the 
mitochondria dependant and independent mechanisms (Adams & Cory, 2007). CUR 
inhibits nuclear factor κB (NF-κB) which subsequently downregulates gene products 
such as Bcl-2 (Maheshwari et al., 2006). CUR also induces apoptosis by 
downregulating AKt/ mammalian target of rapamycin (mTOR) pathway (Johnson et 
al., 2009). Moreover, CUR inhibits tolemerase activity, downregulate Notch-1 
signalling, anti-apoptotic proteins, cytochrome C release and caspases-3 and -9 
activation (Tamvakopoulos et al., 2007). CUR induces p53 and alternate redox status 
of the cells in which both induce apoptosis (Aoki et al., 2007; Dandawate et al., 2012). 
1.3.3 Cocktail of CUR with conventional anticancer drugs 
Several chemotherapeutic agents have been used in cancer treatment however, 
the use of these agents have been restricted due to high cost, toxicity, drug resistance 
that leads to the recurrence of diseases (Kunnumakkara et al., 2007; Sreekanth et al., 
2011). Therefore, combination therapy was proposed as an alternative for enhancing 
chemotherapeutic efficacy, particularly in agents with different mechanisms of actions 
(Kunnumakkara et al., 2007). Furthermore, combination therapy decreases the chances 
of resistance development or toxicity (Kunnumakkara et al., 2007). Researchers have 
studied the effectiveness of combining CUR with conventional chemotherapeutic 
agents in order to sensitize cancer cells towards the chemotherapeutic agents and 
decrease the chances of toxicity (Hour et al., 2002; Nautiyal et al., 2011; Sreekanth et 
al., 2011). 
5-FU plus oxaliplatin (FOLFOX) is considered the backbone cocktail in 
colorectal cancer chemotherapy. However, its toxicity and ineffectiveness have urged 
researchers to investigate combining FOLFOX with a non-toxic but effective agent. Yu 
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et al.,(2009) investigated using either CUR alone or in combination with FOLFOX, as 
a treatment and prophylaxis agent against colorectal cancer recurrence. The study has 
shown that CUR as such or combined with FOLFOX resulted in significant reduction 
in cancer stem cells. Hence, it can cure and decrease the chances of colorectal cancer 
recurrence. In another study, Patel et al.,(2008) found that combining FOLFOX with 
CUR resulted in marked apoptosis of colorectal cancer cell lines HCT-116 & HT-29 
compared to individual therapies. Nautiyal et al.,(2011) studied combining CUR with 
FOLFOX in treating colorectal cancer and found that this combination is highly 
effective in inhibiting the tumour growth. In this study, CUR significantly enhanced the 
sensitivity of colorectal cancer towards FOLFOX. Kamat et al.,(2007) studied the 
apoptic effects of combining CUR with gemcitabine and paclitaxel and found that CUR 
enhanced the chemotherapeutic anticancer activity in bladder regardless of interferon-
α (IFN-α) resistance. In another study, Kunnumakkara et al.,(2007) investigated the 
ability of CUR to sensitize pancreatic cancer to gemcitabine both in vitro and in vivo. 
The study concluded that CUR and gemcitabine could be used as a treatment regimen 
against prostatic cancer. CUR-gemcitabine combination was again studied by Kanai et 
al.,(2011). The findings of this study confirmed the safety and feasibility of using this 
combination for pancreatic cancer treatment. Sreekanth et al.,(2011) found that CUR 
augmented paclitaxel apoptotic activity against cervical cancer cells. The study showed 
that this combination significantly reduced the tumour incidence and volume compared 
to individual therapeutic regimens. Whereas Qian et al.,(2011) studied the combination 
of CUR with adrimycin for hepatocellular carcinoma treatment and concluded that this 
combination resulted in enhancement of adriamycin apoptotic effect. Apart from the 
chemotherapeutic agents, researchers have studied combining CUR with other natural 
products such as green tea, taxol, and Beta-phenylethyl isothiocyanate for oral, cervical, 
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and prostatic carcinogenesis, respectively. These combinations showed promising, 
effective, and non-toxic treatment outcomes (Reuter et al., 2008).  
1.3.4 Clinical studies on CUR as an anticancer agent 
Extensive research has shown the tremendous effectiveness of CUR in 
preventing and treating several types of cancers such as pancreatic, breast, skin, 
stomach, duodenum and colorectal cancer. Animal studies emphasized the dose 
dependant anticancer effects of CUR and recently, the clinical benefits of CUR in 
patients with several types of cancers have been elucidated  (Anderson, 2003; Hatcher 
et al., 2008; Naksuriya et al., 2014; Sharma et al., 2004).  
Several clinical studies investigated the toxicity of CUR, for example, Sharma 
et al.,(2001) study included 15 patients with advanced colorectal cancer who consumed 
a single oral dose of 36-180 mg CUR for a duration of 4 months where the safety of 
CUR was confirmed. Cheng et al.,(2001) studied a higher dose threshold of 500-8000 
mg of daily administration of CUR for three months in 24 patients with resected bladder 
cancer, stomach metaplasia, oral leukoplakia, Bowen’s disease, and cervical 
intraepithelial neoplasm. This study confirmed the safety of CUR through 
pharmacokinetic analysis of blood and urine. Moreover, histopathological monthly 
evaluation was undertaken and in conclusion, they demonstrated the safety, poor 
absorption, and chemotherapeutic effects of CUR.  
Pharmacokinetics studies were performed simultaneously with toxicity studies 
in a phase I clinical trial for oral CUR aimed at establishing the toxicity and systemic 
effects of CUR (Sharma et al., 2004). The pilot study included 15 patients with 
colorectal cancer and analysed three biomarker activity: glutathione S-transferases 
(GST), levels of deoxyguanosine adduct (M1G), and inducible prostaglandin E2 (PGE2) 
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as a reflection of CUR effects on carcinogenesis. The study concludes that CUR is 
effective in preventing and treating colorectal cancer however, low systemic 
bioavailability restricts its effectiveness. These results are in consistence with another 
phase I trials that investigated the pharmacokinetics and chemotherapeutic effects of 
CUR in twelve patients where the findings emphasized the anticancer effects of CUR 
despite its poor bioavailability (Anderson, 2003). The  efficiency of CUR in the 
prevention of colorectal cancer was studied by Carroll et al.,(2011) with  44 participants 
who met the criteria; smokers, older than 40 years old, and has 8 or more rectal aberrant 
crypt foci (ACF) were included. Oral CUR was administered for 30 days and 
researchers assessed the chemoprevention ability of CUR through analyses of 
prostaglandin PGE2 and 5-hydroxyeicosatetraenoic acid (5-HETE) within the ACF. In 
consistence with the findings of Dhillon et al.,(2008), this study showed that CUR was 
poorly absorbed yet managed to reduce the ACF number that demonstrates its 
effectiveness in the prophylaxis against colorectal cancer. 
In conclusion, in vitro, in vivo, and clinical studies suggest that CUR is potent 
against several types of cancer, including colorectal cancer, which is the subject of the 
present investigation. However, its effectiveness is restricted due to its poor systemic 
absorption and low bioavailability. In order to realise the anticancer potential of CUR, 
some form of formulation intervention is required. In the next chapter, I shall review 
current trends in formulation technology that address the constraints associated with the 
effectiveness of CUR and relevant to the present investigation. 
1.4 Nanomedicine 
Nanotechnology has invaded the contemporary industries and is usually 
referred to the design, fabrication, and utilization of materials with nanoscale 
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dimensions (Liu et al., 2007; Park et al., 2008). In the late 1990s, innovative technology 
has merged medicine in nanotechnology in a new term called nanomedicine (Wagner 
et al., 2006). Unfortunately, there is no international definition for nanomedicine. The 
European Science Foundation (ESF) defined nanomedicine as “the science and 
technology of diagnosing, treating, and preventing disease and traumatic injury, of 
relieving pain, and of preventing and improving human health, using molecular tools 
and molecular knowledge of the human body” (Webster, 2006). Whereas the United 
States’ National Institute of Health Roadmap for Medical Research in Nanomedicine 
(NIH) defines nanomedicine as “an offshoot of nanotechnology which refers to highly 
specific medical interventions at the molecular scale for curing disease or repairing 
damaged tissues, such as bone, muscle, or nerve” (Webster, 2006). Nanomedicine 
ramifies into several types of nano-devices including nanomachines, nanofibers, 
nanosensors, and NPs (nanocarriers) (Park et al., 2008).  
Research has been extensively studying the application of nanocarriers in 
various medical applications due to the long list of advantages over conventional 
medicine. Physical properties of nanocarriers such as particle size, size distribution, 
surface charge, and surface modification flexibility allows targeted delivery of the 
cargo (Kumari et al., 2010). Nanocarriers have unique characterization that may be 
exploited for  improved pharmacokinetic properties of drugs compared to traditional 
medicine (Bhaskar et al., 2010). In addition, nanocarriers have the advantage of 
releasing drugs in sustained and controlled manners (Malam et al., 2009). 
Implicating nanocarriers in drug delivery has several advantages including 
improved solubility of cargo, inhibition of systemic clearance, enhancing drug stability 
(Liu et al., 2007), drug delivery across the blood brain barrier (BBB) and blood-
cochlear barrier (Bhaskar et al., 2010),  reduction in toxicity and hence dosage regiment 
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whilst at the same time  enhancing drug efficacy (Malam et al., 2009). Nanomedicine 
has been applied in different healthcare sectors such as in vivo imaging, in vitro 
diagnostics, biomaterials, active implants, drug nanoformulations, and drug delivery 
(Wagner et al., 2006). Functional pharmaceutical nanocarriers have been used in 
dentistry, ophthalmology, pulmonary, cardiology, and neurology, to name few 
(Farokhzad & Langer, 2006). Drug release can be tailored  in response to various 
triggers including pH, temperature and environment or  changes in concentration of an 
analyte or enzyme such as glucose, glutathione, matrix metalloproteinases (Farokhzad 
& Langer, 2006; Mura et al., 2013; Torchilin, 2012). 
Conventional chemotherapeutic drugs are associated with debilitating 
drawbacks such as severe toxicity to normal cells, instability, lack of selectivity, and 
drug resistance (Liu et al., 2007; Park et al., 2008; Shapira et al., 2011). Therefore, 
researchers have extensively studied therapeutic alternatives that manifest fewer side 
effects. Cancer tissues have unique pathophysiology in which tumours have fenestrated 
vasculature that is dilated and poorly differentiated with high interstitial pressure and 
poor lymphatic drainage (Liu et al., 2007; Vlerken et al., 2007). Taking advantage of 
this pathophysiology, nanocarriers can be administered for site-specific delivery into 
tumour tissue where they may accumulate passively or actively. Furthermore, 
nanocarriers can be tailored to enhance the cytotoxicity of chemotherapeutic agents, 
whilst reducing side effects and overcoming drug resistance (Park et al., 2008; Shapira 
et al., 2011; Vlerken et al., 2007).  
Nanocarriers  can be administered  via various routes such as non-invasive 
(intranasal, pulmonary, oral and transdermal delivery) (Sosnik & Sarmento, 2014) as 
well as invasive routes (Intravascular, subcutaneous, intravenous delivery) (Cheng et 
al., 2008).  
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1.4.1 Challenges in Nanomedicine 
The application of nanotechnology in medicine is continuously evolving and is 
seen as a promising approach towards a wide variety of medical applications, such as 
diagnosis, treatment, and prevention of diseases (Kranz et al., 2011; Linkov et al., 
2008). However, there are several challenges associated with nanomedicine. 
The most challenging obstacle in nanomedicine is related to the physico-
chemical  characterization of the nanocarriers so that batch-to-batch variability is not 
easily achieved.  Furthermore, the physico-chemical  properties of the nanocarriers can 
become altered as these delivery systems interact with the biological fluids or 
environmental conditions during storage (Wicki et al., 2015). In addition, the health 
risks and environmental side effects associated with nanomedicine development  and 
manufacturing processes have not been assessed (Baun & Hansen, 2008; Linkov et al., 
2008; Wicki et al., 2015). There are no regulatory or internationally agreed guidelines 
governing the production and usage of this class of dosage forms (Wicki et al., 2015). 
Despite the potential and appealing features associated with nanomedicine in 
cancer diagnosis, treatment, and prevention, research is still constrained by complexity 
and heterogeneity of tumours among patients (Prabhakar et al., 2013; Shi et al., 2016). 
There is also the difficulty of  targeting nanocarriers to solid tumours (Nie, 2010; Shi 
et al., 2016). Biological factors such as NPs-protein interaction, blood circulation and 
extravasation into tumours, possess negative influence in the permeability of 
nanocarriers into the tumour, hence its therapeutic efficacy (Shi et al., 2016). Moreover, 
the majority of the available data about the therapeutic effects of NPs are based on in 
vitro and in vivo studies.  
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1.4.2 Types of “nanocarriers” 
NPs used in drug delivery systems are submicron-sized systems or devices that 
include polymeric NPs, micelles, dendrimers, liposomes, and solid lipid nanoparticles 
(SLN) where each system has unique physico-chemical  properties. 
1.4.2.1 Polymeric nanoparticles 
Polymeric NPs (Figure 1.6) are particles with size below 1 µm fabricated 
usually from biodegradable polymers (Hans & Lowman, 2002). They may consist of 
two or more polymer chains with different hydrophobicity called copolymers that self-
assemble in a core-shell structure in an aqueous environment (Muller et al., 2000). 
Drugs may be conjugated to the side chain of the linear polymers and through 
manipulating the ratios of the forming polymers, we  can control the degradation rate 
of the NPs and hence, drug release (Cho et al.,2008).  Polymers used can be either 
natural such as albumin, alginate, CS, and collagen or synthetic such as polyarcylates, 
polycaprolactones, and polylactide-polyglycoid (Panyam & Labhasetwar, 2003; 
Soppimath et al.,2001; Cho et al.,2008). Natural polymers are less preferred because of 
the variety in purity and degree of crosslinking that might affect the functionality of the 
delivery (Hans & Lowman, 2002). 
37 
 
 
Figure 1.6 Polymeric NPs (adopted from www.dovepress.com) 
  
Several methods are used in the production of polymeric NPs such as solvent 
diffusion, solvent evaporating, solvent displacement, interfacial deposition, 
nanoprecipitation, multiple emulsion, salting out, polymerization, and ionic gelation 
(Hans & Lowman, 2002; Soppimath et al.,2001). According to the method of 
preparation, the embedded drug is either covalently bounded to or physically 
encapsulated in the polymer matrix (Cho et al.,2008). Polymeric NPs can be structured 
either in nanocapsule or nanosphere form, where the former consists of a liquid or semi-
solid core immersed in a solid shell, the latter is completely solid matrix (Vauthier & 
Bouchemal, 2009). 
Polymeric NPs may be biodegradable, biocompatible (Hans & Lowman, 2002), 
flexible, and stable delivery systems that are capable of embedding a wide range of 
therapeutic agents with high loading capacity (Patel et al., 2012) . In addition, they 
protect the embedded agent and release it in controlled and sustained manner 
(Soppimath et al., 2001). Moreover, many polymers used in the fabrication of 
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polymeric NPs have been safely used in humans for decades (Cho et al.,2008; Sanna et 
al.,2014).  
Several polymeric NPs are under preclinical and clinical studies. For example, 
Paclitaxel-incorporating PEG-modified polyaspartate polymeric micelles (NK105) is 
in phase I clinical studies, whereas paclitaxel containing Monomethoxy polyethylene 
glycol-d,l-lactide polymeric micelles (Genexol-PM®), Doxorubicin-incorporated PEG- 
polyaspartic acid polymeric micells (NK911), cyclodextrin-poly(ethylene glycol) 
copolymer conjugated to camptothecin (CRLX101), and Cisplatin-incorporating 
polyethylene glycol poly(glutamic acid) polymeric micelles (NC-6004) are in phase II 
clinical studies (Sanna et al.,2014; Chan et al.,2010; Cho et al.,2008).  
Two polymeric NPs are currently available in market, namely, Aboscan® a 
dextran-fabricated NPs using iron oxide for the diagnostic imaging of the spleen and 
liver, and Abraxane® an albumin-fabricated NPs using paclitaxel for breast cancer 
treatment (Patel et al., 2012). 
1.4.2.2 Micelles 
Introduced in early 1990s, polymeric micelles are a mesoscopic drug delivery 
system with a unique core-shell structure (Figure 1.7). The hydrophobic part of the 
copolymer self-assemble into the inner core which embed the hydrophobic drug, 
whereas the hydrophilic part forms the water shell protecting the encapsulated 
hydrophobic drug from the aqueous environment (Kedar et al., 2010). Polymeric 
micelles can be formed either by a single polymer-drug conjugation or through 
complexation of two oppositely charged poly-ions  (Kataoka et al., 2012). The small 
particle size (<100 nm) of the polymeric micelles gives the resemblance  of  natural 
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carriers such as viruses, hence they cannot be recognized in vivo by the 
reticuloendothelial system (Lavasanifar et al., 2002). 
 
Figure 1.7 Polymeric Micelles (Adopted and modified from 
www.sigmaaldrich.com) 
Polymeric micelles can be fabricated by di-block copolymers, tri-block 
copolymers, or graft copolymers. The selection of the copolymer depends on the 
intended application of the micelles formation. Some polymers are suited for controlled 
drug release, prolong systemic circulation time, or introduction of targeting moieties 
(Kedar et al., 2010). The main driving force for polymeric micelles formation is the 
core segregation from the aqueous environment and it starts upon reaching the threshold 
concentration called critical micelle concentration (CMC). Micelles with lower CMC 
values are more stable and have lower rate of dissociation thus, more drug would be 
available at the target site (Kataoka et al., 2012; Kedar et al., 2010). Formulation of 
polymeric micelles is achieved in two steps: synthesis of the block copolymer and then 
conversion into micelles (Kedar et al., 2010). Micelles can also be formed through 
electrostatic interactions, metal complexation, hydrophobic interactions, and hydrogen 
bonding (Kataoka et al., 2012; Kedar et al., 2010). Methods of micellization are 
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dialysis, self-emulsion evaporation, microsphere separation, oil-in-water emulsion, and 
rapid heating methods (Kedar et al., 2010).  
Compared to amphiphilic micelles, polymeric micelles have lower CMC values 
(Gaucher et al., 2005). The major obstacle in the manufacture of polymeric micelles is 
the temporal control. Temporal control means that a slight deviation in the environment 
temperature from the lower critical solution temperature (LCST) results in micelle 
degradation, hence immature drug release occurs. Therefore, local modification of 
patient body temperature is required (Matsumura, 2008). 
In vitro studies on polymeric micelles incorporating anticancer agents have 
shown promising findings. Therefore, several anticancer agents-loaded with micelles 
are under clinical investigations. Paclitaxel loaded micelles, NK105, is under Phase I/II 
studies for the determination of the recommended dose, maximum tolerated dose, dose-
limiting toxicity, and pharmacokinetics in several  cancers (Matsumura, 2008; 
Matsumura & Kataoka, 2009). Cisplatin-loaded micelles, NC-6004, is under phase II 
studies designed to determine the toxicity (Matsumura, 2008; Matsumura & Kataoka, 
2009). NK102, SN-38 encapsulated micelles is under Phase II studies. The study will 
be continued until disease progression or inadmissible toxicity occurs (Matsumura, 
2008; Matsumura & Kataoka, 2009). NK911, doxorubicin-incorporated micelles is 
under phase II clinical trials against metastatic pancreatic cancer whereas, Epirubicin-
loaded micelles, (NC-6300), is under phase I study to determine the safety and efficacy 
of dose against advanced solid tumours (Cabrala & Kataoka, 2014).  
1.4.2.3 Dendrimers 
First proposed in late 1970’s as a monodispersed and structure-controlled 
system, dendrimers (Figure 1.8), have a unique well-defined, highly branched and 
41 
 
globular polymer architecture formulated in three-dimensional molecular arrangement 
(Emanuele & Attwood, 2005; Esfand & Tomalia, 2001; Gillies & Fréchet, 2005; 
Kurtoglu et al., 2009; Liu & Fréchet, 1999; Zhang et al., 2008). Compared to 
conventional polymers, dendrimers are globular in shape, have more controlled 
structure and molecular weight, and a wider functional surfaces (Emanuele & Attwood, 
2005; Liu & Fréchet, 1999). The unique globular structure comprises of a core (zero 
generation) and multiple layers of repeated units called generations; where low 
generations represent an open structures, and higher generations are more globular and 
dense, therefore, a plethora of dendrimers architectures have been fabricated (Emanuele 
& Attwood, 2005; Liu & Fréchet, 1999; Zhang et al., 2008). 
 
Figure 1.8 Dendrimers (Drawn using Microsoft paint®, 1709) 
Two distinct strategies are used for dendrimers synthesis: The divergent and the 
convergent synthesis. In the former, the dendrimer growth starts from the core followed 
by a stepwise addition of the outer layers. Whereas in the latter, the growth starts at the 
chain ends followed by the addition of molecules towards the core (Esfand & Tomalia, 
2001; Liu & Fréchet, 1999). Both of the strategies involve two-steps reactions 
sequence: growth step and activation step. In addition, clean and side reactions-free 
processes are required in both strategies. Besides the difference in the structural 
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formation order, convergent strategy incurs better control of the structure, while the 
divergent strategy is better for large-scale production (Liu & Fréchet, 1999). However, 
both strategies are tedious and time-consuming. Therefore, new strategies are being 
proposed such as double stage convergent growth and orthogonal coupling strategies 
(Liu & Fréchet, 1999). In nanomedicine, several types of dendrimers have been used 
including polyamidoamines (PAMAM), polyesters (PGLSA-OH), and 
polyproplimines (PPI), among others (Mignani et al., 2013).  
Drugs can be encapsulated in dendrimers via numerous interactions such as 
electrostatic, hydrophobic, hydrogen bond, and covalent interactions (Emanuele & 
Attwood, 2005). Dendrimers can be designed to have therapeutic targeted propensities, 
where disease specific-signals such as oxidative, chemical and environmental changes 
serve as a trigger for the cleavage between dendrimers linkers and thus, drug release 
(Mignani et al., 2013). Dendrimers have been used in various applications including 
enzyme mimicking, gene and drug delivery, diagnostic agents, immunodiagnostics, 
vaccines, antivirals, antibacterial, and anticancer therapeutics (Emanuele & Attwood, 
2005; Esfand & Tomalia, 2001; Gillies & Fréchet, 2005; Liu & Fréchet, 1999). 
Dendrimers have several advantages related to their unique structure such as 
uniformity, controlled size, low polydispersity, flexible surface group (Patri et al., 
2005). Furthermore, they may overcome biological constraints that hinder targeting to 
tumour site (Mignani et al., 2013). Moreover, these delivery systems expedite passive 
targeting of drugs to the solid tumours (Gillies & Fréchet, 2005). The manufacture of 
dendrimers is expensive and raises toxicity and biocompatibility concerns. 
Furthermore, dendrimers have poor biodistribution, which shortens their blood 
circulation time and hence, less therapeutic efficacy is achieved (Liu & Fréchet, 1999). 
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Notwithstanding, there are a number of  dendrimers currently  in preclinical 
development such as folic acid-PAMAM dendrimers, poly propyleneimine dendrimers, 
ligand- conjugated PEG-poly-Ļ-lysine dendrimers, and poly (glycerol-succinic acid) 
dendrimers for epithelia cancer, HIV, malaria, and various cancer treatments, 
respectively. Poly-Ļ-Lysine dendrimer (VivaGel®) is under phase I clinical studies for 
antimicrobial protection from HIV and genital herpes infections (Zhang et al., 2008).  
1.4.2.4 Liposomes 
Liposomes (Figure 1.9) are mesoscopic colloidal particles that can be prepared 
from synthetic or natural phospholipid layers embracing aqueous compartments (Lian 
& Ho, 2001; Mezei & Gulasekharam, 1980; Sharma & Sharma, 1997). Liposomes were 
first introduced in 1970 as drug delivery systems for targeted drug delivery and 
enhancing the  therapeutic indices of drugs (Gregoriadis & Florence, 1993; Lian & Ho, 
2001). The structure versatility of liposomes allows the encapsulation of a wide range 
of drugs with variable lipophilicities (Gregoriadis & Florence, 1993; Sharma & 
Sharma, 1997). The gel-liquid crystalline transition temperature (Tc) of phospholipids 
determines the degree of fluidity of the liposomal membrane at ambient temperature 
(Gregoriadis & Florence, 1993). 
 
Figure 1.9 Liposomes (adopted and modified from www.intechopen.com) 
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Liposomes are mainly composed of neutral charge phosphatidylcholine with 
fatty acid chains of various lengths and degree of saturation. To a lesser extent, 
cholesterol is included in the lipid formulation (Gregoriadis & Florence, 1993; Malam 
et al., 2009). The simplest method of liposomes formulation is the thin-film hydration 
method. However, it produces liposomes with low encapsulation efficiency (EE%). 
Therefore, the freeze-drying preformed liposome dispersion method was developed 
(Sharma & Sharma, 1997). Based on the liposomes composition and intracellular 
delivery mechanisms, liposomes are classified into five types: i) conventional 
liposomes, ii) cationic liposomes, iii) long circulating liposomes, iv) pH-sensitive 
liposomes, and v) immunoliposomes (Sharma & Sharma, 1997). 
Another classification of liposomes is based on the liposomes-biological 
interactions into: non-interactive sterically stabilized liposomes (LCL) and highly 
interactive cationic liposomes. While the former has longer circulation half-life, the 
later has higher affinity to cell membranes, thus, suitable for intracellular genetic 
material delivery (Sharma & Sharma, 1997). 
Liposomal physical properties such as lipid composition, size, charge, 
membrane fluidity, steric hindrance, charge density, and permeability defines 
liposomal-biological interactions, which in turn determine the drug intracellular activity 
(Lian & Ho, 2001; Sharma & Sharma, 1997). Liposomes can be administered orally or 
parenterally (subcutaneously, intramuscularly, intravenously) (Lian & Ho, 2001; Mezei 
& Gulasekharam, 1980) and  they can be used in a wide range of applications such as 
diagnostic imaging, oral drug therapy (Sharma & Sharma, 1997), gene therapy (Lian & 
Ho, 2001), vaccination,  and antimicrobial and antineoplastic therapy (Gregoriadis & 
Florence, 1993). They are biodegradable and have physical and structural similarities 
to biological membranes. They may be used to  enhance the pharmacologic properties 
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of drugs (Gregoriadis & Florence, 1993). Compared to the crude drug in aqueous 
solution, liposomal encapsulation enhances drug absorption and biodistribution (Lian 
& Ho, 2001). However, the therapeutic applications of liposomes are limited due to 
their batch to batch variability, constraints in sterilization, low EE% and rapid clearance 
from systemic circulation (Allen & Cullis, 2013; Lian & Ho, 2001; Sharma & Sharma, 
1997). 
Table 1.2 shows liposome-based products approved for human use, whereas 
Table 1.3 lists liposome-based products in clinical trials (Allen & Cullis, 2013; 
Evaluate, 2017; FDA, 2018; Lian & Ho, 2001; Saif, 2014; Sharma & Sharma, 1997; 
Tak et al., 2018). 
  
Table 1.2  Lipsome-based products approved for human use 
Product Drug Indication 
AbelectTM Amphotericin B Serious fungal infections 
AmbisomeTM Amphotericin B Serious fungal infections 
AmphocilTM Amphotericin B Serious fungal infections 
AmphotecTM Amphotericin B Serious fungal infections 
CPX-351 Cytarabine; Daunorubicin Acute myeloid leukemia 
DaunoXomeTM Daunorubicin citrate Kaposi sarcoma in AIDS 
DepoDurTM Morphine sulphate Pain after surgery 
DepoCytTM Cytosine Lymphomatous 
DiprivanTM Propofol Anesthesia 
DoxilTM 
CaelyxTM 
Doxorubicin - Kaposi sarcoma in AIDS 
- Refractory ovarian 
cancer 
EstrasorbTM Estrogen Menopausal therapy 
ExparelTM Bupivacaine Local anaesthetic 
MyocetTM Doxorubicin Breast cancer 
VisudyneTM Verteporphin Wet macular degenration 
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Table 1.3 Liposome-based products in clinical trials 
Product Drug Status Indication 
Allovectin-7 HLA-B7 
Plasmid 
Phase II Gene therapy for 
metastatic cancers 
Alocrest Vinorelbine Phase I Newly diagnosed 
or relapsed solid 
tumours 
AntragenTM Tretinoin Phase II/III Kaposi sarcoma in 
AIDS 
Brakiva Topotecan Phase I Relapsed solid 
tumour 
CPX-1 Irinotecan HCl: 
Floxuridine 
Phase II Colorectal cancer 
Endo-Tag-1 Paclitaxil Phase II Pancreatic cancer 
NyotranTM Nystatin Phase II/III Candidemia 
VentusTM Prostaglandin E1 Phase III Acute respiratory 
distress syndrome 
MBP-436 Oxaliplatin Phase II Gastric cancer and 
gastro-esophageal 
junction 
MM-302 Doxorubicin Phase I Breast cabcer 
MM-398 CPT-11 Phase III Gastric and 
pancreatic cancer 
ThermoDox Doxorubicin Phase III Refractory chest 
wall breast cancer 
1.4.2.5 Solid Lipid Nanoparticles (SLN) 
SLN (Figure 1.10) were first proposed in 1991 as alternative drug delivery 
systems to conventional carriers such as liquid oils, liposomes, and emulsions (Mehnert 
& Mader, 2001; Muller et al., 2000; Müller et al., 2002). SLN are particles in the nano-
size range with a solid-lipid matrix and are made from solid lipids and stabilized by 
surfactants (Wissing et al., 2004). The solid state of the lipids reduces the mobility of 
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the embedded drugs which hinders the drug release (Mehnert & Mader, 2001; Muhlen 
et al., 1998). 
 
Figure 1.10 SLN (Drawn using Microsoft Paint® 1709) 
SLN are prepared using any of the following  techniques: i) high shear 
homogenization which is sub-divided into hot and cold homogenization methods for 
heat sensitive and highly heat sensitive drugs, respectively ii) microemulsion iii) 
solvent emulsification-diffusion or –evaporation iv) double emulsion, and v) high speed 
sonication/ stirring (Blasi et al., 2007; Mukherjee et al., 2009; Muller et al., 2000). 
Drugs can be embedded between lipid layers, the fatty acid chains, or in 
imperfections within the lipid matrix (Wissing et al., 2004). Based on the drug 
incorporation location, 3 models can be recognised: solid solution model, core-shell 
model which could be either drug-enriched shell or drug-enriched core model (Muller 
et al., 2000). The stability and release of incorporated drugs depend mainly on the 
physical characteristics of the SLN (particle size, zeta potential, crystallinity), (Muller 
et al., 2000) . SLN can be administered via various routes including oral, transdermal, 
ocular, rectal, pulmonary and parenteral routes (Mukherjee et al., 2009; Muller et al., 
2000; Wissing et al., 2004). However, toxicity profiles following parenteral route are 
not available yet (Muller et al., 2000). 
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Various drugs have been incorporated in SLN such as cortisone, diazepam, 
menadione, methasone, valeraten, prednisolone, retinol, timolol, to mention few 
(Mehnert & Mader, 2001). They are physically stable, may manifest controlled release 
kinetics, and have superior tolerability (Wissing et al., 2004). Compared to 
conventional drug delivery systems, SLN may be non-toxic and can be formulated 
without the need for organic solvents. In addition, they can be easily sterilized (Mehnert 
& Mader, 2001; Schwarz et al., 1994). 
1.4.3 Methods of preparation for polymeric nanoparticles 
Polymeric NPs have been extensively studied as a drug delivery system for 
small and large molecules. Therefore, several preparation methods have been proposed 
(Nagavarma et al.,2012; Rao & Geckeler, 2011). Essentially, the preparation 
techniques include two main steps. The first step comprises the preparation of the 
emulsified system, whereas the NPs are fabricated in the second step. Classification of 
the preparation method depends on the first step, which could be either polymerization 
of monomers or dispersion of a preformed polymer (Nagavarma et al.,2012; Vauthier 
& Bouchemal, 2009; Pinto Reis et al.,2006; Rao & Geckeler, 2011). Method selection 
depends on several factors including physico-chemical  characteristics of the target 
drug, required physico-chemical  parameters of the NPs, target site, application, among 
others (Pinto Reis et al.,2006; Rao & Geckeler, 2011). Figure 1.11 illustrates the 
different types of preparation methods. 
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Figure 1.11 Illustration of preparation methods for polymeric nanoparticles 
* SCF: Supercritical fluid technology 
* C/LRP: Controlled/Living Radical Polymerization  
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1.4.3.1 Preparation methods from dispersion of preformed polymer 
Different methods may be used to successfully formulate NPs by dispersion of 
preformed polymers. These methods are reviewed in the following sections. 
1.4.3.1.1 Solvent Evaporation 
Solvent evaporation was the first developed method for polymeric NPs 
preparation from preformed polymers (Nagavarma et al.,2012; Vauthier & Bouchemal, 
2009). In the first step, the emulsion is prepared by dissolving the polymer in a volatile 
solvent such as chloroform, dichloromethane, ethyl acetate or  acetone via high-speed 
homogenization or ultra-sonication (Nagavarma et al.,2012; Vauthier & Bouchemal, 
2009). The formulated emulsions could be either single-emulsions (w/o) or double-
emulsions ((w/o)/w). The NPs are then fabricated by evaporating the solvent of the 
polymer by diffusion through the continuous phase of the emulsion. This step is 
achieved by either continuous magnetic stirring at room temperature or increasing the 
temperature under pressure (Pinto Reis et al.,2006; Rao & Geckeler, 2011). Finally, 
formulated NPs are collected by ultracentrifugation, washing with purified water, and 
finally, lyophylization  (Kumari et al.,2010; Mohanraj et al.,2006). 
The particle size range can be controlled by managing the polymer 
concentrations, type and concentration of the stabilizer, viscosity of aqueous and 
organic phases, stirring speed, and temperature (Mohanraj et al.,2006; Pinto Reis et 
al.,2006). Examples of frequently used polymers are poly(lactide) (PLA), PLGA, 
poly(epsilon-caprolactone) (PCL), ethylcellulose (EC), cellulose acetate phthalate, 
among others (Pinto Reis et al.,2006; Vauthier & Bouchemal, 2009).  
Lee et al.,(2006) used solvent evaporation method to prepare polymeric NPs 
from CS derivatives fluorescein isothiocyanate (FITC)- conjugated glycol CSs (FGCs) 
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using diluted chloroform as the solvent. Fabricated NPs size ranges were 150-500 nm, 
and were stable in phosphate buffered saline (PBS) for 20 days at 37oC. Gómez-Gaete 
et al.,(2007) encapsulated dexamethasone in PLGA NPs using the solvent evaporation 
technique for ocular delivery. Particle size and zeta potential produced were 230 nm, -
4 mV, respectively. Dexamethasone was completely released after 4 hr at 37oC 
medium. However, loading capacity was relatively low (2.3%). Although the solvent 
evaporation method is simple (Rao & Geckeler, 2011), it is time consuming, there is 
the possibility of stabilizer binding on the surface of the NPs, the likelihood of 
nanodroplet cohesion during the evaporation step, and the difficulty of scaling-up 
(Pinto Reis et al.,2006; Rao & Geckeler, 2011; Lee et al.,1999). 
1.4.3.1.2 Nanoprecipitation 
Nanoprecipitation, also called solvent displacement, was first developed by 
Fessi et al.,(1992). Nanoprecipitation technique has three basic components: i) polymer 
(synthetic, semi-synthetic, or natural), ii) polymer solvent iii) non-solvent of the 
polymer (Rao & Geckeler, 2011; Vauthier & Bouchemal, 2009). After dissolving the 
polymer in water-miscible solvent, this organic solution is slowly added to the aqueous 
phase under slight and continuous stirring, vice versa addition successfully formulate 
the NPs as well (Thioune et al., 1997; Yordanov & Dushkin, 2010). Subsequently, rapid 
diffusion of the polymer solution in the non-solvent phase results in the aggregation of 
the polymer chains and thus, instant formation of the NPs (Rao & Geckeler, 2011; 
Galindo-rodriguez et al.,2004). Finally, The polymer solvent is removed by evaporation 
(Vauthier & Bouchemal, 2009; Legrand et al.,2007). 
Polymers commonly used are PLA, PLGA, Eudragit, cellulose derivatives, 
among others (Rao & Geckeler, 2011; Vauthier & Bouchemal, 2009; Bilati et al.,2005). 
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Organic solvents used should be miscible in water and easily evaporated such as 
acetone, tetrahydrofuran (THF), ethanol, mixtures of two or three solvents (Thioune et 
al.,1997; Yordanov & Dushkin, 2010; Rao & Geckeler, 2011; Vauthier & Bouchemal, 
2009).  
The principle of this method is based on the Marangoni effect, which is related 
to the interfacial turbulence of the polymer after displacement of the solvent with water 
(Bilati et al., 2005). This effect results in decreasing the interfacial tension between the 
two phases, hence, increasing the surface area and finally, NPs formation (Rao & 
Geckeler, 2011; Govender et al.,2016; Galindo-rodriguez et al.,2004). 
The physico-chemical characteristics of the NPs are affected by the diffusion 
conditions, miscibility of the organic phase, organic phase and aqueous phase ratio, 
polymer type and concentration, in addition to the surfactant type and concentration, if 
added (Bilati et al., 2005; Govender et al., 2016; Legrand et al., 2007; Yordanov & 
Dushkin, 2010).  
Nanoprecipitation method is a simple, one-step, easy, fast, reproducible, 
economic, and well characterized polymers are used (Bilati et al., 2005; Govender et 
al., 2016; Legrand et al., 2007; Yordanov & Dushkin, 2010). However, water soluble 
drugs are poorly incorporated  (Bilati et al., 2005). 
Shen et al.,(2011) developed PEG-b-PCL and PEG-b- Poly(acrylic acid) (PAA) 
NPs incorporated with β-carotene as a model drug. The NPs were successfully 
developed for biomedical applications, such as imaging and drug delivery. The size 
range was 50-500 nm with a maximum drug loading capacity of 50%. In another study, 
Dhar et al.,(2008) employed the nanoprecipitation technique to fabricate Pt(IV) 
prodrug-PLGA–PEG NPs encapsulating cisplatin targeting prostate cancer. The NPs 
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were formulated to target Prostate Specific-membrane Antigen (PSMA), which is 
overexpressed in prostate cancer. The particle size and loading efficiency were 140 nm 
and 6%, respectively. The release kinetics showed sustained release of drug over 80 hr. 
1.4.3.1.3 Emulsification/solvent diffusion 
Emulsification/solvent diffusion, also called spontaneous emulsification, is a 
modified technique of the emulsification/solvent evaporation technique (Nagavarma et 
al.,2012; Miller, 1988). It was first proposed based on using organic solvents, however, 
it was adapted in the salt-out technique (Pinto Reis et al.,2006). The simplest model of 
this technique comprises of water, hydrocarbon, and fatty acid or a short-chain alcohol 
(Miller, 1988). In more advanced versions, 1-3% of mixed emulsifiers can be added 
(El-Aasser et al., 1988). First, the drug-containing polymer is dissolved in a partially 
water-miscible solvent. Secondly, the solution is saturated with water to reach initial 
thermodynamic equilibrium of both phases (Nagavarma et al.,2012). Thirdly, solvent 
diffusion is promoted by dilution with an excess of water (Bouchemal et al., 2006). 
Fourthly, the super-saturated solution of oil in water is emulsified in an aqueous 
solution containing stabilizer which leads to solvent diffusion to the external phase and 
hence, formation of NPs as an oil droplets in an aqueous continuous phase. Finally, the 
solvent is expelled by filtration or evaporation (Kwon et al., 2001). 
Emulsification occurs in the aqueous phase (Miller, 1988). For successful 
emulsification, fatty alcohol and ionic surfactant should be thoroughly mixed in the 
water phase before the addition to the oil phase (El-Aasser et al., 1988). Examples of 
solvents used are propylene carbonate and benzyl alcohol whereas polyvinyl alcohol 
(PVA) and gelatine can be used as stabilizers (Kwon et al., 2001). The fatty alcohol 
chain length should be at least 12 carbons (El-Aasser et al., 1988). Based on the system 
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composition and their physico-chemical characterization, two mechanisms are 
proposed for the spontaneous emulsification: nucleation and growth, and diffusion and 
stranding (Bouchemal et al., 2008). 
Unlike the emulsification/solvent evaporation technique, spontaneous 
emulsification is not caused by interfacial turbulence but by the diffusional process 
itself (Miller, 1988). The spontaneity of the emulsification process is affected by several 
factors such as the interfacial and bulk viscosity, interfacial tension, surfactant 
concentration and structure, and phase transition region. The spontaneity of 
emulsification in turn, affects the nanoparticle size and size distribution (Bouchemal et 
al., 2008). Usually, size range produced using this technique is 100-450 nm (El-Aasser 
et al., 1988; Kwon et al., 2001). 
Nanoformulations produced by spontaneous emulsification are known to be 
stable. Several hypotheses have been proposed to explain their stability. One hypothesis 
is the formation of a molecular complex at the oil-water interface which decreases the 
interfacial tension (El-Aasser et al., 1988). Another hypothesis is the formation of a 
viscous film at the oil-water interface which acts as a steric stress to aggregation (El-
Aasser et al., 1988). In addition, it is believed that the formation of aqueous crystals 
decreases the van der Waals attractive forces hence, support the stability of the 
nanoformulations. Finally, deterred diffusion of the oil phase to the aqueous phase 
maintains its stability (El-Aasser et al., 1988).  
Examples of drugs encapsulated using this technique are doxorubicin, 
coumarin, indocyanine, and cyclosporine (Nagavarma et al.,2012). Advantages of 
spontaneous emulsification are simplicity, reproducibility, ability of scaling-up, high 
EE%, and narrow size distribution (Nagavarma et al.,2012; Bouchemal et al.,2008). 
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However, a major drawback is the need to expel high volumes of water in which water-
soluble drugs might leak out and hence, decreases the EE% (Nagavarma et al.,2012). 
Quintanar-Guerrero et al.,(1998) studied the possibility of using spontaneous 
emulsification technique in fabrication of biodegradable nanocapsules. They used 
different polymers such as PLA, Eudragit E, and poly (ε-caprolactone). The 
nanocapsules formulation was confirmed by density gradient centrifugation, the 
presence of a unique density band, scanning electron microscopy (SEM) and atomic 
force microscope (AFM) images. Particle size range was 174-346 nm and were stable 
at least for a month. In a different study, PLGA nanospheres were produced using 
spontaneous emulsification technique encapsulating water soluble and insoluble agents, 
5-floruracil (5-FU) and indomethacin, respectively. Both nanospheres were 
successfully formulated using acetone as solvent, in contrast, dichloromethane and 
chloroform failed to produce particles in the submicron size. Particle size ranges were 
200-300 nm and 600-800 nm for 5-FU and indomethacin, respectively. The drugs were 
homogeneously dispersed in the PLGA. 5-FU was poorly encapsulated compared to 
indomethacin and release kinetics showed burst initial release for both drugs. However, 
the initial burst release was avoided in the case of indomethacin by increasing the 
molecular weight of PLGA. Indomethacin release was more sustained for up to 120 hr 
compared to 50 hr for 5-FU nanospheres (Niwa et al., 1993). 
1.4.3.1.4 Salting-out technique 
Salting-out technique, also called reverse-emulsification, is essentially a 
modification in the composition of the emulsion/solvent diffusion technique 
(Nagavarma et al.,2012; Vauthier & Bouchemal, 2009; Pinto Reis et al.,2006). It is 
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based on the separation of the water miscible solvent from the aqueous phase through 
the salting-out effect (Nagavarma et al.,2012). 
Basically, a salting-out agent is used in high concentrations to efficiently 
achieve their effect in the aqueous phase. The selection of the salting-out agent is 
critical as it plays a major role in the EE% (Nagavarma et al.,2012). Examples of 
salting-out agents are electrolytes such as aluminium chloride, calcium chloride, 
magnesium acetate, magnesium chloride, or non-electrolytes such as sucrose 
(Nagavarma et al.,2012; Pinto Reis et al.,2006; Vauthier & Bouchemal, 2009; Ibrahim 
et al.,1992; Allémann et al.,1992; Astete & Sabliov, 2006). Colloid stabilizers, such as 
polyvinylpyrrolidone (PVP) or hydroxyethylcellulose, are used to improve the stability 
of the formulated NPs (Nagavarma et al.,2012; Vauthier & Bouchemal, 2009; Pinto 
Reis et al.,2006). Examples of polymers used in this technique are PLA, PLGA, 
poly(methacrylic) acid, Eudragit E, and ethyl cellulose (EC) (Nagavarma et al.,2012; 
Pinto Reis et al.,2006; Astete & Sabliov, 2006; Allémann et al.,1992). The organic 
phase solvent should be miscible in water, such as acetone and THF (Vauthier & 
Bouchemal, 2009; Astete & Sabliov, 2006). This technique is used to encapsulate 
lipophilic drugs and they are usually dissolved in the organic phase (Vauthier & 
Bouchemal, 2009). 
After dissolving the drug in the organic phase, it is emulsified in an aqueous 
phase containing high concentrations of the salting-out agent and the colloidal stabilizer 
(Nagavarma et al.,2012). Subsequently, the oil in water emulsion is diluted with fast 
addition of excess amount of water until the diffusion of the solvent into the aqueous 
phase is fulfilled (Vauthier & Bouchemal, 2009). The diffusion will induce polymer 
precipitation in the form of NPs. Finally, the solvent and salting-out agent are expelled 
either by filtration or centrifugation (Astete & Sabliov, 2006; Ibrahim et al., 1992). 
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Salting-out technique is low time- and energy-consuming. The major drawback 
is the need for a purification step during the solvent and salting-out agent elimination 
process (Astete & Sabliov, 2006). 
Kumar et al.,(2004) fabricated PLGA NPs using the salting-out technique for 
DNA delivery. The NPs had particle size and zeta potential of 200 nm and 10 mV, 
respectively. The NPs successfully encapsulated DNA to be used in the DNA delivery. 
In another study, Zweers et al.,(2004) studied the degradation of polymeric NPs 
prepared using the salting-out technique. Three types of NPs were formulated, 
poly(DL-lactic acid) (PDLLA), PLGA, and poly(ethylene oxide)-PLGA diblock 
copolymer (PEO-PLGA). PEO-PLGA and PLGA NPs degraded within 8 and 10 weeks 
respectively, whereas PDLLA NPs retained their physico-chemical  properties for two 
years. 
1.4.3.2 Preparation methods from dispersion of monomers 
1.4.3.2.1 Emulsion polymerization 
Emulsion polymerization is one of the fastest NPs preparation techniques 
(Nagavarma et al.,2012). In the industry, this method is of high interest as it forms NPs 
with high concentration of the polymer and low viscosity (Manguian et al., 2006). This 
technique is subdivided into two categories according to the employment of surfactants: 
i) conventional and ii) surfactant-free emulsion polymerization (Rao & Geckeler, 
2011). While the former technique utilizes surfactants for NPs stabilization, the latter 
uses amphiphilic di-block copolymers. The latter is favoured as it is less toxic, time and 
cost saving, and manifests better electrosteric stabilization (Nagavarma et al.,2012; 
Manguian et al.,2006; Rao & Geckeler, 2011). 
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Essentially, the system comprises of monomers of low water solubility and 
water. The system might also include water soluble initiator and surfactant as well 
(Thickett & Gilbert, 2007; Rao & Geckeler, 2011). Colloidal stabilizers can be 
electrostatic, steric, or polymers (Thickett & Gilbert, 2007).  
Generally, this technique has to be processed in acidic conditions to linger the 
anionic polymerization rate and hence, formulate polymeric NPs instead of polymeric 
aggregations (Vauthier & Bouchemal, 2009). In the conventional technique, monomer 
is dispersed into an emulsion, whereas in the surfactant-free technique, the monomer is 
dissolved in an aqueous phase. Afterward, the polymerization is initiated either with an 
initiator molecule (ion or free radical) or by high-energy radiation (gamma radiator or 
UV light). Subsequently, chain growth occurs as the monomers collide with each other 
according to the anionic polymeric mechanism (Nagavarma et al.,2012; Thickett & 
Gilbert, 2007). Eventually, 100 nm particles containing many polymers are collected 
by centrifugation (Mohanraj et al.,2006; Rao & Geckeler, 2011). Drug is either 
dissolved in the polymeric medium or adsorbed onto formed NPs after polymerization 
(Mohanraj et al.,2006). 
Examples of monomers used are styrene, butyl acrylate/ styrene, and methyl 
methacrylate (Rao & Geckeler, 2011). 
This technique has been used for the production of a variety of special polymers 
such as adhesives, binders, construction materials, diagnostic tests, and drug delivery 
systems (Asua, 2004). 
The advantages of this technique include the possibility of producing polymers 
with special properties and environmentally friendly since water is used as the 
dispersion medium (Asua, 2004; Thickett & Gilbert, 2007). However, efficient 
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production requires accurate online control and delicate understanding of the 
polymerization process, difficulty in preparing monodispersed and controlled particle 
size batches. Furthermore, efficient methods are required for residual monomers and 
surfactants discarding (Thickett & Gilbert, 2007; Asua, 2004; Rao & Geckeler, 2011). 
1.4.3.2.2 Interfacial Polymerization 
Interfacial polymerization is one of the well-established methods for polymeric 
NPs preparations (Nagavarma et al.,2012; Rao & Geckeler, 2011). It is considered a 
low-energy emulsification method (Vauthier & Bouchemal, 2009). 
Both positively and negatively charged surfactants can be used either in the 
aqueous or organic phase (Dallas et al., 2007). Lipophilic drugs are encapsulated with 
high EE% using interfacial polymerization such as calcitonin, darodipine, octreotide, 
and insulin (Vauthier & Bouchemal, 2009; Pinto Reis et al.,2006). Physico-chemical 
characterization of the formulated polymers depends on the reaction conditions (Dallas 
et al., 2007). Fabricated NPs using this technique have hollow polymer morphology 
(Rao & Geckeler, 2011). 
Advantages of this technique are reproducibility, high loading efficiencies, the 
ability to increase NPs concentration at final stages of the process, in situ formation of 
the polymers, narrow size distribution, and homogeneous dispersions (Dallas et al., 
2007; Fessi et al., 1989). However, drawbacks of this technique include the need to use 
organic solvents and tedium (Reis et al., 2006). 
Kuo & Wen, (2008) used interfacial polymerization technique for polyaniline 
o/w NPs formation from aniline monomers. Monodispersed spherical particles with a 
size range of 5-15 nm were produced. 
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1.4.3.3 Ionic Gelation 
Ionic gelation technique, also called ionotropic gelation or coacervation, is one 
of the few organic solvent-free techniques used in polymeric nanoparticle fabrication 
as its processed in entirely aqueous media (Nagavarma et al., 2012). In this technique, 
polymeric NPs are fabricated using biodegradable hydrophilic polymers based on 
electrostatic interactions between oppositely charged polymer moieties with the cross-
linking agent to form hydrogels (Mohanraj et al., 2006; Patil et al., 2010). 
Ionic gelation technique includes the drop-wise addition of two dilute aqueous 
phases, the polymer and the cross-linking agent (Nagavarma et al., 2012; de Pinho 
Neves et al., 2014). Inter- and intra- electrostatic linkages created between the 
oppositely charged groups form spherical coacervates in the submicron size range (Patil 
et al., 2010). Eventually, the liquid transforms into hydrogel beads comprising of NPs 
(Fan et al., 2012). 
Physico-chemical characteristics of the NPs varies according to the polymer and 
cross-linking agent concentrations, as well as the ionic gelation conditions (Vauthier & 
Bouchemal, 2009). Alginate, carboxymethylcellulose (CBMC), CS, and gellan gum are 
examples of polymers used in this technique (Patil et al., 2010). 
Ionic gelation technique possesses a long list of advantages such as the 
spontaneity in formation of NPs under mild conditions, non-toxicity, low-cost, non-
requirement of organic solvents, simplicity, convenience, speed, and amenability (de 
Pinho Neves et al., 2014; Fan et al., 2012). On the other hand, NPs formed are of poor 
mechanical strength, which limits their applications in drug delivery (Agnihotri et al., 
2004). 
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Ionic gelation technique has been widely applied in the formulation of NPs for 
the delivery of insulin (Avadi et al., 2010; Sadeghi et al., 2008), proteins (Calvo & 
Remunan-Lopez, 1997), DNA and RNA (Katas & Alpar, 2006), cyclodextrin (Sajeesh 
& Sharma, 2006), and CUR (Chuah et al., 2011).  
1.4.4 Nanomedicine in clinical practice 
Worldwide, over 207 companies have devoted their business share towards 
nanomedicine activities. In fact, amongst the variety of drug delivery systems, 
nanomedicine accounts for more than 70% of the market share (Wang et al., 2012). 
Despite the various challenges in nanomedicine, few first generation formulations have 
shed lights to the market. The most widely used nanotechnology products is colloidal 
gold in vitro diagnosis, which is used as a rapid test kit for HIV, ovulation, and 
pregnancy test (Wagner et al., 2006). Nanomedicine for cancer diagnosis, imaging, and 
treatment has gained intense interest. Some products are already in use while others are 
showing promising outcomes in clinical studies (Shi et al., 2016). 
Tables 1.4 and 1.5 represent examples of nanomedicine products on the market 
and in clinical development, respectively (Kalepu & Nekkanti, 2015; Kudo et al., 2016; 
Shi et al., 2016; Von Hoff et al., 2016; Wagner etr al., 2016; Wang et al., 2012; Zhao 
et al., 2017) 
Table 1.4 Selected nanomedicine products available in market 
Drug Name Composition Indication Type of 
nanomedicine 
Manufacturer’s 
name, county 
Abelcet Amphotericin B Fungal 
infections 
Liposomes Enzon, USA 
Abraxane Paclitaxel Cancer Polymeric NPs Celgene, USA 
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Ambisome Amphotericin B Fungal 
infections 
Liposomes Gilead, USA. 
Fujisawa, Japan 
Amphotec Amphotericin B Fungal 
infections 
Liposomes InterMune, USA 
DaunoXome Daunorubicin Kaposi 
sarcoma 
Liposomes Gilead, Japan 
Doxil Doxorubicin Kaposi 
sarcoma 
Liposomes Ortho Biotech, 
USA. 
Depocyt Cytarabine Cancer Liposomes SkyePharma, 
London 
Epaxal 
Berna 
Hepatitis vaccine Hepatitis A Polymeric NPs Berna Biotech, 
Switzerland 
Feridex Iron oxide NPs 
coated with 
dextran 
Liver/ spleen 
lesion imaging 
Polymeric NPs Berlex, USA 
Genexol-
PM 
Paclitaxil Breast cancer Micelles Samyang, Korea 
Inflexal 
Berna 
Virosomal 
influenza 
vaccine 
Influenza Liposomes Berna Biotech, 
Switzerland 
Marqibo Vincristine 
sulphate 
Post-
gemcitabine 
metastatic 
pancreatic 
cancer 
Liposomes Talon 
therapeutics, 
USA 
Myocet Doxorubicin Breast cancer Liposomes Zeneus pharma, 
UK 
Oncaspar PEGylated 
asparaginase 
Acute 
lymphoblastic 
leukemia 
Polymeric NPs Enzon, USA 
Onivyde Irinotecan Pancreatic 
cancer 
Liposomes Baxalta 
innovations, 
Austria 
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Resovist Iron oxide NPs 
coated with 
dextran 
Liver/ spleen 
lesion imaging 
Polymeric NPs Bayer Schering 
Pharma, 
Germany 
SMANCS Neocarzinostatin Liver and 
renal cancer 
Nanoconjugates Pola pharma, 
Korea 
Panzem 
NCD 
2-
methoxyestradiol 
Gliblastoma Nanocrystals CASI 
pharmaceuticals, 
USA 
Table 1.5 Selected nanomedicine products in clinical development 
Drug Name Composition Indication Type of 
nanomedicine 
Status 
AI-850 Paclitaxel Solid tumours Polymeric 
NPs 
Phase I 
ALN-VSP siRNA Liver cancer Liposomes Phase I 
ABI-009 Rapamycin malignant 
PEComa 
Albumin NPs Phase II 
AuroLase Gold coated 
silica NPs 
Head and neck 
cancer 
Liposomes Phase I 
BIND-014 Docetaxel Prostate 
cancer  
Polymeric 
NPs 
Phase II 
BioVant Calcium 
phosphate 
Vaccine 
adjuvant 
Calcium 
phosphate 
NPs 
Phase I 
CALAA-01 siRNA Cancer Polymeric 
NPs 
Phase I 
NC-6004 Cisplatin Cancer  Phase III 
MBP-426 Oxalipatin Solid tomours Liposomes Phase I 
MM-302 Doxorubicin Breast cancer Liposomes Phase II/III 
NK-012 SN-38 Cancer  Phase II 
NK-105 Paclitaxel Cancer Polymeric 
micelle 
Phase III 
NPI 32101 Silver NPs  Atopic 
dermatitis 
NPs Phase II 
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Paliperidone 
palmitate 
Paliperidone 
palmitate 
Schizophrenia Nanocrystals Phase IV 
ThermoDox Doxorubicin Hepatocellular 
carcinoma 
Liposomes Phase III 
1.4.5 Nanoformulations of CUR 
CUR has been shown to possess promising therapeutic activities against a 
plethora of health conditions. Moreover, CUR has gained special interest due its low 
toxicity even at high therapeutic concentrations. Particularly, CUR is the subject of 
extensive interest as a chemopreventive and chemotherapeutic agent (Yallapu et al., 
2010). However, its therapeutic effectiveness is restrained due to its low oral 
bioavailability, poor pharmacokinetics, poor aqueous solubility, extensive intestinal 
and hepatic metabolism, and rapid elimination (Cheng et al., 2013; Shaikh et al., 2009; 
Yallapu et al., 2010; Yen et al., 2010). 
To overcome these limitations and to enhance its therapeutic effects, research 
has been devoted toward encapsulating CUR in various delivery systems such as 
liposomes, SLN, micelles, and polymeric NPs (Gupta et al., 2009; Yallapu et al., 2010; 
Yen et al., 2010). Moreover, CUR nanoformulations are known to prolong the 
circulation time in the body, manifest sustained release, allow targeted delivery, and 
help to linger its half-life (Cheng et al., 2013). 
Yallapu et al.,(2010) fabricated CUR-PLGA NPs conjugated with monoclonal 
antibodies specific for cisplatin-resistant ovarian cancer treatment. Steady and 
prolonged release of CUR was achieved. Pre-treatment with CUR enhanced the in vitro 
sensitivity on ovarian cancer cells toward cisplatin. Therefore, decreased dose of 
cisplatin and radiation was required for ovarian cancer treatment. In another study, 
Gupta et al.,(2009) encapsulated CUR in silk fibroin and CS NPs for cancer treatment. 
65 
 
In vitro studies demonstrated enhanced cellular uptake and efficiency of CUR against 
MCF-7 and MDA-MB-453 breast cancer cells for eight days. However, a slight loss of 
CUR occurred during the NPs preparation process. Kim et al.,(2011) aimed to enhance 
the water solubility and bioavailability of CUR by encapsulating it in albumin NPs. It 
was believed that this would improve its anticancer activity. Fabricated NPs were in the 
size range of 130-150 nm. Water solubility was enhanced by 300-folds compared to 
pure CUR. Moreover, on-shelf stability was enhanced and hence, its biological 
effectiveness was not affected. The biological distribution was enhanced and 
elimination rates were reduced in mice administered with CUR NPs compared to pure 
CUR. In terms of its anticancer activity, in vivo studies demonstrated that tumour 
growth was significantly suppressed in CUR NPs administered mice compared to those 
received pure CUR.  
Table 1.6 and Table 1.7 summarize available CUR nanoformulations on market 
(Yallapu et al., 2012) and CUR nanoformulations under clinical development (Conlan 
et al., 2017; Kocher et al., 2015; Schiborr et al., 2014; Storka et al., 2015; Yallapu et 
al., 2015), respectively. 
Table 1.6 List of CUR nanoformulations available on market 
Trade name Ingredients, formulation Manufacturer’s name 
and country 
Curcumin C3 
complex®vegetarian 
capsules 
Curcumin C3 complex, 
curcuminoids and piper 
nigrum fruit extract. 
BesVite Inc, USA. 
CurcuPlus D UltraTM  CUR, ascorbyl palmitate, 
microcrystalline 
cellulose, maltodextrin, 
silicon dioxide, soy 
lecithin, and stearic acid 
Advanced 
Orthomolecular research 
Inc., Canada 
Enhansa A special CUR 
compound 
Lee sislby compounding 
pharmacy, USA. 
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Liposomal CUR CUR, lecithin, and 
potassium sorbate. 
Liposomes 
NanoLiposomal 
Nutritionals, USA. 
NanoBioSphereTM CUR, vitamin E, 
sunflower oil, and 
additives. SLN 
Life enhancement 
products, USA. 
N-curcusorb CUR NPs Konark herbals and health 
care, India. 
Nanocurcuma CUR in nanocolloids Nano Tech Miso-N, 
Korea 
Nutrivene LongvidaTM CUR and soy lecithin, 
NPs 
International nutrition, 
USA. 
 
Table 1.7 CUR nanoformulations under clinical development 
Study title Therapeutic 
indication 
Status NCT or Ref. 
Phase I Clinical trial 
investigating the ability of 
plant exosome to deliver 
curcumin to normal and 
malignant colon tissues 
Colon cancer Phase I NCT 01294072 
The oral bioavailability of 
curcuminoids in healthy 
humans is markedly 
enhanced by miceller 
solubilisation but not 
further improved by 
simultaneous ingestion of 
sesamin, ferolic acid, 
naringenin and 
xanthohumol. 
Prevention and 
treatment of 
inflammatory 
diseases 
Phase 0 NCT 01982734 
The oral bioavailability of 
curcumin from micronized 
powder and liquid micelles 
is significantly increased in 
healthy humans and differs 
between sexes. 
Bioavailability 
and toxicity 
studies 
Phase 0 NCT 01925287 
Safety, tolerability and 
pharmacokinetics of 
liposomal curcumin 
(LipocurcTM) in healthy 
humans 
Bioavailability 
and toxicity 
studies 
Phase I NCT 01403545 
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1.5 Drug Delivery to the colon 
Targeted drug delivery to the colon is gaining increased interest not only for 
local disease treatment such as irritable bowel syndrome, IBD, ulcerative colitis, and 
colon cancer (Jain et al., 2007; Yang et al., 2002) but for systemic absorption for drugs 
which are unabsorbed or unstable in the upper GIT as well (Abraham Rubenstein, 1990; 
Sinha & Kumria, 2003). Advantages of using the colon as target site for drug absorption 
in spite of the fact that it is not suited for absorption is that dosage forms have longer 
transit times, there is reduced digestive enzymatic activity, and higher response to 
absorption enhancers in formulation compared to the upper GIT (Jain et al., 2007; Sinha 
& Kumria, 2003). Moreover, targeting drugs to the colon for localised treatment 
reduces the required dose for systemic absorption for the same treatment and thus, side 
effects is reduced (Abraham Rubenstein, 1990; Sinha & Kumria, 2003). Unfortunately, 
successful delivery of drugs to the colon without premature drug release or degradation 
in the upper GIT is challenging (Sinha & Kumria, 2003). 
1.5.1 Strategies for targeted colonic therapy 
The colon is located at the distal part of the GIT and therefore, drug delivery 
systems targeting the colon should protect the cargo from being released in the stomach 
or small intestine. Yet, the delivery system should have the functionality of sensing 
arrival to the colon based on the different anatomical and physiological characteristics 
peculiar to the colon. The sensing should be the basis of trigger of cargo release. In the 
next sections, I shall discuss some of the pharmaceutical strategies designed for the 
development of colon-targeted therapy. 
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1.5.1.1 Pro-drugs 
The term “pro-drug” refers to a pharmaceutical inactive derivative of a drug 
linked to a carrier where cleavage of the prodrug brought about either spontaneously or 
enzymatically leads to drug release (Chourasia & Jain, 2003; Sinha & Kumria, 2003). 
The triggering mechanism for the drug release depends on the type of the linkage 
(Chourasia & Jain, 2003). 
Typical examples of pro-drugs relevant to colonic delivery are the azo-linkages 
in balsalazine, ipsalazine, sulfasalazine, and olsalazine that bears 5-amino salicylic acid 
(5-ASA) for the treatment of IBD (Abraham Rubenstein, 1990; Chourasia & Jain, 2003; 
Rubinstein, 2005). Amino acids with –COOH and –NH2 functionality may be 
conjugated with drugs where the linkage is hydrolysed by colonic microflora (Sinha & 
Kumria, 2003). Sugar conjugates such as cellobiose, galactose, and glucose are further 
examples of prodrugs that may be hydrolysed enzymatically by the colonic microflora 
such as glycosidase and glucuronidase (Sinha & Kumria, 2003; Yang et al.,2002). The 
major drawback in this approach is the need to re-evaluate the pro-drug formulation 
since it is regulatory considered a new chemical substance (Sinha & Kumria, 2003; 
Yang et al., 2002). 
1.5.1.2 pH-dependent systems 
The pH-dependent systems are based on the peculiar pH values of the colon (pH 
6-8) compared to the stomach and small intestine (pH 1-2 and pH 6-7, respectively). In 
such systems, the formulation is coated with polymers that withstand the acidity and 
neutral pH conditions of the upper GIT. However, the polymers may ionize, swell or 
disintegrate in the colon due to the pH and thus release the drug (Chourasia & Jain, 
2003; Rubinstein, 2005). Examples of such polymers are the Eudragit® products. 
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Particularly, Eudragit® L and Eudragit®S (Chourasia & Jain, 2003). In addition to 
cellulose acetaphthalate (Rubinstein, 2005). The disadvantages of this approach are the 
close pH values of the small and large intestine, variance of pH values in some health 
conditions, and inter-/ intra subjects variations (Yang et al., 2002). 
1.5.1.3 Time- dependent systems 
The concept of time-dependent systems in colon drug delivery is delaying drug 
release until the formulation arrives the colon. The formulation should withstand the 
acidic conditions of the stomach and undergoes lag time, which is the time required to 
transit from the mouth to the colon (Yang et al., 2002; Chourasia & Jain, 2003). In these 
systems, the drug is coated with a swellable hydrophilic polymer, which resists the 
acidic conditions in the stomach, swells in the pH medium of the colon and thus, 
releases the drug. The delayed time of release depends on the physico-chemical 
properties and concentration of the polymer (Sangalli et al., 2001). 
The first formulation fabricated based on this system was Pulsincap®. The main 
body is made of hydrogel plug coated with hydrophobic materials that is covered with 
hydrophilic cap. To protect the whole body from the acidic conditions, it is covered 
with an enteric polymer which dissolves in the small intestine, the concentration of the 
hydrogel plug determines the time required for the contents to be released (Chourasia 
& Jain, 2003). 
Hydroxyl propyl methyl cellulose has been used to deliver pseudo ephedrine 
HCl and diltiazem HCl using this strategy (Roy & Shahiwala, 2009). 
The disadvantages of this principle are the variable gastric time emptying, 
unpredictable gastrointestinal motility and its effect on GI transit of the drug, and 
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variability in gastric transit properties in certain health conditions such as IBD, 
diarrhoea, and ulcerative colitis (Philip & Philip, 2010). 
1.5.1.4 Microbially- triggered systems 
The disadvantages of the previously mentioned systems such as pH inter- and 
intra- variability, gastrointestinal transit time variability, and pre-mature drug release 
make these systems unideal for colon drug delivery (Sinha & Kumria, 2003). Therefore, 
researchers have proposed newer approaches to specifically deliver drugs to the colon 
based on microbial trigger (Sinha & Kumria, 2003). The concept utilizes the fact that 
the normal flora of the colon release enzymes specifically there that are capable of 
hydrolysing certain linkages such as the azo and saccharides linkages (Chourasia & 
Jain, 2003; Philip & Philip, 2010; Rubinstein, 2005). The polymers are capable of 
protecting the drug from the pH conditions of the upper GIT. Moreover, specifically 
deliver drugs to the colon (Philip & Philip, 2010). The vast majority of research on 
these systems have been devoted towards using natural polysaccharides. The 
advantages of using them are their availability, reasonable prices, flexibility, and safety 
in use. They can be obtained from natural sources, examples including, pectin (PEC), 
inulin, and guar gum, animals like chondroitin sulphate and CS, or microbial origin 
such as dextran (Philip & Philip, 2010). For example, CS has been used as enteric-
coated capsule to deliver 5-(6)-carboxy fluorescein, CS succinate and PEC for 
diclofenac sodium and Idomethacin delivery, respectively (Philip & Philip, 2010). 
Limitations of this system are the premature drug release in the upper GIT due 
to the swelling of the carrier and the microbial variety among populations (Rubinstein, 
2005). 
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1.5.2 Mucoadhesion 
Mucoadhesion has been employed in delivery systems as an attractive 
incorporation in pharmaceutical formulations where the GI residence time of dosage 
forms can be prolonged significantly (Boddupalli et al., 2010; Carvalho et al.,2010; 
Khutoryanskiy, 2011; Shaikh et al., 2011). The first therapeutic application of this 
concept was Orabase® in which gum tragacanth was mixed with dental adhesive to 
deliver penicillin to the oral mucosa (Khutoryanskiy, 2011). Recent statistics show an 
expanding interest in employing mucoadhesion of drug delivery sector (Andrews et al., 
2009; Khutoryanskiy, 2011). 
Mucoadhesive formulations should be adhesive, small, flexible, have high drug 
loading efficiency, and have controlled drug release properties (Boddupalli et al., 
2010). Mucoadhesive drug delivery systems can be formulated as lozenges, tablets, 
films, gels, and solid micro- and nano- particulate systems (Carvalho et al., 2010; 
Khutoryanskiy, 2011) and they may be administered by ocular, nasal, buccal, gingival, 
gastrointestinal, vaginal, and rectal (Boddupalli et al., 2010; Khutoryanskiy, 2011).  
The advantages of mucoadhesive drug delivery over conventional methods are 
their prolonged residence time that may be used to achieve superior bioavailability of 
cargoes (Andrews et al., 2009; Boddupalli et al., 2010; Khutoryanskiy, 2011; Shaikh 
et al., 2011). 
1.5.2.1 Polymers used in mucoadhesion 
Several factors dictate choice of polymer to achieve mucoadhesive properties, 
including type of functional groups, molecular weight, chain length, conformation, 
degree of hydration, pH, charge, concentration, cross-linking density, and flexibility 
(Andrews et al., 2009; Salamat-Miller et al., 2005). For good mucoadhesive properties, 
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polymers should have certain structural characteristics including strong hydrogen-
bonding groups, strong cationic or anionic charges, high molecular weight, adequate 
chain flexibility, surface energy properties favouring dissemination onto mucous 
(Khutoryanskiy, 2011; Lehr et al., 1992). 
Generally, adhesive polymers are mainly classified into three major categories: 
Synthetic and natural, water soluble and water insoluble, and charged and uncharged 
polymers (Roy et al., 2009). 
1.5.2.1.1 Anionic polymers 
Anionic polymers are the most commonly used mucoadhesive polymers in 
pharmaceutical formulations because of their high mucoadhesive properties and low 
toxicity (Andrews et al., 2009). Typical examples are carboxymethylcellulose 
(CBMC), PAA, poly carbophil, poly(methacrylic acid), PEC, sodium alginate, and 
Xanthan gum (Grabovac et al., 2005; Khutoryanskiy, 2011; Park & Robinson, 1984). 
The strongest mucoadhesive functionality of anionic polymers is observed under acidic 
conditions (Khutoryanskiy, 2011). Amongst the anionic polymers, carbopol, has the 
highest molecular weight and degree of cross-linking, and showed the longest period 
of mucoadhesion (Grabovac et al., 2005). 
Mucin and anionic polymers have several structural similarities including 
negative charge and the presence of network of macromolecules, highly hydrated, form 
expanded networks, and have several carboxyl groups (Andrews et al., 2009). These 
similarities are believed to be the source of the mucoadhesive interactions with anionic 
polymers which leads to four possible mechanisms: i) strong hydrogen-bonding 
between the carboxylic groups and oligosaccharide chains of the anionic polymers and 
mucin, respectively ii) electrostatic interactions iii) hydrophobic interaction, and iv) 
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inter-diffusion of the expanded networks (Andrews et al., 2009; Bernkop-Schnürch, 
2005; Khutoryanskiy, 2011; Leung & Robinson, 1988). In the present work, PEC was 
used as the anionic component of the composite and a detailed discussion of its physico-
chemical properties that are of relevance to the work is discussed in chapter 2. 
1.5.2.1.2 Cationic polymers 
Although anionic polymers show good mucoadhesive properties, they are 
unable of forming mucoadhesive hydrogels. In contrast, cationic polymers have good 
mucoadhesive properties and are capable of forming them (Lehr et al., 1992). 
Mucoadhesive properties of cationic polymers have been extensively studied and used 
in pharmaceutical formulation for mucoadhesive drug delivery (Khutoryanskiy, 2011). 
Examples of such polymers are CS, dimethylaminoethyldextran, aminodextran, 
polylysine, and polybrene (Khutoryanskiy, 2011; Lehr et al., 1992; Park & Robinson, 
1984). Amongst them, CS has been extensively used due to its good biocompatibility, 
biodegradability, and low toxicity (Roy et al., 2009). 
The main mechanism of mucoadhesion is by electrostatic interaction between 
the positive functional groups, and the sialic acid and sulphonic acid substructures of 
the cationic polymer and mucin, respectively (Farokhzad & Langer, 2006). However, 
it is believed that other interactions such as hydrogen-bonding and hydrophobic effects 
also play role in the mucoadhesion functionality of the cationic polymers (Andrews et 
al., 2009; Roy et al., 2009). The degree of contribution of each interaction vary 
according to the solution pH and the presence of other chemicals (Khutoryanskiy, 2011; 
Roy et al., 2009; Smart, 2005). In the present work, CS was used as the cationic 
component of the composite and a detailed discussion of its physico-chemical 
properties that are of relevance to the work is discussed in chapter 2.  
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1.6 Aims and objectives of the present research 
1.6.1 Aims 
The therapeutic efficacy of CUR as an anticancer agent has been widely 
acclaimed. The major drawback for use of CUR in colorectal cancer treatment is its low 
oral bioavailability. In this work, we believe that by encapsulating CUR in 
nanoparticulate delivery system that possess mucoadhesive propensity and capable of 
resisting the degradative effects of the upper GIT, we might be able to deliver 
therapeutic levels of CUR to the colon. We recognize the significance of protecting 
CUR from the onslaught of enzymatic or milieu effects of the upper GIT to act locally 
on tumours. We also recognise that the delivery system should ideally have a wide 
surface coverage to be effective against possible recurrence, especially if malignant. 
Therefore, the overarching objective of the present work was to develop a 
nanoparticulate delivery system with CUR as cargo since these have the largest surface 
area to volume ratio of all dosage forms. The NPs must meet desired physico-chemical 
characteristics and so a significant amount of work was dedicated to in vitro studies. 
Further studies were carried in vivo using animal models in order to test the proof of 
concept. 
1.6.2 Objectives 
 In chapter 2, we shall discuss the effects of formulation and processing 
variables on the physico-chemical properties of the NPs with a view to 
producing particles that demonstrate the lowest z-average, pDI, and 
highest surface charge. 
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 In chapter 3, we shall examine the mucoadhesive properties of the CUR-
CS-PEC-NPs and the release profiles of CUR as a function of several 
physiological constraints. 
 Chapter 4 entails studies on the anti-proliferative effects of the NPs 
CUR-CS-PEC-NPs and investigation of cellular uptake of the NPs by 
the cells.  
 The final chapter (chapter 5) shall examine the proof of the above 
concepts in in vivo settings through bioavailability assessment and other 
physiological studies. 
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Chapter 2 
Formulation of 
Curcumin Chitosan 
Pectinate 
Nanoparticles 
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2 Formulation of curcumin chitosan pectinate nanoparticles 
2.1 Introduction 
2.1.1 Polymer of choice 1: Chitosan 
With regard to oral drug delivery, NPs present several advantages including 
protecting drug from degradation, enhanced cellular uptake by endocytosis (Bowman 
& Leong, 2006; Mohanraj et al., 2006) controlled and sustained drug release, site-
specific targeting and amenability to various other applications (Gelperina et al., 2005). 
NPs can be fabricated to adsorb on tissues and organs (Gelperina et al., 2005; Kayser 
et al., 2005; des Rieux et al., 2006). Moreover, the tiny size dimension means that they 
possess the highest surface to volume ratio of any other type of delivery system. CS is 
biodegradable and biocompatible so it is safe to use on biological systems. Its physical 
properties may be modulated at relevant pH for various applications (George & 
Abraham, 2006; Vaghani et al., 2012). Thus, it has been widely used in the food 
industry as an additive (Lorenzo-Lamosa et al., 1998), in  medicine for  wound healing 
(Skaugrud et al., 1999), in the pharma industry as a pharmaceutical excipient (Dodane 
& Vilivalam, 1998; Singla & Chawla, 2001), and as a permeation enhancer (Bowman 
& Leong 2006; des Rieux et al. 2006). Moreover, CS has mucoadhesive properties and 
recent research have been devoted towards studying its potential as DNA, gene, 
vaccines, protein, peptides carrier, and drug targeted delivery systems (Agnihotri et al. 
2004; Bowman & Leong, 2006; Bayat et al. 2008; Dodane & Vilivalam, 1998; Singla 
& Chawla, 2001). With regard to the present work, we recognise that the major 
limitation  in using CS for colon drug delivery is its rapid dissolution in gastric pH 
(George & Abraham, 2006; Lorenzo-Lamosa et al., 1998). Therefore, some forms of 
formulation intervention must be taken into account if a viable colon-targeted CS 
nanoparticulate system is to be realised. 
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There are a number of CS-nanoparticle dosage forms currently under study. Qi 
et al.(2004) prepared CS NPs encapsulating copper for antibacterial activity. The 
antibacterial activity was studied against several microorganisms where antibacterial 
activity was correlated with adherence of the bacteria to the surface of the NPs. Mitra 
et al. (2001) fabricated dextran-doxorubicin conjugate CS NPs in order to decrease the 
toxicity of doxorubicin. The NPs were prepared using the microemulsion method, 
which produced monodispersed NPs of 100 ± 10 nm diameters. The drug-conjugate 
encapsulated in CS NPs was successfully delivered to the tumour site with extended 
circulation and accumulation time. The mean tumour volume was the lowest in drug-
conjugate CS NPs compared to pure drug-conjugate and crude CS NPs after 90 days of 
treatment. He et al. (2017) formulated CS-Sodium tripolyphosphate (TPP) NPs using 
the ionic gelation method as a carrier for insulin. The NPs had high EE% and released 
insulin in a pH-dependent manner. In another study, Gan et al. (2005) used the ionic 
gelation method to produce CS-TPP NPs intended for gene and protein delivery  with 
a size range of 100-250 nm. Moreover, they found that low molecular weight CS 
produced smaller sized NPs compared to the medium and high molecular weight CS.  
2.1.2 Polymer of choice 2: Pectin 
PEC is a heterogeneous polysaccharide and  is the major component of the cell 
wall of most plants (Ashford et al., 1993; Munjeri et al., 1997). It is made up of 
polygalacturonic acid esterified with methoxy groups via α(1-4)glycosidic linkages 
(Malviya & Kulkarni, 2012; Liu et al. 2006). It may be classified broadly into two major 
groups based on the degree of esterification (Liu et al. 2006). Commercially, PEC is 
extracted from apple pomace and citrus peels (Sriamornsak, 2003; Willats et al., 2006), 
and is produced as a white to light brown powder (Sriamornsak, 2003). It is non-toxic 
and  therefore has been safely used in food industries for many years as a gelling and 
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thickening agent in dairy products (Liu et al., 2006) as a thickener  (Malviya & 
Kulkarni, 2012) and a colloidal stabilizer (Sriamornsak, 2003). In pharmaceutical 
industry, PEC has been used to lower blood cholesterol and glucose concentration, anti-
diarrhoeal agent, and in weight control management (Sriamornsak, 2003; Willats et al., 
2006).  
At low pH, PEC is insoluble and its molecules tend to shrink due to the decrease 
in the carboxylic groups repulsion forces (Awasthi, 2011; Liua et al., 2003; 
Sriamornsak, 2003). Moreover, PEC resists degradation by gastric and intestinal 
enzymes whilst completely degrades by enzymes from  colonic flora (Awasthi, 2011; 
Sriamornsak, 2003). Therefore, PEC possesses requisite properties relevant to the 
present investigation. In fact, this polymer has been extensively studied as a potential 
carrier for targeted colon delivery (Munjeri et al., 1997; Liua et al., 2003; Cui et al., 
2009). However, PEC is soluble in the pH range of the small intestine (pH 6-7), 
resulting in the swelling of delivery systems and premature release of cargo. To 
overcome this obstacle, it is recommended that PEC be used in combination with other 
polymers such as CS, alginate, and Eudragit to form more stable matrices (Liu et al., 
2006; Awasthi, 2011; Semdé et al., 2000). 
Jung et al. (2013) successfully formulated PEC hydrogel beads for colon drug 
delivery with relatively high encapsulation efficiencies and restrained drug release at 
acidic pH, yet significant release at colonic conditions. Therefore, it is sensible to 
consider a composite formulation of PEC and CS to address the requirement of a 
restrained release of cargo in the upper GIT but yield significant release at colonic 
conditions. 
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Composite microparticles based on CS, alginate, and PEC have been produced 
for oral delivery of proteins with a pH-dependent drug release functionality. Drug 
release was significantly higher at higher pH compared to lower pH medium.  
Additionally, drug release was highest  in media of high pH  with colonic enzymes (Yu 
et al., 2009). 
In the present investigation, we wished to fabricate orally administered CUR-
containing NPs that may retain the drug load in the stomach and small intestine and 
only release in the colonic conditions with attendant mucoadhesive functionality. In 
this regard, PEC protects the composite formulation from the pH within the upper GIT. 
Furthermore, degradation of both PEC and CS materialises at the colon, which favours 
release of CUR (Liu et al., 2006; Semdé et al., 2000). 
2.1.3 Sodium tripolyphosphate (TPP) as the cross-linking agent 
Ionic gelation technique was chosen in this study because it is a nontoxic 
procedure and that the use of organic solvents was kept to a minimum. There are a 
variety of other crosslinking agents  including gum arabic, glutaraldehyde, and genipin 
(Shu & Zhu, 2002). However, chemically-induced cross-linking agents such those 
imposed by glutaraldehyde and genipin may alter the physico-chemical  properties of 
CS in resultant formulations, in addition to toxicity and other undesirable concerns (Mi 
et al., 2003; Shu & Zhu, 2002). Furthermore,  gum arabic  interaction with polycationic 
polymers such as CS results in formulations with  low encapsulation efficiencies (Avadi 
et al., 2010). On the other hand, TPP is non-toxic, simple to use (Rodrigues et al. 2012; 
Fan et al. 2012) and relatively inexpensive (Shu & Zhu, 2002). Technically, it has quick 
gelling property and crucially, has been extensively and successfully used as the cross-
linking agent in CS-based NPs (de Pinho Neves et al., 2014; Mi et al., 2003). de Pinho 
81 
 
Neves et al. (2014) formulated CS-TPP (CS-TPP) NPs and in such instances, the 
formation of the NPs is through  ionic interaction between the positively charged amino 
groups of CS (-NH3
+) and the negatively charged tripolyphosphate groups of TPP 
(P3O5
-) which forms inter- and intramolecular cross linkages with CS (Fan et al. 2012).  
2.1.4 Particle size and zeta potential 
Particle size and zeta potential are two essential physical parameters used in 
predicting the stability and functionality of NPs  (Shekunov et al., 2007). The most 
commonly used method for particle size measurement is the Dynamic Light Scattering 
(DLS), also called photon correlation spectroscopy (PCS) and quasi-elastic light 
scattering (Shekunov et al., 2007). As illustrated in Figure 2.1, a laser beam (A) is 
fluctuated according to the NPs Brownian motion (B). Afterward, the detected 
fluctuations (C) are converted to a size dispersion using Stokes-Einstein equation. In 
this technique, cost and  time are an added advantage and values recorded indicate 
absolute measurement without the need for further information (Bootz et al., 2004; Hoo 
et al., 2008; Shekunov et al., 2007). 
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Figure 2.1 Schematic diagram of a typical DLS technique (Adopted and 
modified from www.sustainable-nano.com) 
 The zeta potential gives an indication of the surface charge on the NPs and can 
be correlated to the stability of the dispersion  (Xu, 2008). It can be measured using a 
laser Doppler micro-electrophoresis method in which an electric field is applied to a 
nanoparticle dispersion moving with a velocity related to their zeta potential (Clogston 
& Patri, 2011). The velocity is measured based on the light scattering effects and 
converted to zeta potential using the Henry equation. Advantages of this method are 
accuracy, sensitivity, versatility, and  values are not affected by the liquid motion 
(Clogston & Patri, 2011; Xu, 2008). 
In this study, we aim to study the particle size and zeta potential of particles 
produced as these play essential roles in the effective delivery of the NPs to the 
colorectal tumour cells. For instance, smaller particle size, particularly <500 nm, are 
required for enhanced adhesion and cellular uptake into the colorectal tumour cells 
(Jung et al., 2000; Yin et al., 2005). 
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2.1.5 Scanning Electron Microscopy 
Scanning electron microscopy (Figure 2.2) was introduced by M. Von Adrenne 
in 1938. However, it was subsequently developed until first commercialized in 1965 
(McMullan, 1995; Reichelt, 2007). Compared to light microscopes, SEM provides 
much higher magnification and resolution, up to 150,000x and 10 nm, respectively 
therefore, allowing to distinctly visualise nano-sized objects (Instruments, 2017). 
In SEM, a fine probe of electrons with energies up to 40 kV is focused and 
scanned at the surface of the specimen, which results in the formation of secondary 
electrons, backscattered electrons, auger electrons, photons of various energies, and 
characteristic X-rays. The interpretation of these secondary electrons provides an image 
of the specimen (Bogner et al., 2007; Rochow, 1978).The SEM technique provides two 
and three dimensional image of the specimen shows fine morphological details of the 
particles. The image provides direct information on size and size distribution, which 
are vital parameters in our study (Bogner et al., 2007; Bootz et al., 2004; Reichelt, 
2007). 
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Figure 2.2 Schematic diagram of SEM components (Choudhary & Priyan, 
2017) 
2.1.6 Fourier Transform Infrared Spectroscopy 
The invention of the Fourier Transform Infrared Spectroscopy (FT-IR) can  be 
traced back to late 1880s when Alber A. Michelson invented Michelson interferometer 
(Jaggi, 2006). FT-IR spectroscopy comprises of the emission, absorption, and reflection 
of spectrums attained by fourier transform of an optical interferogram. FT-IR 
spectroscopy is not restricted to the infrared (IR) frequency but  can be used in the 
visible and far UV range as well (Jaggi, 2006). The  instrument includes a black box of 
three optical inputs; IR source, He-Ne laser and a white light (Jaggi, 2006). The optical 
sources share the same beam splitter and mirrors, which are connected to an 
interferometer (Figure 2.3). The later generates a record of intensities as a signal called 
interferogram. The software then converts the interferogram to spectrum which 
represents a measurement of IR light intensity versus a property of light (Jaggi, 2006; 
Smith, 2011). FT-IR is used for the qualitative and quantitative analysis of samples and 
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for the determination of aromaticity, aliphaticity, and oxygenation rate of samples 
(Lamontagne et al., 2001; Smith, 2011; Vlachos et al., 2006). 
In our study, it is essential to investigate whether the formulation process leads 
to the formation of new chemical interactions, which may result in an altered 
performance of the polymers and/or CUR. Therefore, FT-IR analysis was performed as 
an accurate and sensitive method for studying the interactions among the NPs. 
 
Figure 2.3 Schematic diagram of the FT-IR (Adapted from 
chem.libretexts.org) 
2.1.7 X-Ray Diffractometer 
X-ray diffractometry (XRD) is based on the fact that atoms in crystals are 
periodically arranged and so diffract light (Chauhan & Chauhan, 2014). As illustrated 
in Figure 2.4, the XRD comprises of an X-ray source (A), which directs the rays 
towards the sample (B) (US 6,665,372 B2, 2003). A detector (C) that detects the 
scattered, diffracted, or reflected X-rays in a pattern peculiar to the sample’s structure 
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(US 6,665,372 B2, 2003). A goniometer controls the sequential relative angular 
positions between the X-ray source, the sample and the X-ray detector (Goebel, 1994). 
Finally, the intensity of  the pattern is plotted versus the angle of the detector in an 
output called diffractogram (Chauhan & Chauhan, 2014).  
 
Figure 2.4 Schematic diagram of XRD components (Adopted and modified 
from www.slideplayer.com, Brighton, 2015) 
Samples analysed using XRD should be in the form of fine powder. A wide 
variety of samples can be studied including organic and inorganic compounds, 
polymers, metals, fibres, pharmaceutical, and nanomaterials (Chauhan & Chauhan, 
2014). 
XRD can be employed to study the crystalline content and phase of a material 
which might give indication on the release profiles of the material (Chauhan & 
Chauhan, 2014). XRD provides simple, easy, reliable, and sensitive analysis of samples 
(Chauhan & Chauhan, 2014), thus it was used in this study. 
2.1.8 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) (Figure 2.5) is the most commonly 
used thermal analytical  technique where the difference in energy inputs of a sample 
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and a reference is measured as a function of temperature over a duration of time (Barton, 
1985; Gill et al., 1993; Gill et al., 2010; TAInstruments, 2017). 
A furnace generates the main heat flow symmetrically and simultaneously 
through the sample and reference cells located in a disk containing temperature sensors. 
The temperature is then raised over time and endothermic or exothermic energy 
changes required to keep the temperature of both cells identical is plotted as a function 
of time and temperature (Höhne et al., 2003; Gill et al., 2010). 
In nanomedicine, DSC is used for characterization of materials, comparison 
studies, safety and stability investigations, quality control, glass transition and 
crystallization behaviours. In our study, it was used to ascertain the crystalline state of 
the encapsulated CUR  (Höhne et al., 2003; Gill et al., 2010; TAInstruments, 2017).  
 
Figure 2.5 Schematic diagram of DSC components (Adpoted from 
www.linseis.com) 
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2.1.9 Aims and Objectives in this Chapter 
The aim of this chapter was to formulate a CUR-containing CS-pectinate 
composite nanoparticulate using sodium TPP as the cross linker. The effects of 
processing and formulation parameters on the physical properties of the particles were 
also evaluated.  
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2.2  Materials and Methods 
2.2.1 Materials 
Material Supplier 
Curcumin analytical standard Fluka, USA 
Low molecular weight chitosan Sigma Aldrich, USA 
Low methoxy pectin CP Kelco, USA 
Methanol (analytical grade) R&M chemicals, UK 
Absolute ethanol R&M chemicals, UK 
Glacial acetic acid R&M chemicals, UK 
Sodium hydroxide Merck, Germany 
 
2.2.2 Formulation of chitosan-pectinate composite nanoparticles  
2.2.2.1 Preliminary formulations of CUR chitosan-pectinate composite 
nanoparticles based on order of addition  
The stock solution of CUR was prepared by dissolving CUR in methanol at 1 
mg/ml. CS was dissolved in 2% v/v acetic acid at 0.15% w/v and pH adjusted to 5 using 
2M sodium hydroxide (NaOH). TPP, PEC and CaCl2 were dissolved in purified water 
at 0.05% w/v, 0.05%, and 0.943% respectively. Four primary formulations of CUR-
containing CS-pectinate NPs (CUR-CS-PEC-NPs) were prepared as shown in Table 
2.1. The formulations differ in the order of adding the solutions, all of which were 
performed under magnetic stirring at 500 rpm. The formed NPs were centrifuged at 
4000 rpm (18oC) for 20 min and the supernatant discarded. The collected NPs were re-
dispersed in purified water for further analysis. Controls NPs (CS-PEC-NPs) of the four 
formulations were prepared in the same manner without the addition of CUR. 
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Table 2.1 Composition of CUR-CS-PEC-NPs 
Order of 
addition 
Formulation A Formulation B Formulation C Formulation D 
1 300 µg of CUR  
drop wise into 
25 ml of PEC 
solution with 
stirring 
300 µg of CUR  
drop wise into 
25 ml of CS 
solution with 
stirring 
300 µg of CUR  drop wise into 25 
ml of PEC solution with stirring 
2 
25 ml of TPP solution  added at 
12.5 ml/ min with stirring  
25 ml of CS  
solution  added 
at 12.5 ml/ min 
with stirring 
25 ml of CaCl2 
added at 12.5 
ml/ min with 
stirring 
3 
 Additional stirring for 1hr 
Additional 
stirring for 10 
min 
4 25 ml of CS 
solution   added 
at 12.5 ml/ min 
with stirring 
25 ml of PEC  
solution added 
at 12.5 ml/ min 
with stirring 
25 ml of TPP 
solution added 
at 12.5 ml/min 
with stirring 
25 ml of CS  
solution was 
injected with 
stirring 
5 Further stirring for 1hr  
 
2.2.2.2 Sub-formulations and optimization of the preliminary formulation 
Further optimization was carried out by varying the quantities of CS, TPP, and 
PEC (3:1:1, 3:2:1, 4:1:1, 4:2:1, 5:1:1, and 5:2:1, respectively). Subsequent optimization 
of stirring times at order 3 and 5 respectively (2 min and 20 min; 2 min and 40 min, and 
2 min and 60 min) at variable stirring speeds (500, 800, and 1000 rpm).   
2.2.3 Size and zeta potential measurement 
The size of the NPs was assessed as z-average diameter and the surface charge 
as zeta potential using Zeta Sizer Nano Series® (Malvern Instruments, UK) equipped 
with a 4 mW He-Ne laser at wavelength of 633 nm. Hydrodynamic diameter (d nm) 
was measured by Dynamic Laser Scattering (DLS) at a scattering angle of 173o. The 
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zeta potential (mV) was determined by Laser Doppler Anemometry (LDA). The NPs 
were diluted before reading. CS-PEC-NPs and CUR-CS-PEC-NPs were diluted up to 
1 and 10 folds, respectively. Samples were run in triplicate and mean reading was taken. 
2.2.4 FESEM imaging 
Field Emission Scanning Electron Microscopy (FESEM) (Model Quanta 400F, 
FEI Company, US) at 10 kV was used to observe the morphology and surface 
topography of the NPs. Samples were prepared by placing one drop of NPs suspension 
on the stub and left to dry at ambient temperature 24 hr before viewing. 
2.2.5 FT-IR analysis 
FT-IR spectra of CS, PEC, TPP, CUR, CS-PEC-NPs and CUR-CS-PEC-NPs 
were obtained using a Spectrum RX1 FT-IR spectrometer (Perkin Elmer, USA). 
Potassium bromide (KBr) disks containing the material of interest were prepared at a 
ratio of 98:2 KBr to material respectively. Data were acquired between 4000 cm-1 and 
400 cm-1 with 64 runs and 4 cm-1  resolution at interval of 1 cm-1. Data captured were 
presented as the FT-IR spectra. 
2.2.6 XRD analysis 
Evidence of chemical association within the NPs was ascertained using XRD 
7000 diffractometer (Shimadzu, Japan). Freeze-dried samples were finely grounded 
and prepared as a film followed by irradiation with CuKα generated at 40 kV an 80 
mA. Data were recorded at 2θ ranged between 0 and 40o at a scanning speed of 0.5o/min. 
2.2.7 DSC analysis 
Thermal analysis of CUR-CS-PEC-NPs and CS-PEC-NPs were used to provide 
additional information on the polymer-drug interactions, if any and the nature of formed 
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NPs using DSC under nitrogen gas at a flow rate of 20 mL/min. Sample weight ranged 
from 8 to 12 mg except for CUR which was 1.8 mg. Samples were prepared in 
aluminium pans using a standard pneumatic press and then heated from 0oC to 350oC 
at a heating rate of 5oC/min. The reference was sealed aluminium pan. 
2.3 Results and discussion 
2.3.1 Particle size and zeta potential measurement 
The four formulations (A, B, C and D) were formed based on the order of adding 
the components (CS, PEC, TPP) except for formulation D where CaCl2 was used as the 
cross linker instead of TPP. Collected NPs as described in section 2.2.2 were re-
dispersed in purified water for further analysis using Zetasizer® to determine particle 
size and zeta potentials of CS-PEC-NPs and CUR-CS-PEC-NPs. Data collected is 
summarized in Table 2.2 below. 
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Table 2.2 Particle size and zeta potential data obtained for formulations A, B, 
C, and D of CS-PEC-NPs and CUR-CS-PEC-NPs, n=3 
Formulation Particle size (nm) Zeta Potential 
(mV) 
A 
CS-PEC-NPs 1115.0 ± 2.0 * +17.7 ± 0.5 * 
CUR-CS-PEC-NPs 1296.6 ± 5.5 * +13.7 ± 0.3 * 
B 
CS-PEC-NPs Visible particles/ Phase separation 
CUR-CS-PEC-NPs 
C 
CS-PEC-NPs 206.0 ± 0.6 * +24.0 ± 0.3  
CUR-CS-PEC-NPs 211.3 ± 2.0 * +23.5 ± 0.4  
D 
CS-PEC-NPs Visible particles/ Phase separation 
CUR-CS-PEC-NPs 
* Significantly different between groups (P< 0.001) for each formulation 
One of the key goals in nanomedicine is to ensure that the particles are of a low 
size dimension. Therapeutically, this is crucial in instances where uptake of the particles 
by relevant tissue is the goal. Smaller sized NPs are more effectively taken up in the 
epithelia of the colonic mucosa (des Rieux et al., 2006). Phase separation due to 
extremely large particles (macroparticles) was observed in formulations B and D. In 
formulation B, TPP was added to CS, which resulted in the formation of NP whereupon 
the addition of PEC did not result in the incorporation of the latter in the NPs. Instead, 
the negative carboxylic groups of PEC (–COO-) electrostatically interacted with the free 
amino groups of CS (NH3
+) available on the surface of the NPs. This resulted in an 
increase in size and hence the formation of macroparticles. Similarly, in formulation D 
macroparticles were formed because of the use of CaCl2 as the cross linker. PEC-based 
nanoformulations have been fabricated using CaCl2 as cross-linker (Mishra et al., 2012) 
where ionotropic gelation occurs between Ca+2 the –COO- groups of PEC. In 
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formulation D, however, the addition of CS would have been after the NPs were formed 
(due to ionic gelation between CaCl2 and PEC) thus, resulting in another ionotropic 
interaction between free –COO- groups of PEC and the –NH3+ groups of CS. 
Simultaneously, repulsive forces would exist between –NH3+ groups in CS and Ca+2 in 
CaCl2, all of which contribute to the formation of macroparticles. In formulation A, 
both PEC and TPP have negative functionalities and thus compete in interacting with 
the positive binding sites of CS and this impedes cross-linking propensity of TPP with 
CS leading to the formation of microparticles as well. NPs were successfully formed in 
formulation C, where the initial ionotropic interaction was formed between CS and PEC 
thus suppressing the negative functionality of PEC. Therefore, on addition of TPP it 
was possible for the negative groups of TPP to electrostatically interact with any free 
positive binding sites in CS which resulted in the formation of viable NPs. Figure 2.6 
summarizes what we believe are the sequences of events leading to the formation of 
CUR-CS-PEC composite NPs. Formulation C was selected for further optimization 
based on the physical parameters measured. In Formulation C, there was a slight 
increase in CUR-CS-PEC-NPs size (p=0.0143) compared to the blank NPs due to the 
encapsulation of CUR. 
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Figure 2.6 Sequence leading to formation of CUR-CS-PEC-NPs 
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The effects of formulation variables on the physical properties of the NPs are 
summarized in Tables 2.3, 2.4, and 2.5. Table 2.3 shows the effects of varying CS, TPP, 
and PEC concentrations and ratios. Increasing TPP ratio in formulations 3:2:1, 4:2:1, 
and 5:2:1 resulted in a dramatic increase in the size of the particles, causing the 
formation of macroparticles and phase separation. This could be due to increased inter- 
and intramolecular interactions between TPP and CS and PEC (Fan et al. 2012). 
Increasing CS concentration caused a decrease in size of NPs due to the availability of 
free  binding sites explained below (de Pinho Neves et al., 2014). CS molecules have 
two forces in equilibrium namely electrostatic repulsion due to protonated amino 
groups of CS and inter-chain hydrogen bonding interaction between CS molecules. At 
high concentrations of CS (>0.20% w/v) hydrogen interaction between CS molecules 
becomes stronger causing the involvement of more CS molecules in the cross-linking 
during the formation of a single particle thus resulting in an increase in particle size 
(Fan et al. 2012). Therefore, the highest CS concentration used in the present study was 
0.25% w/v. Based on the DLVO theory, higher potential energy is required to achieve 
better stability, thus higher zeta potential values are required. The zeta potential values 
were all in positive; however, we observed higher potentials in the smaller NPs which 
reflects better stability. Hunter (1981) reported that NPs with zeta potential higher than 
30 mV are more stable. This threshold was achieved in formulations 4:1:1 and 5:1:1. 
CUR is known to exist in tautomeric forms such as the 1,3, -diketo and two equivalent 
enols forms (Manolova et al., 2014). The enol form (-RCO4
-) predominates in organic 
solvents as in the present study and competes with the TPP (–P3O10-) for –NH3+ groups 
of CS. Additionally, due to the bulkier size of CUR relative to TPP, some free –NH3+ 
cannot be approached by TPP due to the stearic hindrance and this explains the 
insignificant lower z-potential of CUR-CS-PEC-NPs relative to CS-PEC-NPs. One of 
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the goals in the present formulation work is to produce NPs with practically as low as 
possible z-average due to the intended application. Such NPs with low z-average are 
desirable due to high surface-to-volume ratio. Moreover, narrow size distribution of the 
NPs (pDI< 0.500) enhance their cellular uptake as well as their stability (Nam et al., 
2009), This threshold was achieved in ratio 5:1:1. Thus, ratio 5:1:1 was subsequently 
selected for studying the effect of stirring time and stirring speed on the physical 
properties of the NPs. 
Table 2.3 Z-average, zeta potential, and pDI of CS-PEC-NPs AND CUR-CS-
PEC-NPs as a function of formulation ratios, n=3 
Formulation (CS:TPP:PEC) Particle size (nm) pDI Zeta potential 
(mV) 
3:1:1 
CS-PEC-NPs 206.0 ± 0.6 * 0.475 + 24.0 ± 0.3 
CUR-CS-PEC-
NPs 
211.3 ± 2.0 * 0.574 + 23.5 ± 0.4 
3:2:1 
CS-PEC-NPs 
Visible particles and phase separation CUR-CS-PEC-
NPs 
4:1:1 
CS-PEC-NPs 200.9 ± 6.9 * 0.331 + 30.7 ± 1.8 
CUR-CS-PEC-
NPs 
298.8 ± 9.5 * 0.526 + 30.0 ± 0.4 
4:2:1 
CS-PEC-NPs 
Visible particles and phase separation CUR-CS-PEC-
NPs 
5:1:1 
CS-PEC-NPs 201.9 ± 8.5 0.359 + 35.0 ± 1.5 
CUR-CS-PEC-
NPs 
203.2 ± 3.2 0.381 + 34.5 ± 1.2 
5:2:1 
CS-PEC-NPs 
Visible particles and phase separation CUR-CS-PEC-
NPs 
* Significantly different between groups (P< 0.001) for each ratio 
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From Table 2.4, we observed a direct relation between the stirring time and the 
z-average for both CUR-CS-PEC-NPs and CS-PEC-NPs. Ionic gelation is a 
spontaneous process and so the initially formed NPs become disrupted on prolonged 
stirring and grow in size. This disruption of the nanoparticle fabric also causes a 
decrease in zeta potential with longer stirring times. From a formulation and stability 
standpoint, a stirring speed of 500 rpm for 2 min. after the addition of CS to PEC 
followed by an additional 20 min. of stirring after the addition of TPP was deemed to 
be optimum and selected and so this formulation was further optimized using stirring 
speeds of 500, 800 and 1000 rpm. The data on the effect of stirring speed on the physical 
properties of both the CUR-CS-PEC-NPs and CS-PEC-NPs are shown in Table 2.5. 
Optimal physical properties in terms of z-average and pDI were obtained when stirring 
speed was 500 rpm, however, NPs formed at stirring speed of 800 and 1000 had higher 
zeta potential values which could be attributed to the compromised cross-linking 
properties of the NPs, thus, higher available (NH3
+) groups of CS is available. This 
effect of stirring speed on size of the NPs has also been reported previously and is 
attributed to sheer mixing which interrupts the cross linkages of the fabric imposed by 
TPP much like the effects of extended stirring times (Zhu et al., 2014). 
Table 2.4 Z-average, zeta potential, and pDI of CS-PEC-NPs AND CUR-CS-
PEC-NPs as a function of stirring time, n=3 
Stirring time (min.) Particle size (nm) pDI Zeta potential 
(mV) 
2/20 
CS-PEC-NPs 194.9 ± 1.1 0.341 + 33.8 ± 1.3 
CUR-CS-PEC-
NPs 
200.6 ± 6.6 0.377 + 32.8 ± 0.5 
2/40 
CS-PEC-NPs 195.9 ± 0.4 * 0.312 + 22.4 ± 0.5 
CUR-CS-PEC-
NPs 
285.9 ± 4.1 * 0.510 + 22.0 ± 0.5 
2/60 CS-PEC-NPs 198.9 ± 2.5 * 0.253 + 23.7 ± 0.4 
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CUR-CS-PEC-
NPs 
210.0 ± 3.5 * 0.264 + 23.2 ± 0.7 
* Significantly different between groups (P< 0.001) for each stirring time 
Table 2.5 Z-average, zeta potential, and pDI of CS-PEC-NPs AND CUR-CS-
PEC-NPs as a function of stirring speed, n=3 
Stirring speed (rpm) Particle size (nm) pDI Zeta potential 
(mV) 
500 
CS-PEC-NPs 194.9 ± 1.1 0.341 + 33.8 ± 1.3 
CUR-CS-PEC-
NPs 
200.6 ± 6.6 0.377 + 32.8 ± 0.5 
800 
CS-PEC-NPs 215.2 ± 4.4 0.547 + 43.4 ± 0.6 
CUR-CS-PEC-
NPs 
231.7 ± 9.8 0.662 + 40.6 ± 1.8 
1000 
CS-PEC-NPs 287.0 ± 20.5 0.443 + 37.8 ± 0.9 
CUR-CS-PEC-
NPs 
289.0 ± 9.6 0.721 + 36.5 ± 1.0 
* The data obtained between groups for each stirring speed were statistically 
insignificant (P>0.001) 
2.3.2    Morphology of CUR-CS-PEC-NPs and CS-PEC-NPs 
FESEM was used to study the morphologies and surface topographies of the 
NPs. Representative images of the CUR-CS-PEC-NPs at two magnifications, 10 000x 
(A) and 20 000x (B) of the optimized formulation are shown in Figure 2.7. Generally, 
The NPs were spherical in shape and the sizes were in agreement with those obtained 
from the photon correlation analysis described in section 2.3.1. The NPs in both cases 
appear to be well-separated from each other suggesting that sufficient electrical charge 
is retained by the individual particle. The surface of the NPs is free of fissures or cracks 
which indicate effective cross-linking. Similar findings were observed in the literature 
(Ha et al., 2012; Mathew et al., 2012).
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Figure 2.7 SEM image of the optimized formulation CUR-CS-PEC-NPs at magnification 10 000x (A) and 20 000x (B) 
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2.3.3 FT-IR spectra 
The FT-IR spectra of the raw materials and formulated NPs are presented in 
Figure 2.8. In the raw materials, stretching vibrations of C=O group of CUR (A) appears 
at 1604 cm-1. No peaks can be observed within the range of 1800-1650 cm-1 which 
suggests that CUR is present in the keto-enol tautomeric form (Kolev et al., 2005).The 
CS spectrum (B) shows a broad peak at 3434 cm-1 which is attributed to the stretching 
vibration of the hydroxyl groups whilst the amide I (NH2) bending vibration presents 
at 1653 cm-1. Furthermore, a peak appears at 1389 cm-1 corresponds to the N-H 
stretching of amide and ether bonds and the peak at 1081 cm-1 assigns to a secondary 
hydroxyl group (Paulino et al., 2006; Das et al., 2010). The broad peak of PEC (C) at 
3400 cm-1 is assigned to the stretching frequency of -OH group. The peak at 1051 cm-1 
is related to C=C or C=O double bonds within PEC while the peak at 1639 cm-1 is 
assigned to asymmetric stretching bands of COO- groups (Gopi et al., 2014; Shi & 
Gunasekaran, 2008). The characteristic peak at 1129 cm-1  is assigned to P=O groups of 
TPP (D) while the one at 899 cm-1 is related to the P-O-P asymmetric stretching 
(Martins et al., 2012; Mi et al., 2003).  
The aforementioned bands were all present in both the formulations CUR-CS-
PEC-NPs and CS-PEC-NPs, spectra (E and F, respectively). We may conclude that 
these groups are not typically involved in covalent chemical bonding with the other 
components during the formulation process. The FT-IR spectra of CUR-CS-PEC-NPs 
are similar to those from CS-PEC-NPs except for a slight shifting of the amine peak at 
1562 cm-1 which is attributed to CUR loading in CUR-CS-PEC-NPs. Furthermore, the 
peak attributed to CUR is absent in the CUR-CS-PEC-NPs spectrum which assures 
CUR loading in the latter.  
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Figure 2.8 FT-IR spectra of CUR (A), CS (B), PEC (C), TPP (D), CS-PEC-NPs (E), and CUR-CS-PEC-NPs (F) 
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2.3.4 XRD data 
To investigate the state of CUR after encapsulation into the CUR-CS-PEC-NPs 
an XRD analysis was performed. The XRD data of CUR (Figure 2.9) shows its 
diffraction pattern peaks 7.93o, 12.48o, 17.72o, 18.18o, 23.53o, and 24.60o implying a 
characteristic crystalline structure 2θ range of 7–30°. In contrast, these peaks are absent 
in CUR-CS-PEC-NPs suggesting its conversion to the amorphous state because of the 
intermolecular interaction between CS, PEC, and TPP. A similar change in structure of 
entrapped CUR was also reported by several researchers (Anitha et al., 2011; Gou et 
al., 2011a; Rejinold et al., 2011; Yallapu et al., 2010a; Yen et al., 2010). This is 
crucially significant as the crystalline encapsulation of a drug hinders its release profile.  
 
Figure 2.9 XRD patterns of CUR and CUR-CS-PEC-NPs 
2.3.5 DSC analysis 
To further ascertain the physical nature of the NPs, thermal analyses were 
carried out on both the optimized CUR-CS-PEC-NPs and CS-PEC-NPs in comparison 
with the raw materials. Figure 2.10 shows the DSC data where CUR (A), shows a sharp 
melting peak at 178.7oC, whilst CS (B) shows endothermal peak at 113.9oC and an 
exothermic peak at 307.4oC. PEC (C) has a transition peak at 190oC. Endothermic peaks 
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are correlated with loss of water associated with the hydrophilic groups in CS while the 
exothermic peaks result from the degradation of polyelectrolytes followed by the 
hydration and depolymerization reactions which happen due to the partial 
decarboxylation of the protonated carboxylic groups and oxidation reactions of the 
polyelectrolytes (Sarmento et al., 2006). TPP (D) shows a typical melting point of the 
salt at 116.6 oC. The thermograms of the physical mixture of CS, PEC, TPP, and CUR 
(E) showed similar peaks observed in the pure samples.  
Thermograms of the formulations (CS-PEC-NPs and CUR-CS-PEC-NPs, F and 
G, respectively) show a broad endothermic peak at about 89.5oC this is due to 
complexation of TPP because the sharpness of this peak in the physical mixture is lost 
but prominent in TPP. There is a broad exothermic peak at 269.3oC in both formulations 
and this is due to CS but is slightly shifted at 307.4oC in pure CS because of weak 
interaction. Furthermore, the melting point of CUR cannot be seen in the thermograms 
of CUR-CS-PEC-NPs because CUR is molecularly dispersed in the NPs in the 
amorphous state. This finding agrees with those of (Dandekar et al., 2010; Mohanty & 
Sahoo, 2010; Xie et al., 2011). Data obtained from the DSC analysis complements those 
of the FT-IR and X-ray diffractometry. 
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Figure 2.10 DSC thermograms of CUR (A), CS (B), PEC (C), TPP (D), physical mixture 
of CUR, PEC, CS, and TPP (E), CS-PEC-NPs (F), and CUR-CS-PEC-NPs (G). 
2.4 Conclusion 
In summary, CUR-CS-PEC-NPs have been successfully formulated and optimized 
in terms of desirable physical properties. The most enticing properties were found with 
CS:TPP:PEC ratio of 5:1:1, most optimum stirring speed and stirring time were found to 
be 500 rpm and 2 min./20 min., respectively. The NPs were characterised in terms of size, 
pDI, zeta potential, morphology, chemical functional groups, and the physical state of 
CUR. These data present us with the incentive for further optimisation in terms of EE% of 
the NPs for CUR, release profile of CUR as a function of various physiological challenges, 
stability, and mucoadhesion at relevant physiological conditions. These would be discussed 
in detail in Chapter 3. 
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3 Mucoadhesion, release, and stability studies 
3.1 Introduction 
3.1.1 Mucin 
The intestinal mucus is synthesized by specialized goblet cells and secreted by 
the epithelial GIT surface and is a water insoluble viscoelastic gel that adheres to the 
epithelia of the GIT (Atuma et al., 2001; Strugala et al., 2003; Andrews et al., 2009). 
The thickness of the GIT mucus varies  between 50-500 µm in the stomach and decrease 
distally to a range of 15-150 µm in the colon (Pullan et al., 1994; J et al., 1991; Bickel 
& Kauffman, 1981; Bravo-Osuna et al., 2007). A balance between synthesis and 
secretion rates and abrasion through enzymatic digestion and/or mechanical shear 
maintains the thickness. Any imbalance may led to pathological conditions such as 
ulcerative colitis (Atuma et al., 2001). Despite the low pH of the luminal cavity of the 
stomach, the pH of the mucosal surfaces ranges from 5.23-8.1 throughout the entire 
GIT (Atuma et al., 2001; Bahari et al., 1982; Flemstrom & Kivilaakso, 1983). 
About 95% of the mucus gel comprises of water along with sulphated 
glycoproteins (up to 5%), and to a lesser extent free proteins, mineral salts, and lipids 
(Allen & Snary, 1972;  Allen & Garner, 1980). The gel-forming properties of the mucus 
are manifested due to the high molecular weight of mucin. The glycoproteins are rich 
in amino acid residues such as serine, proline, and threonine. Moreover, glycoproteins 
contain fructose, glucosamine, galactose, galactosamine and sialic acid. Glycoprotein 
units are joined by disulphide bridges covalently attached to protein cores. In addition 
to glycoproteins, 5-10% of mucin consists of non-covalently bonded proteins. The 
sialic acid units of the glycoproteins (pKa =2.6) and the sulphate groups are responsible 
for the negative surface charge of mucin at neutral pH (Andrews et al., 2009). 
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Functionally, the mucus layer protects epithelia from the degradation and 
erosive effect of gastric acid, digestive enzymes, free radicals, and bacterial and 
ingested toxins and abrasion. Furthermore, it acts as lubricant, facilitating the passage 
of food through the GIT and protects it from mechanical injury. In the colon, the 
mucosal layer serves as a favourable environment for the colonic microflora, whilst at 
the same time, prevents bacteria from adhering onto it. This way, bacterial infections 
are prevented (Atuma et al., 2001; Bickel & Kauffman, 1981; Carbajal et al., 2000; 
Strugala et al., 2003). 
3.1.2 Mucoadhesion process 
The term “adhesion” refers to the molecular interaction at the interface between 
materials (Marshall et al., 2010). When, at least, one of these materials is a biological 
surface, it is called “bioadhesion”. When the biological material is particularly 
restricted to the mucus layer, the term “mucoadhesion” is used (Smart, 2005; Bravo-
Osuna et al., 2007; Chickering & Mathiowitz, 1999). Recently, researchers have shown 
interest in taking advantage of mucoadhesion in localized and systemic drug delivery 
due to the extended contact time (Smart, 2005) of formulation with mucosa. 
Researchers have proposed several theories explaining the mucoadhesion 
mechanism including adsorption, diffusion, electronic, fracture, mechanical, and 
wetting theories (Dodou et al., 2005; Smart, 2005; Peppas & Sahlin, 1996; Chickering 
& Mathiowitz, 1999). Therefore, we may conclude that mucoadhesion is a complex 
process that cannot be explained based on a single theory. The phenomenon of 
mucoadhesion is best explained by a combination of theories. Firstly, the contact stage, 
where the mucoadhesive compound binds to the mucus (mechanical theory), gets 
wetted and swells (wetting theory). Through this wetting stage, the mucus-material 
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interfaces are physically bonded (electronic and adsorption theories) so that the material 
and mucin chains interpenetrate and entangle (diffusion theory) forming additional 
covalent and non-covalent bonds (diffusion, electronic, and adsorption theories) 
(Dodou et al., 2005; Smart, 2005; Bravo-Osuna et al., 2007; Chickering & Mathiowitz, 
1999). Mucoadhesive materials bind to mucus through a variety of forces including van 
der Waal’s, hydrophobic, hydrogen, ionic, or covalent bonds (Dodou et al., 2005; 
Bravo-Osuna et al., 2007; Peppas & Sahlin, 1996; Marshall et al., 2010; Chickering & 
Mathiowitz, 1999). 
Factors affecting the mucoadhesive propensity of a material include intrinsic 
(structural) factors such as optimum molecular weight, degree of cross-linking, high 
chain flexibility, optimum surface tension, or external (environmental) factors such as 
the environment pH and temperature, length of contact time, presence of metal ions, 
and the shear rate of the environment (Dodou et al., 2005; Bravo-Osuna et al., 2007; 
Smart, 2005; Chickering & Mathiowitz, 1999). 
3.1.3 High Performance Liquid Chromatography 
The High Performance Liquid Chromatography (HPLC) technique was 
proposed in the late 1960s and has undergone several modifications since (Ornaf & 
Dong, 2005). It is a physical separation and quantification technique operated by 
carrying the analyte in a liquid phase. The separation is achieved by the distribution of 
the constituents between the mobile phase (MP) (liquid phase) and immobilized 
stationary phase (column) (Ornaf & Dong, 2005). There are several other 
chromatographic techniques however HPLC is the most versatile (Sandie Lindsay, 
1997; Ornaf & Dong, 2005; Zhang et al., 2008; White, 1981) because of its superior 
sensitivity, precision, resolution, reliability, reproducibility, shorter analysis time, and 
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lower cost (White, 1981; Zhang et al., 2008). HPLC technique is widely used in food, 
forensic, environmental, clinical, and pharmaceutical industries (Zhang et al., 2008).  
Physical separation is achieved in the stationary phase (column), which consists 
of uniform silica particles with spherical or irregular shape with sizes that range 
between 3-50 µm. They may be coated with various chemical groups in order to impart 
the desired level of polarity. This in turn is the basis of separation between analytes and 
the bonded phase of the column (Engelhardt, 1979; Lindsay, 1997; White, 1981). Based 
on the stationary phase polarity, two separation modes are available, namely, normal 
phase and reversed phase (RP) chromatography. The former comprises of a polar 
(silica) stationary phase, whereas the latter consists of non-polar (C18) stationary phase 
(Lindsay, 1997). The MP is carefully chosen in order to match the right balance 
between retention of analyte of interest against a matrix background. 
Separated constituents are detected by a wide variety of detectors such as IR, 
refractive index, fluorescence, and ultraviolet light (UV/visible) detectors. The latter is 
the most frequently used detector due to its reasonable prices and sensitivity (Zhang et 
al., 2008; Lacourse, 2002; Christie, 1992). The choice of the detector is aligned to the 
maximum sensitivity obtained for the analyte. In the present pursuit, a UV detector was 
used for CUR because of the sensitivity of this technique to maximum absorption at 
specified wavelength. 
3.1.3.1 HPLC analysis of CUR 
Several HPLC methods have been proposed for the quantification of CUR, 
mostly employing UV-vis for detection (Wichitnithad et al., 2009; Wang et al., 1997; 
Syed et al., 2015; Pak et al., 2003; Hsu et al., 2001; Ireson et al., 2002; Ma et al., 2007; 
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Garcea et al., 2004). In this chapter, we used the method proposed by Wichitnithad et 
al., (2009) due to simplicity and sensitivity, albeit after minor modification. 
3.1.4 Aims and Objectives 
CUR-CS-PEC-NPs were successfully formulated and characterized as 
described in chapter 2. This chapter was dedicated to studying the mucoadhesion 
properties of the NPs, CUR release in various media as well as the stability of CUR-
CS-PEC-NPs. 
3.2 Materials and Methods 
3.2.1    Materials 
Material Supplier 
CS-PEC-NPs Prepared as described in Chapter 2 
CUR-CS-PEC-NPs Prepared as described in Chapter 2 
Curcumin analytical standard Fluka, USA 
Low molecular weight chitosan Sigma Aldrich, USA 
Low methoxy pectin CP Kelco, USA 
Methanol (analytical grade) R&M chemicals, UK 
Absolute ethanol R&M chemicals, UK 
Glacial acetic acid R&M chemicals, UK 
Sodium hydroxide Merck, Germany 
Acetonitrile (HPLC grade) RCI Labscan, Thailand 
Phosphate-Buffered Saline (PBS) pH 7.4 Sigma Aldrich, USA 
Mucin type III from porcine stomach Sigma Aldrich, USA 
Pectinase (Aspergillus niger) Abnova, Taiwan 
Pepsin (from porcine stomach) Nacalai Tesque, Japan 
Pancreatin Nacalai Tesque, Japan 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Nacalai Tesque, Japan 
Hydrochloric Acid (37%) R&M chemicals, UK 
Sodium Deoxycholate ≥97% Sigma Aldrich, Germany 
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3.2.2 Mucoadhesion studies 
The mucoadhesive propensity of the CUR-CS-PEC-NPs was determined by 
dispersing them in type III mucin solution obtained from porcine stomach at 0.1, 0.2, 
0.4 and 0.6 mg/ml. The degree of mucoadhesion was obtained by measuring the 
changes in the zeta potential of the particles after interaction with mucin (Bhatta et al., 
2012; Takeuchi et al., 2005). The CS-PEC-NPs and CUR-CS-PEC-NPs mucin 
suspension were vortex-mixed for one minute followed by incubation in an incubating 
shaker operated at 180 rpm for 1 hr at 37oC. The zeta potential of the NPs was then 
measured using the Zetasizer and the drop in zeta potential was recorded as a measure 
of degree of interaction of CS-PEC-NPs or CUR-CS-PEC-NPs with mucin. 
3.2.3 HPLC assay for CUR 
An HPLC method adapted from Wichitnithad et al., (2009) was used for the 
detection of encapsulated CUR within CUR-CS-PEC-NPs and for the CUR release 
after minor modification. The HPLC system comprised of a Series 200 pump, Perkin 
Elmer, USA equipped with UV/Vis detector (Series 200 UV/Vis detector, Perkin 
Elmer, USA) operated at a detection wavelength of 425 nm. A reverse phase column 
(ZORBAX Eclipse Plus C18, 250 mm x 4.6 mm, 5 µm, Agilent, USA) was used as the 
stationary phase and the MP consisted of 40:60 acetonitrile: 2% acetic acid filtered 
through 0.45 µm regenerated cellulose membrane filter (Agilent Technologies, 
Germany) prior to analysis which was run at a flow rate 2.0 ml/min.  
CUR standard solutions were prepared in methanol (0.15625-10 µg/ml). The 
responses from the calibration curve were then quantified based on the area under the 
curve (AUC).  The coefficient of determination (R2) and line equation were determined 
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from the calibration curve. Sample concentrations were determined by comparing 
resulting area with those obtained from the standard calibration curve. 
3.2.4 HPLC method validation 
Because of the slight modification in the HPLC method used, validation in terms 
of method repeatability and accuracy was done. CUR solutions comprised 0.3125, 50 
and 100 μg/mL representing low, medium and high concentration, respectively. The 
three concentrations of CUR solution were analysed in triplicate on the same day to 
determine intra-day precision and accuracy, whereas triplicate analysis on three 
consecutive days were performed for inter-day precision and accuracy determination. 
3.2.5 Determination of encapsulation efficiency 
The unbound CUR from CUR-CS-PEC-NPs pellet collected by centrifugation 
as described in section 2.2.2.2 was washed off twice in methanol. The amount of CUR 
in the methanol rinse and the supernatant were both analysed to determine the total 
unbound CUR using the HPLC method described in section 3.2.3. For the supernatant 
and rinse, 20 µl was injected directly onto the HPLC. The reported values are the means 
of three independent runs. The percentage of EE% was calculated as follows: 
% EE% =
Total CUR added−unbound CUR
Total CUR added
X 100%               Eq. 3.1 
3.2.6 CUR release from CUR-CS-PEC-NPs 
3.2.6.1 CUR release from CUR-CS-PEC-NPs in different simulated fluids 
The variation in pH within the GIT and the effects of colonic enzymatic activity 
on the integrity of CUR-CS-PEC-NPs were studied. For this purpose, CUR-CS-PEC-
NPs were collected by centrifugation as described in section 2.2.2.2 and washed. A 20 
mg/ml suspension of CUR-CS-PEC-NPs were suspended in phosphate buffer saline 
114 
 
(pH 6.4) containing 1% (w/v) tween 80 and 2.5% (w/v) pectinase enzyme as simulated 
colonic content. Similarly, CUR-CS-PEC-NPs were suspended in 0.1 N HCl (pH 1.2) 
and HEPES buffer (pH 6.8) mimicking the stomach and small intestine mediums, 
respectively (Dutta & Sahu, 2012; Saboktakin et al., 2011; Beaulieu et al., 2002; Luo 
et al., 2012; Chen & Subirade, 2005; Jain et al., 2006).  Each of the three types of the 
fluids containing CUR-CS-PEC-NPs were seeded into eight sampling vials and 
subjected to rotary shaking (WiseCube®, Witeg Inc., Germany) at 180 rpm incubated 
at 37oC. CUR release was studied over 6 hr at 20 min., 40 min., 1 hr, 2 hr, 3 hr, 4 hr, 5 
hr, and 6 hr by withdrawing one vial from each of the media and its content centrifuged 
at 4000 rpm for 10 min to pellet the particles. The amount of CUR released was 
determined in the supernatant using the HPLC analytical procedure described in section 
3.2.3 in three independent runs.  The percentage of CUR released was calculated from 
the calibration curve described in section 3.2.4 and calculated as follows: 
% released CUR =  
Amount of released CUR
Amount of CUR initially added
 X 100%    Eq. 3.2 
To study the protective effects of PEC on the CUR-CS-PEC-NPs, PEC-free NPs 
were prepared as described in section 2.2.2.2  (i.e. without the addition of PEC). CUR-
CS-PEC-NPs and PEC-free NPs were suspended in 0.1 N HCl (pH 1.2) for 1 hr, 
removed and air-dried followed by viewing under FESEM as described in section 2.2.4.  
Since the CUR-CS-PEC-NPs are designed to transit the upper GIT followed by 
exposure in the alkaline conditions of the distal GIT, the effect that this variable pH 
might have on the physical integrity of the CUR-CS-PEC-NPs was studied by 
suspending the NPs in pH 1.2 for one hr, retrieving by centrifugation and then re-
exposure in pH 6.8 for 2 hr. The zeta potential values and percentage retention of CUR 
were determined as described in sections 2.2.3 and 3.2.5, respectively. 
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3.2.6.2 CUR release from CUR-CS-PEC-NPs in simulated gastrointestinal tract 
fluids 
CUR-CS-PEC-NPs are designed to transit the upper GIT followed by the 
alkaline conditions of the distal GIT. Thus, the effects of such pH variation and 
enzymatic activity on CUR release from the CUR-CS-PEC-NPs were studied. Firstly, 
the collected CUR-CS-PEC-NPs were suspended in simulated gastric fluid (SGF) (0.1 
N HCl, pH 1.2, containing pepsin at concentration of 0.1% (w/v)) for 1 hr. Then, CUR-
CS-PEC-NPs were retrieved and suspended in simulated intestinal fluid (SIF) (HEPES 
buffer (pH 6.8) containing pancreatine and sodium deoxycholate at concentrations of 
1% and 0.8% (w/v), respectively), for two hr. Finally, CUR-CS-PEC-NPs were 
retrieved and suspended in simulated colonic fluid (SCF) (PBS (pH 6.4) containing 1% 
(w/v) tween 80 and 2.5% (w/v) pectinase enzyme) (Dutta & Sahu, 2012; Saboktakin et 
al., 2011; Beaulieu et al., 2002; Luo et al., 2012; Chen & Subirade, 2005; Jain et al., 
2006). Figure 3.1 illustrates the aforementioned process. At designated time intervals 
(20 min., 40 min., 1 hr, 2 hr, 4 hr, and 6 hr) the amount of CUR released was determined 
in the supernatant using the HPLC method described in section 3.2.3 in three 
independent runs and reported as the mean of these runs. The physical integrity of CUR-
CS-PEC-NPs were investigated by studying the morphological changes on them at 30 
min, 2.5 hr, and 6 hr using the SEM imaging as described in section 2.2.4. 
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Figure 3.1 CUR release at simulated GIT fluids (adopted with modification 
from www.jocuri-fotbal.info) 
3.2.7 Stability Studies 
3.2.7.1 Storage  
The effects of storage on the physical integrity of CUR-CS-PEC-NPs was 
conducted at 4oC for 14 days. Physical characterization of CUR-CS-PEC-NPs 
including particle size, zeta potential, and SEM imaging were conducted as described 
in sections 2.2.3 and 2.2.4, respectively. Studies were conducted on day 0, 7, and 14. 
3.2.7.2 Photosensitivity 
CUR is photosensitive, therefore, CS-PEC matrix must offer necessary 
protection to encapsulated CUR from the degradative effects of light. This was studied 
after exposing equivalent concentrations of CUR encapsulated in CUR-CS-PEC-NPs 
and free CUR within transparent vials to sunlight and UV light (263 nm) for 6 hr. At 
predetermined time intervals (2, 4, and 6 hr) CUR-CS-PEC-NPs were collected by 
centrifugation. CUR was retrieved by hydrolysing the CUR-CS-PEC-NPs in methanol 
with vortex mixing for 1 minute followed by filtration through 0.22 µm syringe filter. 
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The filtered solution was then run using the HPLC method described in section 3.2.3. 
The reported values are the means of three independent runs. The percentage of retained 
CUR was calculated as follows: 
% CUR retained =  
Amount of CUR determined from analysis 
Amount of added CUR
X100%                Eq. 3.3 
3.2.7.3 Thermal  
To investigate the extent of protection offered by the CS-PEC matrix to CUR 
against hydrolysis induced by thermal exposure as is likely under physiological 
conditions, (37oC), equivalent concentrations of CUR encapsulated in CUR-CS-PEC-
NPs and free CUR were exposed to 37oC for three days. At day 1, 2, and 3, samples 
were sacrificed and CUR-CS-PEC-NPs were collected by centrifugation at 4000 rpm 
for 10 min. and then hydrolysed by vortex shaking the samples in methanol. This was 
further centrifuged at 4000 rpm for 10 min and the supernatant filtered using a 0.22 µm 
syringe. CUR was quantified using the HPLC method described in section 3.2.4 and 
the % of retrieved CUR was calculated using Eq. 3.3. 
3.3 Results and Discussion 
3.3.1 Mucoadhesion studies 
The term “adhesion” refers to the attractive interaction between two different 
surfaces (Salamat-Miller et al., 2005). Mucoadhesion, in particular, is the process 
where materials attach to the mucosal membranes of the body (Salamat-Miller et al., 
2005).  
As explained in section 3.1.2, there are six theories explaining the 
mucoadhesion process. Namely, the electronic, the adsorption, the wetting, the 
diffusion (Dodou et al., 2005), the mechanical, and the fracture theories (Smart, 2005). 
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In practice, however, the mucoadhesion process is complex and it includes a 
combination of all of the mucoadhesion theories (Dodou et al., 2005). Figure 3.2 
illustrates the behaviour of mucoadhesive NPs at the mucosal layers (Bravo-Osuna et 
al., 2007). 
 
Figure 3.2 Schematic illustration of the penetration of polymeric NPs into the 
GIT mucosa 
Hydrophilic polymers interact with the mucosal layer through interpenetration 
followed by secondary non-covalent bonding (hydrogen bonding). The degree of 
polymer/mucous interaction depends mainly on the polymeric structure, type of 
functional groups, degree of hydration, and polymer concentration (Andrews et al., 
2009). 
Several experimental setups are available for evaluating the mucoadhesion of 
formulations including tensile tests, rheology (Tamburic & Craig, 1997), atomic force 
microscopy (AFM) (Sudhakar et al., 2006), and mucin- interaction assessments 
(Woertz et al., 2013). Generally, in vitro evaluation is preferred over in vivo studies 
mainly due to cost and ethical constraints related to sacrificing animals for such studies 
(Woertz et al., 2013). Using freshly excised animal mucosa provides characteristics 
close to those of humans, however, its use is restricted due to intra-subject 
heterogeneity, partial loss during purification and ethical issues (Woertz et al., 2013). 
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Therefore, researchers have developed synthetic materials from animal and plant 
sources as a substitutes for mucous membrane (Woertz et al., 2013). Mucin type III 
from porcine stomach is one such example. After the rehydration of the lyophilised 
mucin, it possesses similar physiological, histological, and structural properties to those 
of the human mucosal membrane with minimal variability between batches (Sudhakar 
et al., 2006; Liu et al., 2005). 
In the present study, the mucoadhesive propensities of the CS-PEC-NPs and 
CUR-CS-PEC-NPs were determined using mucin type III in four different 
concentrations (0.1, 0.2, 0.4, and 0.6 mg) maintained in three different pH media (pH 
1.2, 6.8, and 7.4) representing different mucosal thickness and GIT segments, 
respectively. The magnitude of mucoadhesion was obtained by directly measuring the 
changes in the zeta potential of the NPs after interaction with mucin (Bhatta et al., 2012; 
Takeuchi et al., 2005).  
Figure 3.3 represents the drop in zeta potential at pH 1.2 (A), 6.8 (B), and 7.4 
(C) where a direct relationship between the drop in zeta potential and mucin 
concentration is observed. The drop in zeta potential is a measure of the extent of 
mucoadhesion to CS-PEC-NPs and CUR-CS-PEC-NPs by mucin (Figure 3.4) (Bhatta 
et al., 2012). The drop in zeta potential of the CUR-CS-PEC-NPs and CS-PEC-NPs at 
pH 6.8 (B) was more drastic compared to in pH 1.2 (A), suggesting that the NPs are 
more mucoadhesive at pH 6.8. At pH 7.4 (C), both CS-PEC-NPs and CUR-CS-PEC-
NPs registered higher mucoadhesion than in both pH 1.2 and 6.8. Variation in pH 
affects the surface charge on mucin, CS-PEC-NPs and CUR-CS-PEC-NPs. Mucin has 
sialic acid residues which have a pKa of 2.6, resulting in a negative charge at 
physiological pH (pH 7.4).  
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There was a positive correlation between the drop in zeta potential and pH and 
this can be explained partly due to the low solubility of CS in acidic media (Lehr et al., 
1992) and to the fact that at higher pH the ionised carboxyl functional groups of mucin 
(COO-) repel each other and change the spatial conformation from a coiled state into a 
“rod-like” structure, which results in higher accessibility for inter-diffusion and 
interpenetration (Bansil & Turner, 2006). The COO- in mucin allows the positively 
charged –NH4+ groups of CS to form polyelectrolyte complexes which results in 
mucoadhesion. At higher pH, the amine groups in CS become more positive and 
therefore forms stronger polyelectrolyte bonds with mucin. Moreover, at higher pH, 
PEC tends to ionize and swells, resulting in inter-diffusion and formation of inter-chain 
bridges with the mucin (Lehr et al., 1992). Therefore, the particles are completely 
covered by mucin at higher pH and thus register identical zeta potential as mucin. In 
addition, secondary hydrogen bonding between the functional groups of mucin and the 
OH and NH2 groups and COOH groups of CS and PEC, respectively, may contribute 
in the mucoadhesive propensities of the NPs  (Lehr et al., 1992; Sriamornsak et al., 
2010).  
Both CS and PEC possess polymeric characteristics crucial for mucoadhesion 
including strong hydrogen-bonding functional groups, high molecular weight, strong 
anionic charges, chain flexibility, and enough surface energy to spread onto mucous 
(Lehr et al., 1992). 
Chuah et al., (2011) reported higher mucoadhesion in CUR-containing NPs 
compared to control NPs and attributed this to hydrogen bonding and hydrophobic 
interactions from the phenolic groups and aromatic rings of CUR, respectively. 
However, this phenomenon was not observed in the present study. In fact, both CUR-
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CS-PEC-NPs and CS-PEC-NPs showed identical mucoadhesive propensities in all 
media studied.  
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Figure 3.3 Changes in zeta potential of CUR-CS-PEC-NPs and CS-PEC-NPs in pH 
1.2 (A), pH 6.8 (B), and pH 7.4 (C) 
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Figure 3.4 Schematic diagram of the drop in zeta potential in mucoadhesion 
3.3.2 HPLC assay for quantification of CUR 
The amount of CUR encapsulated or released from the CUR-CS-PEC-NPs was 
quantified using an HPLC system described in section 3.1.3.1. Samples containing CUR were 
calculated by comparing responses with a standard curve prepared in the same manner. Ideally, 
the ratio of the peak area to its height is constant, therefore, both peak area and peak height can 
be used to determine analytes concentration (Lough & Wainer, 1995). However, variations in 
peak heights may be observed in the presence of peak asymmetry, therefore, most HPLC 
analysis employ peak area for quantitative calculations as a more reliable alternative (Lough & 
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Wainer, 1995). Most CUR HPLC analyses are performed using reverse phase HPLC system 
(Ireson et al., 2002; Wichitnithad et al., 2009; Ma et al., 2007; Garcea et al., 2004) with UV 
detection as in the present study..  
Figure 3.5 shows representative chromatogram obtained by adapting the method 
described by Wichitnithad et al., (2009) with slight modification. From the chromatogram, it 
can be seen that peak is fairly symmetric, sharp, well resolved and free from interfering peaks 
with a retention time of 10.5 min. Figure 3.6 shows linear calibration curve in the range 
0.15625-10 µg/ml and R2 value of 0.9997. 
 
Figure 3.5 Representative chromatogram for CUR at 425 nm (5 µg/ml) 
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Figure 3.6 Standard calibration curve of CUR 
The repeatability or precision of the HPLC analysis was determined as inter- and intra-
day precision of the measurements (Table 3.1) for the concentrations 100, 50, 0.3125 µg/ml 
representing the high (HC), medium (MC), and low (LC) concentrations, respectively. The % 
relative standard deviation (%RSD) were all below 5.5%. The accuracy of the method was 
assessed and were in the range of 99.26-109.45% for the HQ and MQ, whereas the LQ accuracy 
was in the range of 109.86-118.61%. The limit of detection (LOD) and limit of quantification 
(LOQ) were calculated from equations 3.4 and 3.5, respectively and found to be 0.006 µg/ml 
and 0.019 µg/ml, respectively. 
𝐿𝑖𝑚𝑖𝑡 𝑜𝑓 𝐷𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 = 3.3 𝑋 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑙𝑜𝑤 𝑐𝑜𝑛𝑐.
𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑐𝑢𝑟𝑣𝑒
          Eq. 3.4 
𝐿𝑖𝑚𝑖𝑡 𝑜𝑓 𝑄𝑢𝑎𝑛𝑡𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 = 10 𝑋 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑙𝑜𝑤 𝑐𝑜𝑛𝑐.
𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑐𝑢𝑟𝑣𝑒
               Eq. 3.5 
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Table 3.1 Precision and accuracy of the HPLC method. 
 Concentration 
(µg/ml) 
Accuracy 
(%error) 
Precision 
(%RSD) 
Intra-day (n=3) 
HQ 100 109.45 0.56 
MQ 50 104.60 0.14 
LQ 0.3125 109.87 0.01 
Inter-day (n=3) 
HQ 100 106.05 5.55 
MQ 50 105.81 1.41 
LQ 0.3125 113.39 0.01 
 
3.3.3 Encapsulation efficiency (EE%)  
CUR is poorly adsorbed from the GIT and possesses very low bioavailability following 
oral administration hence, various formulations have been proposed to address the poor uptake 
from the GIT. Das et al., (2010) managed to encapsulate CUR in alginate-CS-pluronic NPs and 
the EE% was as low as 13%. In contrast, higher CUR EE% was achieved in other formulations. 
For example, Anitha et al., (2011) encapsulated CUR in dextran sulphate-CS-NPs at 74% EE%, 
Maya, et al., (2011) had EE% of 87% of CUR in O-carboxymethyl CS NPs, and Liu et al., 
(2012) formulated CUR-CS-NPs and achieved EE% of 70.9%. CUR is usually dissolved in 
ethanol prior to the encapsulation process therefore, the water miscibility of ethanolic solutions 
of CUR behaviour in the aqueous media is crucial to achieving successful encapsulation. This 
is because CUR is hydrophobic and requires to be in the dissolved state prior to formulation 
(Das et al., 2010). Higher concentration of CS may enhance the %EE however, this may also 
increase the particle size (Maya, et al., 2011). In this study, the EE% of the freshly prepared 
CUR-CS-PEC-NPs was found to be 64%±1.40. The incorporation of ethanolic solution of CUR 
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into PEC aqueous solution resulted in nanocrystals of CUR. As described in section 2.2.2.2, 
CS was added to PEC-CUR solution followed by TPP, thus, CUR nanocrystals were 
incorporated within the CUR-CS-PEC-NPs. EE% can be enhanced by increasing the 
concentration of CS, however, this will cause increase in the particle size of CUR-CS-PEC-
NPs (Murkerjee et al., 2009; Das et al., 2010).  
3.3.4 CUR release from CUR-CS-PEC-NPs 
Cumulative CUR release in pH 1.2, pH 6.8 and 6.4 (with pectinase) are presented in 
Figure 3.7. A burst release of 15% of CUR obtained in the first 20 min. was followed by a 
gradual release over 5 hr. Eventually, a plateau was manifested in 5 hr with cumulative CUR 
release of 70.0% ± 0.2 at the end of study. 
 
Figure 3.7 Cumulative release profiles from CUR-CS-PEC-NPs in pH 1.2, 6.8, and 
6.4 (with pectinase), n=3
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Since CS and PEC have different pKa values (6.1-6.5, 2.9-4.1 respectively), 
based on the Henderson-Hasselbalch equation, they act differently in terms of 
protonation/deprotonation as a function of pH. In acidic conditions (pH 1.2), the amine 
groups of CS become protonated, whereas the carboxylic groups of PEC become 
neutralized. Since the ionization of carboxylic groups of PEC is limited and it has the 
dominant effect, the coulombic repulsion of the carboxylic groups is reduced which 
protects CUR-CS-PEC-NPs (Bigucci et al., 2008), however, negligible leaching of 
CUR was observed at this pH. At pH 7.4, the number of negatively charged carboxylic 
groups of PEC increases and hence electrostatic repulsion between ionized groups lead 
to chain repulsion (Munjeri et al., 1997). However, CS is insoluble at this pH so that 
CUR release was impeded (Yu et al., 2009). Despite this interaction and subsequent 
cross-linking, the catalytic effect of pectinase on the α-1,4-glycosidic linkages of PEC 
lead to breakage of existing bonds formed between PEC and CS which causes an initial 
burst release (Kashyap, 2001). In addition, some of the CUR adsorbed on the surface 
of CUR-CS-PEC-NPs and those encapsulated near the surfaces might have partially 
contributed to the initial burst release (Anitha et al., 2011). A maximum release of 70% 
of CUR over the duration of the study reflects that a significant amount of CUR is 
retained within CUR-CS-PEC-NPs as similarly observed by other researchers (Das et 
al., 2010; Yallapu et al., 2010; Murkerjee et al., 2009; Anitha et al., 2011).  
At acidic pH, the amino groups of CS undergo protonation hence, becomes 
soluble in aqueous media (Anitha et al., 2011; Agnihotri et al., 2004). This enhanced 
solubility of CS allows the penetration of water through CUR-CS-PEC-NPs, which 
results in swelling that facilitates diffusion of CUR from matrix (Agnihotri et al., 2004). 
Makhlof et al., (2011) evaluated the release of insulin from CS-TPP NPs in acidic 
conditions and they found that the NPs were only stable at pH > 3.0. In contrast, in the 
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typical pH range of the stomach (pH 1-2), the NPs rapidly released insulin due to 
disintegration and subsequent dissolution. In another study, Boonsongrit et al., (2006) 
studied the release of insulin and salicylic acid from CS-microspheres at pH 3 showed 
a burst release of 100% and 80% of insulin and salicylic acid respectively. On the other 
hand, PEC resists the degradative effects of acidic media and it is readily digested by 
the colonic microflora (Subudhi et al., 2015). However, PEC is highly hydrophilic and 
thus, formulations swell easily at the pH range of the small intestine (4.5-7.4) resulting 
in premature drug release (Mishra et al., 2012). Subudhi et al., (2015) studied the 
release of 5-FU from PEC-NPs in different pH solutions where a negligible amount of 
5-FU was released at pH 1.2 (<12%), whereas rapid release was observed at the pH 
range (4.5-7.4) despite the absence of enzymatic activity. Similar results were obtained 
in another study, where Vaidya et al., (2009) evaluated the release of metronidazole 
from PEC-microspheres at pH 1.2, 4.5, 6.8, and 7.4. Metronidazole release profiles 
were directly proportional to the pH of the media, with the least drug release of 23%, 
which increased to 100% after change in the pH from 1.2 to 7.4, respectively. These 
findings strongly suggest that PEC formulations might have the ability of maintaining 
their integrity in the gastric media, but may swell and degrade in pH (5.0-7.4), thus 
resulting in premature drug release in formulations targeting the colon. In this context, 
these constraints were overcome by fabricating a composite nanoparticulate system 
comprising of CS and PEC. In such a formulation, PEC contributes to maintaining the 
integrity of CUR-CS-PEC-NPs in the upper GIT, whereas CS protects CUR-CS-PEC-
NPs from swelling in the pH of the small intestine (pH 7.4). With this plan, CUR-CS-
PEC-NPs may successfully unload the cargo after colonic arrival prompted by 
degradation by the colonic microflora. 
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To study the level of protection offered by PEC against degradation in the acidic 
medium of the upper GIT, CS-PEC-NPs and PEC-free NPs were suspended in a 0.1 N 
HCl solution (pH 1.2) for 1 hr and the morphology of both NPs were studied under 
FESEM (Figure 3.8). PEC-free NPs (A+B) appear swollen and deformed with some 
degree of distortion after this treatment, which suggests degradation. Despite some 
negligible swelling, CS-PEC-NPs (C+D) maintained their morphology and integrity.  
 
Figure 3.8 FESEM images of PEC-free NPs (A,B) & CS-PEC-NPs (C,D) after 
treatment with 0.1 N HCl (pH 1.2) 
From Table 3.2 we note that there was an increase in the zeta potential of the 
NPs after exposure to pH 1.2 (P=0.0383), representing the stomach. This increase in 
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zeta potential is due to protonation of the amine groups of CS. At this pH, there is also 
a reduction in the magnitude of the negative charge on the carboxylic moiety of PEC. 
This combined effect on the amine groups and carboxylic acid in acidic media 
contributes to rise in surface charge. On the other hand, exposure of the CUR-CS-PEC-
NPs to pH 6.8 after treatment in pH 1.2, caused a fall in the zeta potential to the initial 
value (P=0.0395). This change in zeta potential can be attributed to the deprotonation 
of the carboxylic group of PEC to the charged species (–COO-), allowing electrostatic 
interaction between –NH3+ of CS. In parallel, the percentage retention of CUR within 
the CUR-CS-PEC-NPs was ascertained after exposure to the different media. The 
percentage retention of CUR decreased slightly (P=0.2735) after exposure to pH 1.2, 
with further decrease (P=0.1963) in pH 6.8, however, this decrease is minimal and 
suggests that the CUR-CS-PEC-NPs have the potential to retain a significant amount 
of the payload against a variable pH profile within the GIT.  
Table 3.2 Zeta potential and percentage retention of CUR in CUR-CS-PEC-
NPs after exposure to pH 1.2 and 6.8, n=3 
 
CUR-CS-PEC-NPs 
prior to exposure to 
media 
CUR-CS-PEC-
NPs after 
exposure to pH 
1.2 
CUR-CS-
PEC-NPs after 
exposure to 
pH 6.8 
Zeta potential 
(mV) 
+33.1 ± 1.1 +37.9 ± 2.5 +33.0 ± 1.3 
Retention (%) 64% ± 2% 62% ± 2% 60% ± 1% 
 
Following oral delivery, the CUR-CS-PEC-NPs will transit through the stomach 
and the small intestine before arriving the colon. Therefore, the release of CUR in these 
sequential sections of the GIT was studied in vitro as follows. Initially, CUR-CS-PEC-
NPs were exposed to SGF for 1 hr, retrieved, and then re-suspended in SIF for 2 hr. 
Finally, CUR-CS-PEC-NPs were suspended in SCF for 4 hr and then retrieved by 
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centrifugation. The CUR release data (Figure 3.9) indicates up to 14% release in the 
SGF which is attributable to slight swelling (see Figure 3.10B) in this medium. As 
discussed earlier in this section, this swelling is attributable to CS. In SIF, further 
swelling can be observed (see Figure 3.10C), however the release was negligible. In 
contrast to both of these media, release of CUR was fast in colonic medium. Maximum 
cumulative release of 86% was observed after 7 hr of the study. Similar drug release 
profiles were reported in the literature for PEC-formulation for colon delivery of 5-FU 
and metronidazole (Subudhi et al., 2015; Vaidya et al., 2009), respectively. Figure 
3.10D shows the morphology of CUR-CS-PEC-NPs after the 7 hr study period where, 
CUR-CS-PEC-NPs appear to have lost their integrity. Furthermore, very tiny debris can 
also be seen which might constitute degraded fragments of the NPs. 
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Figure 3.9 % cumulative CUR release from CUR-CS-PEC-NPs in simulated fluids, n=3 
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Figure 3.10 Morphology of fresh CUR-CS-PEC-NPs (A), and after exposure 
to treatment in SGF (B), SIF (C), and SCF (D) 
CUR  release from polymeric NPs depends on degree of cross-linking, size, 
density, and morphology (Agnihotri et al., 2004). In addition, environmental factors 
such as pH of medium and the presence of enzymes play a vital role in the drug release 
(Agnihotri et al., 2004). In the present study, we believe that CUR release is a 
combination of three release phases: firstly, the slight release of CUR in the upper GIT 
in simulated GIT and SIF fluids is attributable to CUR that was absorbed at the surface 
and near surface area of within the matrix of the NPs. Further release in these two media 
may involve leached CUR from the swelled matrix. After its exposure to the colonic 
simulated fluids, PEC became degraded, hence the degraded fragments of the NPs 
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provided a larger mass transfer of the cargo to the medium and hence a faster rate of 
release was observed.  
3.3.5 Stability Studies 
3.3.5.1 Storage stability studies 
The stability of the CUR-CS-PEC-NPs  with regard to storage like any other 
dosage form is crucial as it determines the possible shelf life of the particular 
formulation (Wilson et al., 2010). Such studies might include physical appearance, 
texture, odour, colour, particle size, morphology, and chemical changes (Wilson et al., 
2010). In the present study, the tendency of the CUR-CS-PEC-NPs to maintain their 
physico-chemical characteristics (size, zeta potential, and morphology) as a function of 
time was studied by storing the NPs in a refrigerator (4oC) for 14 days. Collated data 
on particle size and zeta potential as well as morphology are presented in Figures 3.11 
and 3.12 respectively. In Figure 3.11, we observed a significant decrease in the particle 
size of CUR-CS-PEC-NPs at day 7. However, Figure 3.12B (Day 7) shows a collection 
of large and small particles, which can be explained by the fact that the DLS analysis 
is based on an average determination. The increase in pDI value (p=0.0113) reflects the 
high variability in the particle size distribution. Therefore, stability analysis based on 
DLS analysis alone may lead to misleading conclusions.  
It is likely that the smaller sized fraction in the range are contribution from 
fragments of the particles produced during storage whilst the larger sized particles are 
produced due to swelling or Ostwald’s ripening. Swelling is likely to be the cause for 
the increase in size of CUR-CS-PEC-NPs because the particles retained their spherical 
morphology (Figure 3.12B). In contrast, Figure 3.12C (Day 14) shows an irregularly 
shaped particles (pointed with red arrows) which might be attributed to the 
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degradation/fragmentation and shrinkage of the NPs followed by a minor degree of 
swelling. This phenomenon was confirmed by the observation in further decrease in 
particle size observed from the DLS measurements. On the other hand, there was an 
insignificant decrease in zeta potential between day 7 and day 14 (p=0.5525 and 0.2659 
for days 7 and 14, respectively). This attest to the fact that the zeta potential is mainly 
contributed by the surface moieties. Due to the changes in size and morphology with 
storage, the shelf-life stability studies were discontinued at day 14. These findings 
reflects the low storage stability of CUR-CS-PEC-NPs, thus, the particles need to be 
freeze-dried and reconstituted prior to administration. 
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Figure 3.11 Size, zeta potential, and pDI values of CUR-CS-PEC-NPs at days 0, 7, and 14 of shelf storage (n=3) 
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Figure 3.12 Morphology of freshly CUR-CS-PEC-NPs (Day 0) (A), at day 7 (B) and day 14 (C) during storage at 4oC 
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Polymeric NPs such as those containing PEC and CS lose their integrity in the 
presence of enzymes such as pectinase. However, it was reported that such NPs 
prepared by ionic gelation might degrade in aqueous media in the absence of enzymes 
(López-León et al., 2005). NPs storage stability also depends on the ionic strength of 
the medium, pH conditions, cross-linking density, particle size, and particle size 
distribution (Fan et al., 2012). CUR-CS-PEC-NPs were metastable and failed to 
maintain their integrity upon storage. This could be attributed to the erosion of the NPs 
in aqueous environments. Subsequently, increment in particle size was observed in 
Figure 3.12B and eventually, spontaneous disintegration (López-León et al., 2005). In 
addition, the free polymeric chains might have interacted with the NPs network leading 
to further intermolecular entanglements and swelling (Rampino et al., 2013).The small 
size of CUR-CS-PEC-NPs is partially responsible for its poor stability. In fact, larger 
polymeric NPs have more inter-and intra-hydrogen bonding, thus, produce more stable 
nanogels (Rampino et al., 2013). 
Spontaneous disintegration and aggregation of polymeric NPs under mild 
storage conditions in short duration of time is common amongst the polymeric NPs 
(Rampino et al., 2013; López-León et al., 2005; Borchard, 2001; Luo et al., 2004). In 
contrary, some research reported the stability of polymeric NPs for durations exceeded 
3 months (Wilson et al., 2010; Fan et al., 2012). NPs stability might be enhanced by 
increasing the cross-linking density via increasing suitable cross linker such as TPP. 
However, this significantly increases the NPs diameter as reported in section 2.3.1 (Fan 
et al., 2012). Stabilizers such as polyethylene glycol (PEG) and PVA might be used to 
enhance the NPs stability (Wu et al., 2011).  
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3.3.5.2 Protection of CUR from photodegradation 
CUR undergoes photodegradation both in solid and solution forms. Research 
found that photoanalysis of CUR upon exposure to sunlight is higher compared to UV 
light. In fact, CUR has been used as a photosensitizer in micellar formulations 
(Priyadarsini, 2009). The mechanism of photo-degradation in CUR is not well 
understood, however, it is believed to occur by the cleavage of the β-diketone link 
resulting in the formation of smaller phenolic compounds such as vanillin and ferulic 
acid. The presence of iron and aluminium salts influence CUR photo-degradation 
(Priyadarsini, 2009). Coradini et al., (2014) studied the photoprotection of CUR 
encapsulated in lipid-core nanocapsules. The study included the exposure of CUR 
nanocapsules to UV light and found that the lipid nanocapsules significantly protected 
CUR from UV-decomposition. Half-lives of CUR solution and CUR-loaded lipid 
nanocapsules were 4.29 ± 0.62 and 7.25 ± 0.54 min., respectively. Xiao et al., (2015) 
found that encapsulated CUR in polymeric matrix immensely protected it against UV 
degradation. After 270 min. of UV treatment, only 25% of CUR was retrieved from 
ethanolic CUR solution. On the other hand, >50% of CUR was retrieved from 
carboxymethyl CS NPs.  
Since CUR is encapsulated in its inactive form in CUR-CS-PEC-NPs, it is 
hypothesized that CUR wont undergo degradation when exposed to light. To ascertain 
this hypothesis, equivalent amounts of pure CUR and CUR-CS-PEC-NPs were exposed 
to sunlight and UV light (253 nm) in transparent vials for 6 hr. % retrieved CUR as 
shown in Figure 3.13. From the data obtained in Figure 3.13A, pure CUR undergoes 
extensive photodegradation and was almost completely degraded at the end of the 
study, in contrast, CUR-CS-PEC-NPs significantly protect CUR from degradation, and 
however, 23% of CUR had undergone photo-degradation at the end of the study. UV 
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light had a milder photo-degradative effect on both CUR and CUR-CS-PEC-NPs 
(Figure 3.13B). 94% of encapsulated CUR was protected in CUR-CS-PEC-NPs, 
whereas more than 50% of pure CUR was degraded at the duration of the study.  
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Figure 3.13 % retention of CUR from CUR-CS-PEC-NPs and CUR ethanolic solution vials upon exposure to sunlight (A) and 
UV light at 253 nm (B), n=3 
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The enhanced photostability of CUR in the NPs could be attributed to its 
encapsulation in the inactive form (Jiayin Zhao & Wu, 2006). In addition, the 
accumulation of CUR within CUR-CS-PEC-NPs protected by the polymeric matrix 
away from light and the oxidizing environment such as ROS and water could be a 
contributing factor (Suwannateep et al., 2012). Thus, CUR photostability was assured 
via encapsulation in the CS-PEC-NPs. 
3.3.5.3 Protection of CUR from thermal degradation 
CUR might undergo decomposition at physiological temperature (37oC) during 
its transit to the colon. To ascertain the stability of the CUR-CS-PEC-NPs in protection 
of the CUR by thermal degradation, CUR-CS-PEC-NPs and pure CUR were placed in 
water bath at 37oC for three days. Sampling was performed at the end of each day where 
retrieved CUR was assayed using HPLC. The CS-PEC-NPs matrix protected CUR from 
thermal degradation for the whole duration of the study, whereas gradual 
decomposition of pure CUR was observed where less than 60% of CUR was retained 
at the end of the study (Figure 3.14). It is believed that due to the presence of CUR in 
amorphopus state in the CUR-CS-PEC-NPs in addition to the protection offered by the 
CS-PEC-NPs matrix, CUR was less prone to becoming degraded due the thermal 
changes. These findings were in agreement with Kumara & Madhysydhan (2015) and 
Rahman et al. (2014).  
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Figure 3.14 Thermal stability of CUR-CS-PEC-NPs and CUR at 37 oC, n=3
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3.4 Conclusion 
In this chapter, the ability of CS-PEC-NPs to encapsulate CUR, maintain their 
integrity in the upper GIT and unload CUR in the colonic conditions were confirmed 
in vitro. The in vitro mucoadhesion between CUR-CS-PEC-NPs and mucin was also 
confirmed. These findings could provide indication on how CUR-CS-PEC-NPs might 
interact with the various GIT conditions in vivo. It is anticipated that CUR-CS-PEC-
NPs would behave in a similar manner in vivo, where prolonged contact with the 
colonic epithelium might occur, in addition, CUR-CS-PEC-NPs might remain intact 
through their transit in the upper GIT and eventually, deliver CUR in the colon. The 
CUR-CS-PEC-NPs appeared to be unstable for storage up to 14 days when in solution, 
however, freshly prepared CUR-CS-PEC-NPs significantly protect their CUR cargo 
from light and thermal effects of the physiological temperature. The CUR-CS-PEC-
NPs are thus well primed for further investigation where the anti-cancer and apoptotic 
efficacy and as well cellular uptake will be discussed in chapter 4. 
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Chapter 4 
In Vitro Cell 
Evaluation of 
Formulation 
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4.         In Vitro Evaluation of Formulation 
4.1 Introduction 
4.1.1    Cell culture 
Cell culture, first introduced in 1907, is the process by which cells are removed 
from an animal or plant and subsequently grown in controlled artificial environment 
(Invitrogen 2010; ATCC, 2003). The primary culture is the first batch of cells after 
isolation from the tissues and the subculture (passage) represent subsequent cultures 
from the primary stock. Subcultures require a new vessel and fresh growth medium for 
growth to manifest (Invitrogen, 2010).  
Primary cultures generate heterogeneous population of cells, whereas 
subcultures cells generate a homogeneous cell line (subclone) (ATCC, 2003). The 
primary cells can undergo limited number of passages due to Hayflick Limit effect, 
culture conditions, and depletion of nutrients (ATCC, 2003). Essential nutrients for 
cells growth include amino acids, carbohydrates, salts and vitamins which are supplied 
by the growth medium. Growth factors, hormones, lipids, and binding proteins can be 
obtained from the serum (Allaire et al., 2010; Invitrogen, 2010). Foetal and new-born 
calf sera are favoured for cell culture work as they provide higher concentrations of 
components (Langdon, 2003). Environmental conditions include controlled 
temperature (36.5oC ± 1oC), pH (7.2-7.4), gases (O2 and 5% CO2), and osmotic pressure 
(Invitrogen, 2010). 
Cell culture is one of the essential tools used in cellular and molecular biology, 
it is used as a model system for studying the normal physiology of cells, cytotoxicity 
testing, nutritional studies, carcinogenesis (ATCC, 2003; Invitrogen, 2010). It is 
extensively used in drugs development and genetic engineering (Allaire et al., 2010). 
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The main advantages of employing cell culture for these applications are the 
consistency and reproducibility of the obtained results (Invitrogen, 2010). 
One of the major challenges in cell culture is contamination which could be 
bacterial, viral, yeast, or fungal (Perlman, 1962). Biological effects resulting from 
contamination include competition for nutrients with host cells, secreted by-products 
which stops the growth of the host cells (Allaire et al., 2010). There are several 
antibiotics that can be used in cell culture like penicillin, streptomycin, amoxicillin, 
gentamycin, or combination of two antibiotics. However, long term use of antibiotics 
is not favourable as it results in antibiotics resistance and hides the presence of 
contamination such as mycoplasma contamination (Perlman, 1962).  
4.1.2 Cell lines 
Human colorectal adenocarcinoma cell line HT-29 was used to study the anti-
proliferative effects of CUR and CUR-CS-PEC-NPs. The cells produce the secretory 
component of IgA, carcinoembryonic antigen (CEA), transforming growth factor 
binding protein, and most crucially, mucin (ATCC, 2017a). HT-29 is one of the most 
commonly used cell lines for studying the antiproliferative effects of new drug entities 
or for formulations against colorectal cancer. It was used to study the antiproliferative 
effects of CUR (Goel et al., 2001; Aggarwal et al., 2003; Song et al., 2005; Johnson & 
Mukhtar, 2007; Lee et al., 2009) and CUR-nanoformaulations (Ha et al., 2012; Deepa, 
et al., 2014; Anitha, et al., 2014) against colorectal cancer. 
MRC-5 are normal lung fibroblast, originally isolated from human lung tissues 
of 14-weeks old Caucasian male foetus (ATCC, 2017b). It is the most commonly used 
fibroblast human cells in the production of viral vaccines (Zhang et al., 2014). The 
major advantage of MRC-5 is its capability to grow for more than 40 passages while 
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maintaining normal diploid karyotype. Its use as control (normal) cell line against 
colorectal cancer cell lines have been extensively reported in the literature (Herlyn et 
al., 1979; Frixen et al., 1991; Bhattacharyya et al., 1994; Tokunaga et al., 2000; Tan et 
al., 2011; Gandin et al., 2012). Therefore, it was used as the control cell line in this 
study. 
4.1.3 Fluorescence microscopy 
Several subjects can be viewed by the light microscope via light reflection, 
scattering, and absorption. However, the light microscope is not capable of providing 
optical contrast necessary for detailed visualisation of structural components in 
materials such as colloids, polymers, crystals, and biological cells (Lavrentovich, 
2012). Therefore, fluorescence microscopy was developed in which the contrast 
between the material (signal) and the surrounding (background) is enhanced (Lichtman 
& Conchello, 2005). Fluorescence microscopy provides intrinsic selectivity, therefore 
this technique has become the most commonly used microscopy in biology (Lichtman 
& Conchello, 2005). 
In fluorescence microscopy (Figure 4.1), a laser beam is directed to the 
specimen. This causes excitation of fluorophores and a shorter wavelength is emitted 
nanoseconds later. The difference between the excited and emitted wavelength is called 
Stokes shift. The exciting light is then filtered out while the emitted fluorescence is then 
reflected as a fluorescent image (Lichtman & Conchello, 2005; Mueller, 2005). 
Subjects can be detected by fluorescence microscopy only if they have 
fluorophores. The efficiency of a subject fluorescing depends on the wavelengths of 
absorption and emission as well as the outermost electron orbitals of the fluorophores 
(Lichtman & Conchello, 2005). Organic objects may be intrinsically fluoresce if they 
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have fluorophores (auto-fluorescence) or they can be labelled with fluorescent 
compounds (Lichtman & Conchello, 2005). The fluorescent specimen can be viewed 
directly by the eye or via a rapid camera attached to arc lamps. Light sources of 
fluorescence microscope are mercury and xenon arc lamps. The former provides several 
extremely intense light, whereas the latter is relatively even in covering the wavelengths 
of UV, visible, and near IR. However, both of them are expensive, dangerous, and 
require special lamp houses (Lichtman & Conchello, 2005). 
 
Figure 4.1 Basic components of inverted fluorescence microscope (Adopted 
from www.jic.ac.uk) 
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4.1.4 Mycoplasma 
Amongst the various contaminants prone to cell culture, the most common 
concern contamination is mycoplasmic infections (Drexler & Uphoff, 2002). 
Mycoplasmas are tiny self-replicating organisms (Timenestsky, 1997). Contrary to 
regular bacteria, mycoplasma lack rigid cell walls (Timenestsky, 1997) and grow very 
slowly (Drexler & Uphoff, 2002). Mycoplasmas were first isolated in 1957 
(Timenestsky, 1997). Mammalian and avian cell lines are more vulnerable to 
mycoplasmic infections (Timenestsky, 1997). Continuous cell lines are more frequently 
infected compared to primary cell culture (Rottem et al., 2012). 
The extent of mycoplasma infection on inhabitant cells depends on the type of 
the cell lines, the culture conditions, mycoplasma species, and the intensity and duration 
of mycoplasma infection (Drexler & Uphoff, 2002). The effects might be minimal and 
the cells might appear healthy, mycoplasmas might interfere in the cell culture 
structure, growth, and metabolism (Timenestsky, 1997). Nonetheless, mycoplasma 
infection can cause severe cytopathic effects characterized by feeble, abnormal growth 
and degeneration of cells, and eventually death of cells (Rottem et al., 2012). A vast 
array of detection methods have been developed to detect mycoplasma infection in cell 
cultures such as SEM, colony formation on agar, universal PCR primers, and RNA 
hybridization (Drexler & Uphoff, 2002). However, these techniques vary in their 
overall efficiency, require very close quality control and specialized techniques 
(McGarrity et al., 1983). DNA fuorochrome staining such as 4’,6’-diamidino-2-
phenylindole (DAPI) and Hoechst 33258 staining provides sensitive, specific, simple, 
efficient, and cost effective detection method (Drexler & Uphoff, 2002). In such 
procedure, mycoplasmas characteristic particulate around the host cells can be viewed 
under fluorescence (Figure 4.2) (Rottem et al., 2012). 
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Figure 4.2 Mycoplasma positive cells after DAPI staining (Adopted from 
www.bionique.com) 
4.1.5 MTT assay 
The cell viability and proliferation studies are amongst the most crucial in vitro 
assays in new drugs or formulations development process. The yellow tetrazolium MTT 
(3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide) assay has been widely 
employed for cell proliferation measurements (Riss et al., 2013; ATCC, 2017). MTT 
assay has been widely reported in studying cross-resistance amongst drugs, drug 
sensitivity, drug screening on cell lines, and testing drugs combinations (Langdon, 
2003). 
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MTT gives a yellow aqueous solution and easily penetrates viable cells. It is 
positively charged and become reduced via the hydrogenases produced by the 
metabolically viable cells to the water insoluble violet-blue formazan (Figure 4.3) 
(Stockert et al., 2012; Riss et al., 2013). The generated formazan precipitate inside the 
cells and near cell surface.  
 
Figure 4.3 Insoluble formazan precipitated inside and near viable cells(Riss et 
al., 2013) 
4.1.6 Aims and objectives 
The CUR-CS-PEC-NPs were successfully optimized and characterised as 
described in chapter 2. The mucoadhesive propensity, drug release profiles, and 
stability studies were studied in chapter 3. In this chapter, the antiprofilerative efficacy 
and cellular uptake of CUR-CS-PEC-NPs against colorectal cancer cell lines (HT-29) 
155 
 
were evaluated. The selectivity of the CUR-CS-PEC-NPs was also studied. The 
therapeutic efficacy of CUR-CS-PEC-NPs was studied in comparison with the free 
CUR to ascertain whether that the anticancer effects of CUR are maintained after 
encapsulation in CS-PEC-NPs. 
4.2       Materials and methods 
4.2.1    Materials 
Material Supplier 
CS-PEC-NPs Prepared as described in Chapter 2 
CUR-CS-PEC-NPs Prepared as described in Chapter 2 
Dulbecco's Modified Eagle's Medium 
(DMEM), 4.5 g/l glucose with L-
glutamine.Sodium pyruvate-free. 
NacalaiTesque, Japan 
Roswell Park Memorial Institute (RPMI) 
– 1640 Medium 
Sigma Aldrich, USA 
Foetal Bovine Serum (FBS) NacalaiTesque, Japan 
Trypsin EDTA NacalaiTesque, Japan 
(3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyl tetrazolium bromide) (MTT) 
NacalaiTesque, Japan 
Dimethylsulfoxide (DMSO) NacalaiTesque, Japan 
Calcium and Magnesium free Phosphate 
Buffered Saline (PBS) pH 7.4 
NacalaiTesque, Japan 
Trypan Blue Sigma Aldrich, USA 
4’,6’-diamidino-2-phenylindole (DAPI) NacalaiTesque, Japan 
Penicillin-Streptomycin mixed solution 
(stabilized) 
NacalaiTesque, Japan 
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4.2.2    Maintenance of cell culture 
The human colorectal adenocarcinoma cell line HT-29 and normal lung 
fibroblast MRC-5 were both donated by the National Cancer Council, Malaysia 
(MAKNA) laboratory, University Putra Malaysia, Malaysia. The HT-29 and MRC-5 
cells were grown as a monolayer culture in Dulbecco's Modified Eagle's Medium 
(DMEM) and Roswell Park Memorial Institute (RPMI) – 1640, respectively. Media 
were supplemented with 10% FBS under standard cell culture conditions of 37oC and 
5% CO2. 
4.2.3    Subculture of cells 
For both cell cultures, cells were harvested by aspirating the medium and gently 
rinsing the cells with Ca+2 and Mg+2 free PBS, twice. Trypsin-EDTA was added to the 
flasks to detach the cells. After incubation at 37oC for 5-7 min, flasks were gently 
tapped to detach all cells from the culture surface. The cells were then viewed under 
inverted microscope (Nikon Esclipse TS1100-F, Japan) to ascertain that all cells were 
detached. The cells were then re-suspended in fresh media and centrifuged at 1000 rpm 
at 25oC (Eppendorf 5424, Germany) for 8 min. The supernatant was discarded and the 
harvested cells were re-suspended in fresh growth media. The cells suspension was then 
diluted and distributed into several flasks. Penicillin-Streptomycin mixed solution was 
occasionally used at 1% concentration, however, at least three passages of antibiotics-
free media were cultured before any evaluation to minimize any possible interferences 
in the data duo to antibiotics use. 
4.2.4    Cells counting 
The cells were harvested from the flask of confluent cells as described in section 
4.2.3 and properly diluted with media. A 10 µl aliquot of cells were thoroughly mixed 
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with 10 µl of trypan blue. A cover slip was placed on the counting chamber and then10 
µl of the cells suspension was applied to the surface of the hemacytometer using the 
two opposing edges of the cover slip and allowed to spread into the chamber by 
capillary force. The chamber was then viewed under the inverted microscope with a 
10X objective. Cells in the four outside gridded squares excluding dead cells stained by 
trypan blue and the two outer perimeters (Figure 4.4) were counted. The number of 
cells per 1mm2 was calculated as the average of the four counted chamber sides. The 
total number of cells was calculated as follows: 
Number of cells per 1 ml = average cells per 1mm2x 104 
Total number of cells = number of cells per 1 ml x dilution factor of trypan blue x 
dilution   factor of media 
 
Figure 4.4 Hemacytometer grid (A) viable cells (not stained by trypan blue) 
inside the grid and at the interior perimeters are counted (B) (Adopted and modified 
from www.humanimmunologyportal.com) 
4.2.5   Check for mycoplasma 
The HT-29 cells were tested for possible mycoplasma contamination by seeding 
1 x 105 cells on a sterile cover slip in a 6 well plate and allowed to attach for 24 hr with 
appropriate medium. The medium was aspirated and the cells were gently washed with 
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PBS, twice. The cells were then fixed with 3.7% formaldehyde for 10 min. followed by 
aspiration and washing of with PBS, once. The cover slips were left to dry for 10 min. 
A 2 ml aliquot of DAPI working solution (1µg/ ml) was added to the cover slips and 
incubated for 15 min. in dark. Finally, the cover slips were washed with PBS and 
viewed under inverted fluorescence microscope (AX10, Carl Zeiss, Germany) with 
430-495 filter.  
4.2.6    MTT assay 
4.2.6.1    MTT assay for HT-29 cells 
The cell viability (MTT) assay was carried out to determine the effects of CUR-
CS-PEC-NPs on HT-29 cell growth. The cells were seeded in a 96 well plates at 2 x 
103 cells/well and allowed to attach for 24 hr. The culture medium was then replaced 
with medium containing free CUR and CUR-CS-PEC-NPs at the following 
concentrations: 75, 90, 110, 130, and 150 µM. The cells treated with CS-PEC-NPs and 
Dimethylsulfoxide (DMSO) were used as negative controls whereas 15 µM of 5-FU 
was used as positive control. At time intervals of 24, 48, and 72 hr, treatment media 
were aspirated and 10 µl of MTT solution (5mg/ ml) added. After 4 hr of dark 
incubation at 37oC, 100 µl aliquot of DMSO was added and mixed at 40 rpm using a 
laboratory shaker (S1000 Gyrotwister, Labnet, USA). The plate absorbance was then 
measured at 570 nm using microplate reader (Epoch, Biotek, USA). The relative growth 
inhibition compared to untreated cells was measured and the mean values were 
presented (n=5).  
4.2.6.2   MTT assay for MRC-5 cells 
The MTT assay was carried out on MRC-5 cells to study the selectivity of CUR-
CS-PEC-NPs against tumour cells rather than normal cells. Cells were seeded in 96 
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well plates at 1x105 cells/well and allowed to attach for 24 hr. The culture medium was 
then replaced with media containing free CUR and CUR-CS-PEC-NPs at 75 or 150 
µM, representing low and high treatment concentration, respectively. The cells treated 
with CS-PEC-NPs and DMSO were used as negative controls whereas 15 µM 5-FU 
was used as positive control. At time points of 24, 48, and 72 hr, MTT assay was carried 
out as described in section 4.2.6.1. The relative growth inhibition compared to untreated 
cells was measured and the mean values were presented (n=5).  
4.2.7    Cellular uptake 
4.2.7.1    Qualitative cellular uptake 
Naturally, CUR emits green fluorescence when viewed under a 535-600 nm 
filter (blue filter, FITC channel). Thus, HT-29 cells were harvested from a confluent 
culture flask and the cells were seeded in 6 well plates at 1 x 105 cells/well and left to 
attach for 24 hr. The culture media were then replaced with treatment media containing 
free CUR and CUR-CS-PEC-NPs at 75 and 150 µM, representing low and high 
treatment concentration, respectively. Controls used were untreated cells and cells 
treated with DMSO and CS-PEC-NPs. At time points of 24, 48, and 72 hr, cells were 
gently washed with PBS, thrice. Fresh PBS was added and cells were viewed under 
fluorescent microscope with 535-600 nm (blue) filter. 
4.2.7.2   Quantitative cellular uptake 
The HT-29 cells were harvested from a confluent culture flask and the cells 
were seeded and treated as described in section 4.2.7.1. At time points of 24, 48, and 
72 hr, treatment media were aspirated and cells were gently washed with PBS. Trypsin 
EDTA was then added and dark incubated at 37oC for 15 min. PBS was then added and 
cells centrifuged at 1000 rpm for 8 min. The supernatant was then removed and cells 
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were lysed using methanol with vortex mixing for 1 minute. The suspension was then 
filtered with 0.22 µm syringe filter and the amount of CUR taken-up by the cells was 
quantified using the HPLC method described in chapter 3, section 3.2.3. 
4.2.8   Cellular apoptosis viewed under fluorescent microscope 
The HT-29 cells were harvested from T-25 tissue culture flask and seeded on 
cover slips fitted in 6 well plates at 1 x 105 cells/well and allowed to attach for 24 hr. 
Then the medium was aspirated and replaced with medium containing CUR-CS-PEC-
NPs representing the lowest and highest effective concentration (75 µM and 150 µM, 
respectively) and equivalent concentrations of free CUR. Untreated cells, CS-PEC-
NPs, and DMSO were used as negative control whilst 5-FU (15 µM) was used as 
positive control. After 24 hr of treatment, cells were fixed and stained with DAPI 
solution as described in section 4.2.5 and viewed under fluorescent microscope using 
430-495nm (red) filter. 
4.2.9    Statistical analyses 
All values were expressed as mean ± SD. Statistical significance was 
determined by paired t-test using GraphPad® Prism 5 software, GraphPad Software Inc. 
Statistical significance was indicated when P-values<0.05. 
4.3       Results and discussion 
In this chapter, several cellular studies were conducted in an attempt to 
determine the efficacy as well as the selectivity of CUR-CS-PEC-NPs as anticancer 
agent. Free CUR was studied as well in order to compare its anticancer activity as crude 
drug and after encapsulation into CUR-CS-PEC-NPs. The anticancer activity of CUR-
CS-PEC-NPs was investigated using the MTT cell viability assay whereas its apoptotic 
effects were evaluated using fluorescent microscopy. Cellular uptake of CUR-CS-PEC-
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NPs by cells was evaluated both qualitatively and quantitatively using fluorescent 
microscopy and spectrophotometric analysis, respectively.  
4.3.1    Maintenance of HT-29 and MRC-5 cells 
HT-29 and MRC-5 cells were maintained at standard cell culture conditions. 
Cells were passaged when confluency is reached every 3-4 days and 5-7 days for HT-
29 and MRC-5 cells, respectively. Antibiotics were seldom used, however as 
precaution, at least three passages of antibiotics-free cultures were carried out before 
any study to avoid any interference in the obtained results. Figure 4.5 shows HT-29 
(A+B) and MRC-5 (C+D) cells viewed under inverted microscope. Both cell lines 
images show 70% confluency, the beaming circular objects (pointed by red arrows) are 
floating growing cells which represents the healthiness of the passaged cells. 
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Figure 4.5 HT-29 cells (A,B) and MRC-5 cells (C,D) viewed under an inverted 
microscope under 20x and 40x magnification, respectively. 
4.3.2    Mycoplasma detection 
The HT-29 cells were checked for the presence of mycoplasma infection before 
performing the studies to exclude the possibility of data interferences. Figure 4.6 
depicts cells stained with DAPI viewed under fluorescence microscope. The DAPI 
staining caused the cells to appear in blue and the image shows no mycoplasma. 
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Figure 4.6 HT-29 cells viewed under fluorescence microscope with 430-495 nm filter 
under 20x (A) and 40x (B) magnification 
4.3.3    Cell viability assay 
We performed the MTT assay to characterize the anticancer properties of CUR-
CS-PEC-NPs using human colorectal carcinoma cells HT-29. To study the selectivity 
of the anti-cancer activity of CUR-CS-PEC-NPs we used normal human lung 
fibroblasts MRC-5. HT-29 cell lines were exposed to five different concentrations of 
CUR-CS-PEC-NPs (75-150 µM), besides equivalent concentrations of free CUR and 
CS-PEC-NPs. Whereas MRC-5 cells were exposed to the lowest and highest treatment 
concentration of CUR-CS-PEC-NPs (75 and 150 µM of CUR load respectively), in 
addition to equivalent concentrations of free CUR and weight of void NPs (CS-PEC-
NPs). The anticancer activity was inversely related to % cell viability which was 
measured in comparison to untreated cells. In both cell lines, 15 µM 5-FU and DMSO 
respectively were used as positive and negative controls. Figure 4.7 shows that CUR-
CS-PEC-NPs suppressed cell proliferation in a dose- and time- dependant manner at 
concentrations similar to that of free CUR. However, both CUR-CS-PEC-NPs and free 
CUR had negligible toxicity on MRC-5 (Figure 4.8) which confirms the selectivity of 
CUR-CS-PEC-NPs to HT-29 cells and this can be inferred to as selectively cancer cells.  
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In the HT-29 cells, increasing CUR-CS-PEC-NPs concentrations caused a 
significant decrease in % cell viability. Cells treated with 150 µM showed less than 
20% viability on days 1 and 2 and less than 12% on day 3, respectively. In contrast, 75 
µM treatments showed % cell viability of 68-77% on days 1 and 2, and 64% on day 3, 
respectively. On day 3 a significant decrease in cell viability was observed at all 
concentrations. The IC50 was 110 µM on days 1 and 2, while it was 90 µM on day 3. 
As illustrated in Figure 4.7, there was an insignificant difference in % cell 
viability between and CUR-CS-PEC-NPs and CUR at all concentrations for the three 
days of study, except for concentrations 110 and 150 µM on day 1 and 110 µM on day 
3. The CS-PEC-NPs aptly showed negligible toxicity against both HT-29 and MRC-5 
cells, which confirms that the carrier matrix is non-toxic. In contrast, 5-FU showed % 
cell viability of 43.07% ±13.79, 52.45% ±1.64, and 15.31% ± 3.59 against HT-29 cells 
on days 1, 2, and 3, respectively. Similar behaviour of 5-FU was observed against 
MRC-5 cells where % viability observed were 50.51% ±4.04, 38.06% ± 6.35, and 
30.51% ± 2.11 on days 1, 2, and 3, respectively. 
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Figure 4.7 HT-29 cell viability after treatment with free CUR, void NPs (CS-PEC-NPs), and CUR-CS-PEC-NPs on days 1, 2, and 3(ns: 
not significant; ***p<0.001), n=5
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Figure 4.8 MRC-5 cell viability after treatment with free CUR, void NPs (CS-PEC-NPs), and CUR-CS-PEC-NPs on days 1, 2, 
and 3, n=5
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CUR is highly sensitive and vulnerable to degradation. Hence, it is crucial to 
ascertain  whether the anticancer properties was retained after fabrication as CUR-CS-
PEC-NPs. Reports on encapsulated CUR in CS/poly(butyl cyanoacrylate) NPs (Duan 
et al., 2010), PLGA NPs (Nair et al., 2012), CS-g-poly(N-vinylcaprolactam) NPs 
(Rejinold et al., 2011), β-cyclodextrin NPs (Kazemi-Lomedasht et al., 2013), and 
sulphate-CS NPs (Anitha et al., 2011) have shown at least similar anticancer activity of 
encapsulated CUR compared to free CUR. Similarly, the CUR-CS-PEC-NPs showed 
proportionate cytotoxic activity against HT-29 compared to free CUR, suggesting that 
the anticancer activity of CUR was not compromised during the nanoparticle 
fabrication process. On the contrary, both CUR and CUR-CS-PEC-NPs showed no 
signs of toxicity against MRC-5 cells, which confirms their selectivity towards tumour 
cells. The CUR uptake by tumour cells was favoured over normal cells not only due to 
the former being leakier and larger in size, but also due to differences in membrane 
structure and protein composition (Anitha et al., 2011; Rejinold et al., 2011; Kunwar 
et al., 2008). The CS-PEC-NPs showed no toxicity against both HT-29 and MRC-5 
cells, therefore, CS-PEC-NPs did not contribute to the cytotoxicity observed against 
HT-29 cells. We may also conclude that the carrier is safe and nontoxic to normal cells. 
The lack of cytotoxic behaviour of CS-NPs (Das et al., 2010; Anitha et al., 2011; 
Archana et al., 2013), PEC-NPs (Zhang et al., 2015), and CS-PEC-NPs (Luo & Wang, 
2014; Maciel et al., 2017) have also been previously reported.  
4.3.4    Morphological changes of cells by CUR-CS-PEC-NPs 
To study the induction of cellular apoptosis after the various treatments, cells 
were examined microscopically after DAPI staining. The morphology of cells treated 
with CS-PEC-NPs and DMSO (Figure 4.9, B-C), respectively, depicts no signs of 
hindrance to cell proliferation and similar cell colonies to those observed by control 
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cells (Figure 4.9A). In addition, no morphological changes to the nuclei was observed, 
remaining spherical and shiny. This indicates that DMSO and CS-PEC-NPs do not 
induce apoptosis to HT-29 cells. In contrast, cells treated with equivalent high and low 
concentrations of CUR-CS-PEC-NPs and free CUR, as well as 15 µM 5-FU showed 
significant changes in nuclear morphology (Figure 4.9, D-H), respectively. Apparently, 
there were internal deflection, fragmentation, formation of irregular edges around the 
nuclei. Furthermore, the cell membrane looked serrated in this treatment group, 
suggesting that the apoptotic effects of CUR-CS-PEC-NPs, free CUR and 15 µM 5-FU 
were manifested in a similar manner.  
Bisht et al., (2011) encapsulated CUR in polymeric NPs using N-
isopropylacrylamide (NIPAAM), vinylpyrrolidone (VP), and acrylic acid (AA). The 
capability of free CUR and CUR-polymeric NPs to induce stellate cell apoptosis after 
morphological examination of the nucleus showed that the fragmentation of the nucleus 
was dose-dependent. Tang et al., (2010) developed CUR-polymeric conjugates as 
anticancer agent. The cellular apoptotic effects were studied against SKOV-3 and 
OVCAR-3 ovarian cancer cells and MCF-7 breast cancer cells. The nucleolus 
fluorescence images obtained by DAPI staining showed significant apoptosis and only 
few cells survived at the end of the study. Chang et al., (2013) fabricated a water soluble 
CUR-PLGA NPs for cancer treatment. They studied the anticancer effects of CUR-
PLGA-NPs against human oral cancer, CAL27-cisplatin resistant (CAR) cells. 
Compared to untreated (control) cells, cells treated with CUR-PLGA-NPs showed 
apoptotic morphological features such as internucleosomal fragmentation under 
fluorescence microscopy. We may conclude that data from the above studies strongly 
confirms the apoptotic effects CUR is not markedly changed when fabricated in a 
suitable nanoformulation.  
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Figure 4.9 Fluorescent nuclear images of untreated cells (A), cells treated with 
CS-PEC-NPs (B), DMSO (C), 75 µM (D) and 150 µM (E) of CUR-CS-PEC-NPs, 75 
µM (F) and 150 µM (G) of free CUR, and (H) 15 µM of 5-FU. Arrows indicate 
fragmentation and formation of irregular edges around the nuclei 
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4.3.5    Cellular uptake  
Cellular uptake studies are vital in ascertaining the ability of the anticancer 
formulation to target cells. Capitalizing the photochemical properties of CUR, 
fluorescence spectroscopy was used to qualitatively evaluate the HT-29 cellular uptake 
of free CUR and CUR-CS-PEC-NPs. As illustrated in Figure 4.10, untreated cells and 
CS-PEC-NPs fluorescence images were captured as controls. Images of the cells were 
taken at 24-hr intervals for 72 hr. Control fluorescent microscopy images seemed dark 
due to the absence of fluorescence. At low CUR concentration (75 µM) both free CUR 
and CUR-CS-PEC-NPs, showed moderate fluorescence intensity on day 1. However, 
the fluorescence intensity of free CUR rapidly decreased with time that it almost 
diminished on day 3. However, fluorescence intensity of CUR-CS-PEC-NPs, although 
faint, yet was more visible on days 2 and 3. This could mean that CUR-CS-PEC-NPs 
are more efficiently assimilated by the cells than free CUR at this concentration. This 
outcome explains the higher cytotoxicity of CUR-CS-PEC-NPs compared to free CUR 
at low concentrations on days 2 and 3 (as discussed in section 4.3.3). At both 
concentrations, CUR gives a green fluorescence from the entire cells which indicates 
cellular internalization rather than adhesion to the surface of the cells (Ha et al., 2012). 
Previous studies reported that CS formulated NPs distribute in the whole cells via 
several discrete pathways (Yun et al., 2009). The results summed up above are in 
concert with previous reports that indicate that encapsulating CUR in nanocarriers 
enhances its cellular uptake and subsequent properties (Aseh & Ríos, 2009; Liu et al., 
2012). In contrast, on day 1 of high CUR concentration (150 µM) treatment, both free 
CUR and CUR-CS-PEC-NPs showed highly intensive fluorescence at similar extent. 
However, the fluorescence intensity decreased gradually on the subsequent days, even 
though still visible. 
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Figure 4.10 Fluorescence microscopy imaging of the cellular uptake of CUR 
from high and low equivalent doses of CUR-CS-PEC-NPs and free CUR on days 1, 2, 
and 3. (20x magnification). 
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Quantitative analyses of CUR after cellular uptake were performed 
spectroscopically by determining the CUR concentration from the lysed cells. Figure 
4.11 shows that CUR cellular uptake was highest on day 1 followed by gradual decrease 
in the subsequent days. The findings of the cytotoxicity and qualitative cellular uptake 
studies indicated that CUR uptake by the HT-29 cells was higher from CUR-CS-PEC-
NPs compared to free CUR at low concentration (75 µM) on days 2 and 3. This could 
be attributed to the mucoadhesive properties of CUR-CS-PEC-NPs which promoted 
extended contact time with the cells with subsequent release and uptake of CUR at this 
low concentration. There is also the possibility that intact CUR-CS-PEC-NPs were 
taken up as well. However, this mucoadhesive advantage was insignificant at high 
CUR-CS-PEC-NPs concentration which could be diminished due to the high available 
concentration of CUR. The quantitative cellular uptake showed similar data compared 
to the qualitative cellular uptake findings. 
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Figure 4.11 Retrieved CUR after treatment with high and low doses of free CUR and CUR-CS-PEC-NPs on days 1, 2, and 3, n=3
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NPs can be internalized within the cells via several pathways including direct 
penetration (Gref et al., 2000), endocytosis, enterocytosis (Jiang et al., 2008), 
micropinocytosis, and receptor mediated endocytosis (RME) (Alkilany & Murphy, 
2010). NPs within the size range of 20-50nm are mostly taken up by nanophagocytosis, 
whereas nanoparticle in the range of 100-200nm are preferentially taken up by 
enterocytes (Froehlich, 2016).  
Several physico-chemical  properties such as particle size, molecular weight, 
particles shape (Nam et al., 2009), solubility, and surface functionality (He et al., 2010) 
affect the cellular uptake and intracellular trafficking of the NPs. In addition, the 
structural influence of the cell type also plays a role in cellular uptake (Nam et al., 
2009).  For example, small and uniformly sized NPs have better cellular uptake 
compared to larger particles (Nam et al., 2009). The surface properties of the NPs play 
major role in their uptake as hydrophobic and positively charged NPs show better 
cellular uptake (Sanjeeb et al., 2002).  
In the present formulation, the small size of the CUR-CS-PEC-NPs, its spherical 
shape and positive surface charge contributed to the high cellular uptake observed since 
these factors are crucial to and promote uptake into cells. Consequently, high 
concentrations of CUR-CS-PEC-NPs led to better cellular uptake of CUR by the HT-
29 cells. However, the mucoadhesive properties of CUR-CS-PEC-NPs influenced the 
cellular uptake of the low initial CUR concentration, whereas at high initial CUR 
concentrations, the high availability of CUR had the dominant effect in the cellular 
uptake rather than the mucoadhesion effects. The time-dependant decrease in cellular 
uptake could be attributed to the degradation of CUR into smaller molecules such as 
trans-6-(4-hydroxy-3-methoxyphenul)-2,4-dioxo-5-hexenal, ferulic acid, feruloy 
methane, and vanillin which lack the auto-fluorescence properties of CUR (Ha et al., 
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2012) or to the efflux of CUR from the cells with time (Mulik et al., 2010). At low 
CUR concentration treatment at days 2 and 3, higher cellular uptake of CUR-CS-PEC-
NPs was obtained compared to free CUR. This could be attributed to the mucoadhesion 
of the NPs and to the slow release of CUR from CUR-CS-PEC-NPs, similar results 
were obtained by Mohanty & Sahoo, (2010) where they have reported higher cellular 
uptake of CUR-nanoformulation compared to free CUR at low concentrations by 
different tumour cells. On the other hand, both CUR and CUR-CS-PEC-NPs presented 
similar cellular uptake behaviour at high CUR concentration, particularly, 67.97 ± 2.09, 
30.81 ± 0.30, and 11.64 ± 0.05 for CUR-CS-PEC-NPs, and 72.21± 0.79 , 37.11 ± 0.66, 
and 14.64 ± 0.69 for free CUR, on days 1, 2, and 3, respectively. However, CUR-CS-
PEC-NPs have the added advantage of better assimilation in the cell, hence likely to 
result in better bioavailability at the target site than free CUR.  
4.4      Conclusion 
In summary, the antiproliferative effects and cellular uptake of CUR was 
demonstrated upon encapsulation in CUR-CS-PEC-NPs. In fact, the uptake was 
enhanced after encapsulation, especially at lower concentrations. Morphological 
examination of nuclei confirmed the apoptotic properties of CUR-CS-PEC-NPs. Thus 
far, the preceding chapters have indicated that the CUR-CS-PEC-NPs have the property 
of retaining their integrity when exposed to acid and alkaline milieu and release only a 
minimal percentage of CUR. They have also demonstrable mucoadhesive properties 
and release CUR more favourably in the colonic media. More importantly, the CUR-
CS-PEC-NPs have demonstrable apoptotic properties comparable to that of pure CUR. 
On the basis of these findings, we are primed to perform an in vivo study using animal 
models in order to assess the bioavailability and prove the concept, to be discussed in 
chapter 5. 
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 5  Development and Validation of a HPLC method and pharmacokinetic 
studies on CUR-CS-PEC-NPs 
5.1 Introduction 
5.1.1  HPLC method development and validation 
HPLC is an advanced form of liquid chromatography and it is one of the most 
commonly used analytical techniques in new drugs and formulations development. 
HPLC developed analytical method should be simple, utilizes the most common 
stationary phases and MP, and preferably uses binary MP rather than tertiary or 
quaternary MP (Shabir, 2004).  
The development of an HPLC analytical method comprises of the following 
steps: Step 1, selection of the preliminary HPLC method and the initial system based 
on the data available in the literature for the particular analyte (Shabir, 2004). In this 
step, the basic parameters are chosen, such as sample preparation, mode of 
chromatographic separation, type of elution (gradient/ isotonic) and type of the detector 
(Guidlines, 2017). Step 2 entails the selection of chromatographic conditions to retain 
all analytes, such as the MP strength and the flow rate (Shabir, 2004). Step 3 aims to 
achieve the best resolution and minimum run time, hence parameters such as column 
dimensions, packing particle size, run time, and flow rate are optimized in this step 
(Guidlines, 2017). The final step, step 4, is the method validation which is performed 
to ascertain the reliability and reproducibility of the analytical method (Shabir, 2004; 
WHO, 2017). 
The extent of the method validation depends on both the purpose of the analysis 
and to whether the HPLC method was completely developed or slightly modified from 
a previously validated method  (WHO, 2017). Quantitative analytical methods are 
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validated against several parameters such as specificity, precision, linearity, accuracy, 
and the limit of detection (UNODC, 2009). The internal standard (IS) is commonly 
used in analytical methods where it is added in constant volume to both the calibration 
standards and samples (SW846, 2003). The calibration curve employs the ratio 
response of the analyte to the IS plotted against their concentrations (Dolan, 2012). 
The IS is usually used in methods where multiple sample preparation steps is 
required and volume recovery at each step may vary (Dolan, 2012). The purposes 
behind using IS are to minimize the volume variations introduced into the 
chromatography system and minimize the response variations of the chromatography 
system, thus, enhancing  the accuracy of the analytical method (Dolan, 2012; SW846, 
2003). IS used in an analytical method should never be expected to be found in 
analytical samples, must be available in pure form, responsive to analytical method, 
have structural resemblance to the analytes, and, ideally, eluted after the analyte (Dolan, 
2012; SW846, 2003). 
5.1.2  In vivo pharmacokinetics studies 
As discussed in chapter 1, CUR possesses a variety of therapeutic activities, 
including anticancer activities. However, its therapeutic usefulness is restricted due to 
low water solubility (Yallapu et al., 2010), extensive intestinal and hepatic metabolism, 
and rapid clearance,  all of which results in poor bioavailability following oral 
administration (Cheng et al., 2013). Therefore, research has been focused on 
encapsulating CUR in delivery systems such as polymeric NPs (Gupta et al., 2009) with 
a view to addressing some of the above constraints. In general, drug delivery systems 
developed for enhancing the oral bioavailability of drugs, particularly hydrophobic 
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drugs, are evaluated through studying the pharmacokinetics behaviour of the respective 
drugs using animal models (Sjödin et al., 2011; Wan et al.,, 2012). 
Sulphasalazine (SSZ), an anti-inflammatory agent, is composed of 
sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA) with diazo bond linkage. 
Following oral administration of SSZ, a small amount of the drug is absorbed in the 
small intestine, whereas the majority of the dose is hydrolysed by the colonic microflora 
into SP and 5-ASA, where the former is completely absorbed in the colon (Gu et al., 
2011). Thus, SSZ has been used as a marker drug for studying the orocaeceal transit 
times of dosage forms (Wong & Yuen, 2001; Björnsson & Olsson, 2005; Sunesen et 
al,, 2005). 
In pharmacokinetics and in vivo investigations, it is usually imperative to 
perform a pilot study on a limited number of animal models before transposing and/or 
fine-tuning to the study proper. It allows us to test the feasibility of methods and 
procedures to be used on a larger scale (Thabane et al., 2010). Pilot studies can be used 
to assess study procedures, estimate sampling rates, and determine study parameters, 
among others. In pharmacological studies, it is referred to “proof of concept” studies. 
Essentially, pilot studies are followed by a full and larger study to obtain clinically 
relevant data (Arain et al., 2010).  
5.1.3    Aims and objectives 
The CUR-CS-PEC-NPs were successfully formulated, characterized and 
studied with regard to in vitro release and mucoadhesion in Chapters 2 and 3. The anti-
proliferative activities and cellular uptake of the CUR-CS-PEC-NPs were further 
discussed in chapter 4. The data obtained so far indicates that the CUR-CS-PEC-NPs 
are mucoadhesive, especially in the colonic milieu whilst the physical integrity of the 
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particles are retained in the upper GIT. Furthermore, there is evidence that the CUR is 
released in colonic conditions. To investigate this hypothesis, a pilot study using rats as 
animal model was performed and the data obtained is discussed in detail henceforth. 
Pharmacokinetic investigations rely on a credible analytical procedure able to 
detect  plasma concentrations of drugs being analysed. Consequently, the work in this 
chapter was divided into two parts; i) development and validation of HPLC analytical 
methods for the quantitative determination of CUR and SP in plasma and ii) 
pharmacokinetic studies of CUR-CS-PEC-NPs and SSZ-CS-PEC-NPs on animal 
models. 
5.2 Materials and methods 
5.2.1 Materials 
Material Supplier 
CUR-CS-PEC-NPs Prepared as described in chapter 2 
Curcumin analytical standard Fluka, USA 
Acetonitrile (HPLC grade) RCI Labscan, Thailand 
Methanol (HPLC grade) RCI Labscan, Thailand 
Glacial acetic acid R&M chemicals, UK 
Sodium acetate trihydrate NacalaiTesque, Japan 
Sulphapyridine Tokyo Chemical Industry, Japan 
Piroxicam NacalaiTesque, Japan 
17-βestradiol NacalaiTesque, Japan 
Absolute ethanol R&M chemicals, UK 
Theophylline R&M chemicals, UK 
Sulphasalazine Tokyo Chemical Industry, Japan 
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5.2.2 HPLC methods development and validation 
5.2.2.1 HPLC instrumentation and conditions 
The HPLC system comprised of a Series 200 pump, Perkin Elmer, USA 
equipped with UV/Vis detector (Series 200 UV/Vis detector, Perkin Elmer, USA). The 
stationary phase used was a RP-column ZORBAX Eclipse Plus® (C18, 250mm x 4.6 
mm, 5 µm), (Agilent, USA) for both the analysis of CUR and SP. 
For the CUR analyses, the method described by Heath et al. (2003) was adopted 
with slight modifications as follows: a 1 L MP was prepared by adding 410 ml of 
acetonitrile, 360 ml of water, 230 ml of methanol, and 10 ml of glacial acetic acid. The 
resulting mixture was vacuum filtered through 0.2 µm filter paper, thrice and run at rate 
of 1 ml/min on the HPLC system. The sample volume was 50 µl and the detector set at 
425 nm. A 20.0 µg/ml 17-β-estradiol (EST) solution in methanol was used as the IS 
and deproteinising agent for the plasma samples and simultaneously detected at 262 
nm. 
For SP analyses, the MP comprised of 80% of acetate buffer (pH 4) and 20% 
Acetonitrile. Acetate buffer was prepared by mixing 847 ml of 0.1 M acetic acid and 
153 ml of 0.1 M sodium acetate trihydrate (Amekyeh, 2016), the resulting mixture was 
then vacuum filtered with 0.2 µm filter paper, thrice. The MP was run at 1.2 ml/min 
and 30 µl of the sample was injected with the detector set at 260 nm. A 5 µg/ml 
theophylline (TP) solution in methanol was used as IS and detected at the same 
wavelength. The IS solution was also used as the deproteinising agent for these plasma 
samples. 
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5.2.2.2 Plasma standards 
Stock plasma solutions containing CUR and SP at 50 µg/ml and 40 µg/ml, 
respectively, were prepared by spiking the appropriate amounts of the drugs solutions 
into appropriate volumes of the human plasma. The stock solutions were subsequently 
diluted with blank human plasma to prepare the calibration standards for each drug. For 
methods validation, three concentrations of each drug representing low (LC), mid 
(MC), and high (HC) concentrations. The LC, MC, HC for CUR were 0.03, 0.3, and 10 
µg/ml, and for SP 0.1, 0.5, and 20 µg/ml, respectively. 
5.2.2.3 Plasma sample preparation 
The plasma samples for validation analyses were prepared by transferring 100 
µl of drug-spiked plasma and 150 µl of the IS solution into microcentrifuge tubes. The 
tubes were vortex mixed for 2 min. and then centrifuged at 14000 rpm for 10 min. The 
clear supernatants were aspirated and filtered using 0.20 µm syringe filter and directly 
injected onto the HPLC system. 
5.2.2.4 Specificity 
The specificities of the analytical methods were based on individual observation 
of the chromatograms obtained for the analytes and IS prepared in appropriate solvents. 
A further test of specificity was based on a run of drug-free plasma and observation of 
the resulting chromatograms for any interferences at the retention time of the analytes 
or their respective IS. Finally, analytes and IS were spiked separately in plasma and 
their chromatographs were visually observed as before. The specificity studies are 
crucial in excluding peak interferences from the plasma, ascertaining that the analytes 
elute similarly as pure drug solutions or spiked in plasma, and that the elution of the 
analyte is not affected by the IS or vice versa.  
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5.2.2.5 Linearity and range 
The calibration curves for CUR and SP in drug-spiked plasma were obtained 
over the following concentration ranges: 0.05-10 µg/ml and 0.1-20 µg/ml, respectively. 
The calibration curves comprised of the ratio of the peak signal of each analyte to that 
of the respective IS, plotted against the respective concentration. Each analysis response 
represents the mean of five separate runs.  
5.2.2.6 Precision 
The intra-day and inter-day precision of the analyses at the three validation 
concentrations for each drug was determined as the reproducibility and repeatability of 
the developed methods. The percentage coefficient of variation (%CV) was used as the 
mean value of five independent runs at each concentration and calculated as follows: 
%CV =  
Standard deviation (SD)
Mean concentration
 x 100%    Eq. 5.1 
5.2.2.7 Accuracy 
The intra-day and inter-day accuracy of the analysis at the three validation 
concentrations for each drug was determined to study the reliability of the results 
obtained from the developed method. The elative error was used as the mean value of 
five independent runs at each concentration and calculated as follows: 
Relative error =  
mean measured concentration−true concentration
True concentration
x 100%  Eq. 5.2 
5.2.2.8 Recovery 
Retrieving CUR and SP from plasma samples after the extraction procedure was 
investigated by comparing the peak signal of each drug at the three validation 
concentrations from the spiked plasma samples with those obtained from pure drug 
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solutions in respective solvent. The data was presented as % recovery and calculated as 
follows (n=5): 
% Recovery =  
Mean concentration of drug in spiked plasma
Mean concentration of pure drug solution
 x 100%     Eq. 5.3 
5.2.2.9 Limits of detection and quantification 
The sensitivity of the developed methods were assessed in terms of LOD and 
LOQ and were determined by employing the lowest concentration of each analyte (LC) 
and calculated as follows: 
LOD =
3xSD of the LC
Slope of the calibration curve
      Eq. 5.4 
LOQ =
10xSD of the LC
Slope of the calibration curve
     Eq. 5.5 
5.2.3 In vivo Study 
5.2.3.1    Preparation of CUR-CS-PEC-NPs and SP-CS-PEC-NPs 
CUR-CS-PEC-NPs were prepared as discussed in section 2.2.2.2. SSZ-CS-
PEC-NPs were formulated using the same procedure, however, by using the same 
amount of SSZ instead of CUR. 
5.2.3.2    Animals 
Pharmacokinetic studies on CUR and SSZ after oral administration of CUR-
CS-PEC-NPs and SSZ-CS-PEC-NPs were conducted on male Sprague-dawley rats 
(250 g) with prior approval by AWERB, University of Nottingham, UK, approval 
reference number UNMC7. The animal studies were conducted according to the 
requirements of the UK Animals (Scientific Procedures) Act 1986 (ASPA) draft Code 
of Practice for the care and accommodation of animals (February 2013) and carried out 
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by competent technicians. The rats were obtained from the animal holding unit of 
University of Science, Malaysia, Penang. The animals were acclimatized 7 days prior 
to the experiment under standard conditions of temperature, humidity, and light with 
free access to food and water. The animals were fasted overnight (12 hr). After PO 
treatment, water and food were allowed at 2 and 4 hr, respectively.  
5.2.3.3    Procedural care of the rats 
The rats were allowed to move freely in their respective cages throughout the 
study period. However, they were restricted in metabolic cages during the blood 
sampling periods. The amount and rate of samplings were limited to decrease the 
discomfort. The tail end of each rat was clipped only once during the initial blood 
sampling time. After each sampling time, the wounded tails were swabbed with cotton 
wool rinsed with 70% alcohol to reduce infections. Wounds were monitored for 
bleeding after each sampling. Water and food supply were resumed after 2 and 4 hr 
post-administration, respectively. At the end of the study, the rats were humanely 
sacrificed.  
5.2.3.4   Pharmacokinetics studies 
Pharmacokinetic studies were carried out to proof the concept of the colon-
specific delivery of CUR in CUR-CS-PEC-NPs. Sprague-dawley rats were randomly 
divided into three groups (n=4) receiving CUR-CS-PEC-NPs, SSZ-CS-PEC-NPs, and 
free CUR containing equivalent amount of drug (10 mg/kg body weight). Treatments 
were administered orally in 2 ml suspensions. Under topical anaesthesia, about 500 µl 
of blood sample were collected at predetermined time intervals (0, 1, 2, 4, 6, 8, 12, and 
24 hr) from the tail into heparinized microcentrifuge tubes. The blood samples were 
centrifuged upon collection at 14000 rpm for 10 min. and the supernatant was aspirated 
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and stored at -80oC until use. CUR and SP concentration in the supernatant were 
determined by HPLC methods developed in sections 5.3.2.1 and 5.3.2.2, respectively.  
5.2.3.5 Data and statistical analyses 
Pharmacokinetic parameters were calculated using standard model-independent 
pharmacokinetic formulas. The obtained plasma concentrations (ng/ml) were plotted 
against their respective times and the resulting curves were used to obtain the peak 
plasma concentration (Cmax), time of occurrence (Tmax), and elimination half-life (t1/2) 
which was calculated as 0.693/Kel . The extent of drug absorption was measured by 
calculating the area under the plasma drug concentration time curve (AUC) which was 
calculated using log trapezoidal rule using GraphPad® Prism 5 software. Absorption 
rate (Ka), elimination rate (Kel) as well as the statistical analysis were calculated using 
GraphPad® Prism 5 software. Statistical analyses were performed using the student’s t-
test where p values less than 0.01 and 0.001 are deemed as statistically significant and 
very statistically significant, respectively. 
5.3 Results and Discussion 
5.3.1 Selection of the internal standard 
As discussed in section 5.1, the IS should ideally have similar solubility and 
chromatographic behaviour as the analyte (Dolan, 2012). In this regard, the IS should 
have close structural properties as the analyte. The used HPLC system (Series 200, 
Perkin Elmer, USA) provides simultaneous multi-wavelength detection, thus, detection 
of the IS at the same wavelength as the analyte was not necessary in this study. 
5.3.1.1 Internal standard for CUR analysis method 
IS that have been used in HPLC analyses for CUR include emodin (Han et al., 
2011; Sun et al., 2013), 4-hydroxybenzophenone (Ma et al., 2007), tetra-(m-
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hydrophonyl)-chlorine (Ireson et al., 2001), and EST (Heath et al., 2003a; Pak et al., 
2003; Yu & Huang, 2012). Since EST was the most commonly used IS and readily 
available, it was chosen as the IS for this procedure. 
Figure 5.1 shows a representative chromatogram of a solution containing 20 
µg/ml of CUR and 10 µg/ml of EST as IS, detected at 262 nm. The retention times 
obtained were 6.4 and 9.4 for EST and CUR, respectively. Independent runs of EST 
and CUR were performed to assign the respective peaks. The chromatogram clearly 
shows a fairly symmetric and sharp peak of EST using the preliminary HPLC analytical 
method of CUR, however, optimization of the analytical method was necessary and 
will be discussed in section 5.3.2. 
 
Figure 5.1 Chromatogram for EST (10 µg/ml) and CUR (20 µg/ml) 
5.3.1.2 Internal standard for SP analyses method 
IS that have been used in HPLC analysis of SP include benzamide (Chungi et 
al., 1989), caffeine (CAF) (Kasprzyk-Hordern et al., 2007; Tolika et al., 2011), 
sulfamethizole (Maudens et al., 2004), piroxicam (PIR) (Amekyeh et al., 2015), and 
dimenhydrinate (Gu et al., 2011). Amongst all, CAF and PIR were readily available 
and known for their simple detection with intense peak response (Tolika et al., 2011; 
Amekyeh, 2016). TP, up to our knowledge, has never been used as IS for SP analysis. 
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However, it is commonly used as IS in analytical methods, easily dissolved and 
detected, inexpensive, readily available (Fitzpatrick & Mcclelland, 1983; Marten et al., 
2017), can be detected in short time using readily available MP (Charehsaz et al., 2014), 
and, most importantly, its chemical structure resembles that of SP (Figure 5.2). 
Therefore, CAF, PIR, and TP were initially selected as IS for this analytical method.  
 
Figure 5.2 Chemical structures of SP (A) and TP (B) (obtained from 
www.sigma-aldrich.com) 
Figure 5.3 shows representative chromatograms for CAF (A), PIR (B), and TP 
(C) at 80 µg/ml, 60 µg/ml, and 40 µg/ml respectively, under the same chromatographic 
conditions. The peak responses were detected at 1.86, 13.82, and 3.29 min. for CAF, 
PIR, and TP respectively. CAF eluted too early and likely to overlap with the plasma 
peaks and the response peak was relatively broad. PIR run time was too long with 
improper base peak. In contrary, TP response peak was sharp with suitable retention 
time. Hence, it was selected as the IS for SP analytical method.  
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Figure 5.3 Chromatograms for CAF (A), PIR (B), and TP (C) under the same HPLC 
conditions 
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5.3.2 Mobile phase composition and elution method 
One of the preliminary and essential parameters in HPLC method development 
is choosing the elution mode, isocratic or gradient elution. If the composition and flow 
rate of the MP remains constant throughout the sample run, then it is referred as 
isocratic elution. On the other hand, changing the ration of polar to non-polar 
compounds in the MP during the sample run is known as gradient elution (Schellinger 
& Carr, 2006). 
Gradient elution is usually used in analysing multi-component samples of a 
wide range of polarities (Barkovich, 2017; Schellinger & Carr, 2006), by which 
separation can be achieved in shorter run times (Barkovich, 2017). However, isocratic 
elution is simpler, easier to transfer between columns, instruments and laboratories 
(Schellinger & Carr, 2006), maintain constant flow rate and provides better 
reproducibility (Barkovich, 2017). 
Essentially, both elution methods can be used for any sample analysis and the 
choice is based on the number and polarity of the sample components (Schellinger & 
Carr, 2006). In this study, samples will contain one component only, thus, isocratic 
elution was chosen for both CUR and SP analytical methods. 
5.3.2.1 HPLC method for CUR determination 
Heath et al. (2003b) developed an HPLC method for determination of CUR in 
plasma and urine using MP containing acetonitrile: methanol: de-ionized water: acetic 
acid at ratio 41:23:36:1, respectively. 20µl of samples containing EST as the IS were 
injected onto the HPLC system. The MP was run at 1 ml/min and samples detected at 
262 nm.  
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Based on the aforementioned conditions, a preliminary run of 20 µg/ml CUR 
and 10 µg/ml EST as IS solution in methanol was performed under the same conditions. 
Figure 5.4 shows the chromatogram obtained where both EST and CUR peaks appear 
sharp and fairly symmetric at 6.38 and 9.32 min., respectively. 
 
Figure 5.4 Chromatograms for EST and CUR using Heath et al. (2003b) 
method 
 Although the peaks obtained by Heath et al. (2003b) method were sharp, 
resolved, and fairly symmetric, the sensitivity of the detector to CUR was poor. It must 
be added that it is not very crucial if the sensitivity of the detector to the IS is not high 
because that can be compensated by using a higher concentration. From a prior UV 
scan, we are aware that CUR absorb at maximum at 435 nm. Therefore, sample run was 
detected simultaneously at two separate wavelengths of 262 nm and 425 nm. 
Chromatograms obtained (Figure 5.5) clearly shows a more intense detector response 
to CUR, however, EST peak was not detectable at 425 nm. Since the HPLC instrument 
is capable of simultaneously detecting samples at multi-wavelengths without the need 
to re-run the samples, both wavelengths 262 nm and 425 nm were subsequently used 
for detecting EST and CUR, respectively. Detecting the IS at different wavelength of 
the analyte was previously reported (Pak et al., 2003), where the IS (EST) and CUR 
were detected at 280 nm and 430 nm, respectively. 
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Figure 5.5 Chromatogram of CUR at 425 nm 
5.3.2.2 HPLC method for SP determination 
The HPLC method for SP determination was developed based on Amekyeh et 
al. (2015) method for the determination of SP along with amphotericin B and 
paracetamol. In Amekyeh et al. (2015) method, gradient elution of the MP comprised 
of Acetate buffer (pH 4) and acetonitrile, SP was detected at 254 nm. 
Preliminary runs comprised of three samples of 40 µg/ml SP dissolved in the 
following solvents: (i) DSMO: methanol, 1:1, (ii) methoanol, and (iii) acetate:methanol, 
1:1. A 30 µl aliquot of the samples were injected into the HPLC system and the MP 
was run at 1 ml/min and SP detected at 254 nm.  The MP comprised of [A] acetate 
buffer (pH 4), and [B] acetonitrile, with isocratic elution was used and the ratios of A 
to B was varied between 60-90:40-10 for each of the 3 samples. Optimum analyte peak 
in terms of shape and retention time was achieved at the MP ratio of 70:30 with 
methanol (ii) as solvent. Figure 5.6 shows the chromatogram obtained from 40 µg/ml 
SP dissolved in methanol where, the peak was eluted at 3.83 min. Thus, these 
chromatographic conditions were selected for further optimization of the analytical 
method.  
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Figure 5.6 Chromatogram of SP dissolved in methanol using MP ratio 70:30 
(acetate buffer (pH 4) : acetonitrile) 
A mixture of 20 µg/ml SP and 5 µg/ml TP as IS was run using the 
aforementioned method, however, unresolved peaks with high noise was obtained 
(Figure 5.7A), hence, the analytical method was further optimized with MP ratio set at 
80:20 (acetate buffer at pH4 :acetonitrile), flow rate 1.2 ml/min and detection 
wavelength 260 nm. Figure 5.7B illustrates the resulting chromatogram showing 
distinctive and fairly symmetric peaks of both SP and TP eluted at 3.00 and 5.07 min, 
respectively. The optimized chromatographic conditions were further selected for 
subsequent work. 
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Figure 5.7 Chromatograms of TP and SP at MP ratio and detection wavelength of 
70:30, 254 nm (A) and 80:20, 260 nm (B), respectively 
5.3.3 Effects of the plasma and the deproteinising agent on peak resolution and 
symmetry 
Precipitation of protein is essential in excluding artefacts and interferences from 
biological samples in analytical work (Daykin et al., 2002). It is the most commonly 
used method due to its simplicity and ability to denature protein and destroy its drug 
binding ability (Polson et al., 2003). Protein solubility in biological fluids is attributed 
to its hydrophilic surface and ionic interactions (Chang et al., 2007) and to the repulsive 
electronic forces between similarly charged molecules. At the isoelectric point (pI) 
proteins become insoluble due to the lack of a net charge (Polson et al., 2003). 
The goal of protein precipitation is essentially to decrease its solubility by direct 
and indirect interactions between the deproteinizing agent and protein moieties (Chang 
et al., 2007). A vast array of methods have been used for protein precipitation such as 
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pH adjustment, addition of salts, ultrafiltration (Daykin et al., 2002), use of strong acids 
or basis (Chamberlain, 1995) and thermal precipitation (Burgess, 2009). However, the 
drawbacks of  these methods are their potentially degradative effects on the analyte and 
the possibility of the analyte becoming trapped in protein aggregates (Chang et al., 
2007). 
Organic solvents such as acetone, ethanol, and acetonitrile have been used for 
decades as deproteinizing agents (Burgess, 2009). They decrease the dielectric constant 
of the plasma protein solubility, displace the water molecules on the protein surface, 
thus decreasing its hydrophobic interaction and eventually leading to protein 
precipitation (Polson et al., 2003).  
Protein precipitation using organic solvents is an easy, simple, and fast method 
that can be used for a wide range of applications. In addition, these agents are volatile 
and can be used as MP (Sedgwick et al., 1991). The type and amount of the organic 
solvent determine the protein precipitation efficiency (Chang et al., 2007). Another 
concern with regard to the use of deproteinizing agents is that if they are markedly 
different from the MP, there could be a transient modification to the MP at the time of 
injection and this can perturb the elution dynamics of the analyte. The most preferable 
practice is using the MP as the deproteinizing agent and its addition to the IS solution 
as this would cause only a nuanced change in MP composition when injected.  
In this study, the MP described in sections 5.3.2.1 and 5.3.2.2 were used both 
as deproteinizing agents and solvents for the IS in CUR and SP analytical methods, 
respectively. However, modifications to the peak such as broadening, baseline bias and 
tailing were observed (Figure 5.8). The MP were thus substituted with methanol (Figure 
5.9) where peaks clearly appear well resolved, sharp, fairly symmetrical, on the 
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baseline, and without splitting. Thus, methanol was used subsequently both as the 
deproteinizing agent and solvent for the IS. Using different solvents as deprotenizing 
agents and solubilizing the IS would result in analytes dilution in the plasma samples, 
this effect was avoided in this study while effective protein precipitation was 
maintained. 
 
Figure 5.8 Chromatograms of CUR (A) and SP (B) and their respective IS 
using the MP as deproteinizing agent 
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Figure 5.9 Chromatograms of CUR (A) and SP (B) and their respective IS 
using methanol as deproteinizing agent 
5.3.4 HPLC method validation 
A number of HPLC methods for the detection of CUR and suitable IS in 
biological fluids have been reported (Yang et al., 2005; Gou et al., 2011; Wan et al,, 
2012; Khatik et al., 2013; Anitha et al., 2014). In general, SP is detected using complex 
methods simultaneously with other sulphonamides (Maudens et al., 2004; Gu et al., 
2011; Tolika et al., 2011). In the present study, two separate methods for analyses of 
CUR and SP, which would be suitable for the bioavailability studies of CUR using SP 
as a marker drug, were developed. EST and TP were used as the IS for the CUR and 
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SP analytical methods, respectively. The results of the method validation parameters 
for CUR and SP are summarized in Tables 5.1 and 5.2, respectively. 
5.3.4.1    Specificity 
The specificity is one of the firstly checked and most crucial validation 
parameter in analytical method development to ascertain that the analytical method is 
specific to the particular analytes. In this regard, individual drugs and their respective 
IS were injected onto the HPLC system separately to obtain the individual retention 
times to assign each peak. The MP compositions, simple isocratic elution method, and 
the RP- ZORBAX Eclipse Plus® column (C18, 250 mm x 4.6 mm, 5 µm) were suitable 
for the determination methods of CUR and SP. Figure 5.10 illustrates the 
chromatograms obtained when pure drug solutions containing identical concentrations 
(22.0 µg/ml each) of CUR and EST (IS) (A), and SP and TP (IS) (B) were injected on 
the system.  
The retention times obtained were 7.21 and 10.98 min. for EST and CUR, 
respectively, and 3.58 and 7.26 min. for TP and SP, respectively. The chromatograms 
obtained show low baseline noise and no interfering peaks which reflects the specificity 
of the methods for the analytes. 
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Figure 5.10 Chromatograms of pure solutions of CUR and EST (A) and SP and TP 
(B). 
5.3.4.2 Effect of plasma (matrix effect) 
Injecting blank plasma onto the HPLC system showed low baseline noise and 
no interfering peaks at the retention times for CUR (Figure 5.11A) at both studied 
wavelengths and for SP (Figure 5.11B) as well as their respective IS, further confirming 
the specificity of the HPLC analytical methods. 
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Figure 5.11 Chromatograms of the methanolic extract of blank human plasma using 
CUR (A) and SP (B) analytical methods 
  Plasma samples spiked with the analytes and IS, treated as described in section 
5.3.3 and injected onto the HPLC system produced the chromatograms shown in 
Figures 5.12A for CUR and Figure 5.12B for SP and their respective IS. The figure 
clearly shows that the peaks for all drugs maintained their resolution and symmetry in 
plasma, with slight increases in the retention times of some of the analytes compared 
with the respective peaks obtained from the pure drug solutions in Figure 5.10. 
Particularly, the retention times of CUR, which increased from 10.98 to 11.19 at 262 
and 425 nm, whereas EST retention time increased from 7.21 to 7.26 at 262 nm. 
However, no change in retention times was observed for TP and SP.  The peaks in 
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Figure 5.12 were obtained by spiking solutions of the analytes into plasma to the same 
analyte concentrations in solution as in Figure 5.10. Differences in the peak response 
(absorption) was observed in CUR and SP peaks at 425 and 260 nm, respectively. 
Particularly, CUR and SP absorption increased from 600 to 700 mAU and from 175 to 
250 mAU at 425 and 260 nm, respectively. This is attributable to the plasma matrix 
effect and it shows that it varies for different analytes. However, this difference was 
consistent for all of the subsequent plasma analyses and therefore inconsequential. 
 
Figure 5.12 Chromatograms for spiked plasma showing CUR and EST (22.0 
µg/ml, each) (A) and SP and TP (22.0 µg/ml, each) 
 
206 
 
HPLC is a powerful, sensitive and reproducible analytical technique used for 
the quantitative determination of drugs and their metabolites in biological fluids.  
However, one of the major challenges in bioanalytical method development is the 
“matrix effect”  (Mei et al., 2003). “Matrix” refers to all components in the sample 
other than the analytes of interest (Trufelli et al., 2011). Body fluids are complex 
matrices that comprise of various compounds (Lagerwerf et al., 2000). These fluids 
include blood, urine, bile, faeces, and tissue samples and the effects of these matrices 
may vary among individuals (Hall et al., 2012). 
The matrix effect may compromise the reproducibility, accuracy, and linearity 
of the bioanalytical methods (Trufelli et al., 2011). The co-eluting molecules may cause 
suppression or enhancement of the analytes signals compared to the matrix-free 
samples (Stüber & Reemtsma, 2004; Taylor, 2005). 
The exact mechanism by which the matrix effect manifests is not well 
understood, however, it is believed that the co-eluting matrix compete with the analytes 
of interest on the stationary phase, hence, influences the signal intensity (Taylor, 2005; 
Trufelli et al., 2011). The majority of plasma components are water-soluble, thus, 
highly polar analytes are generally affected at greater extent compared to non-polar 
analytes (Taylor, 2005; Hall et al., 2012). This was manifested in the present study 
where SP was the most effected analyte. 
The matrix effect can arise from various matrix components including 
endogenous biological components such as carbohydrates, phospholipids, and residual 
formulation components (Hall et al., 2012). Thus, the Sprague-Dawley rats used in the 
present study had not been used prior to this project and were not subjected to any drug 
substance prior to the study. Furthermore, they were fasted before the study. 
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The matrix components such as salts, amines, triglycerides, and fatty acids, 
among others, that contribute in the matrix effect can be reduced by diluting their 
amount in plasma, however, this further dilutes the analytes of interest (Stüber & 
Reemtsma, 2004). Other approaches to remove matrix components during the sample 
clean-up process are protein precipitation, liquid-liquid extraction, and solid phase 
extraction (Lagerwerf et al., 2000). The usage of IS also helps in minimizing the matrix 
effect which was employed in this study (Mei et al., 2003). 
The results obtained so far clearly showed that the developed HPLC methods 
were suitable for the assay of CUR and SP along with their respective IS, in the presence 
or absence of the biological matrix, plasma. 
5.3.4.3  Linearity and range 
The linearity of the method was assessed based on the coefficient of correlation 
between peak response and analyte concentration over the working drug concentration 
ranges. Figure 5.13 illustrates the calibration curves for CUR and SP in plasma; both 
calibration curves are linear over the concentration ranges of 0.05-10 µg/ml and 0.1-20 
µg/ml, respectively. The coefficients of determination were 1 and 0.9999, respectively, 
indicating good linearity in both analytical methods. 
Shaikh et al. (2009); Wan et al. (2012); Khatik et al. (2013) studied the 
pharmacokinetics of CUR after oral administration of CUR formulations at doses 10-
100 mg/kg which resulted in Cmax values of 0.08-0.5 µg/ml. Whereas doses of 20 mg/kg 
of SSZ produced Cmax values of SP ranging 0.15-4.76 µg/ml (Bates et al.,1977; Sjödin 
et al.,2011; Zamek-Gliszczynski et al.,2012). In the present study, 10 mg/kg doses of 
CUR-CS-PEC-NPs and SSZ-CS-PEC-NPs were orally administered to the rats. Based 
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on the aforementioned data, the concentrations ranges were selected to be suitable for 
the plasma detection of the analytes in rat plasma. 
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Figure 5.13 Standard calibration curves of the peak response ratios of analyte to IS versus the corresponding concentration of 
CUR (A) and SP (B) in human plasma 
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5.3.4.4    Precision 
The precision reflects the closeness of individual measures of an analyte when 
the analytical method is applied repeatedly and is represented as %CV (WHO, 2017). 
The intra-day precision determines the precision during a single analytical run (under 
the same conditions), whereas the inter-day precision assesses precision with time and 
may involve different equipment, reagents, laboratories, and analysts. The intra-day 
precision assessment gave values of 1.29-1.90% for CUR and 1.58-10.51% for SP. On 
the other hand, the inter-day evaluation were 1.05-9.66% for CUR and 1.16-9.81 for 
SP. The precision (%CV) must ideally be less than 15% at all concentrations except for 
the LC where it should not exceed 20% (WHO, 2017). Based on the aforementioned 
data, the maximum value of precision was 10.51%, which indicates an acceptable 
degree of variation in both analytical methods.  
The analytical methods for determination of CUR developed by Han et al. 
(2011); Heath et al. (2003b); Sun et al. (2013) produced maximum intra-day precision 
values of 12.0%, 6.2%, and 5.33%, respectively, and maximum inter-day precision 
values of 3.77%, 13.9%, and 5.33%, respectively. For SP, Intra-day and inter-day 
precision were in the ranges of 2.2-9.2% and 2.17-8.4%, respectively. The data from 
this study are either tantamount or even better than those obtained in the aforementioned 
studies. 
5.3.4.5    Accuracy 
The accuracy of an analytical procedure is a measure of the closeness between 
the actual and expected concentrations of an analyte and is represented as percentage 
relative error (Shabir, 2004). The relative error for this study were in the ranges 2.09-
12.90% for CUR and 1.91-7.70% for SP, and 2.82-10.87% for CUR and 1.36-8.86% 
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for SP, in the intra-day and inter-day accuracy precision assessments, respectively. The 
relative error value should ideally be a maximum of 15% and 20% for HC and MC, and 
LC, respectively (Shabir, 2004). As all of the accuracy results in this study are below 
15%, this indicates that both of the analytical methods are of acceptable accuracy. The 
accuracy values reported in the literature were in the range of 1.2-12.7% and 2.0-6.6% 
for CUR (Heath et al., 2003b; Pak et al., 2003; Han et al., 2011) and SP (Maudens et 
al., 2004; Gu et al., 2011), respectively. 
The data obtained from the precision and accuracy assessments show that both 
of the developed analytical methods for the determination of CUR and SP are repeatable 
and reproducible.  
5.3.4.6   Recovery 
The recovery of an analyte from a biological fluid against a biological matrix is 
crucial in choosing analytical procedure. The recovery is measured as the ratio of the 
peak response obtained of the analyte spiked in plasma, compared to that obtained of 
the same amount of analyte in pure solution (UNODC, 2009). For CUR, the recovery 
values obtained were 91.81, 96.53, 93.07% for LC, MC, and HC, respectively. For SP, 
the recovery values were 87.83, 103.74, and 89.91% for LC, MC, and HC, respectively. 
The data obtained shows maximum 12% matrix effect in the quantification of the 
analytes at all concentrations. Since the % recovery should ideally be in the range of 
85-115%, the above data confirms good analyte recoveries in both analytical methods. 
The mean recoveries reported in the literature were in the range of 82.9-112.0% for 
CUR (Heath et al., 2003b; Han et al., 2011) and 87.0-96.0% for SP (Kasprzyk-Hordern 
et al., 2007; Gu et al., 2011). The recoveries values obtained in the present study are 
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comparable to those reported in the literature and this confirms the suitability of the 
developed methods for the determination of CUR and SP in plasma.  
5.3.4.7   LOD and LOQ 
LOD refers to the smallest concentration of an analyte that can be detected but 
not necessarily quantified. Whereas LOQ is the smallest concentration of analyte that 
can be quantified with acceptable accuracy and precision. LOD and LOQ are estimated 
to be three and ten times the noise level, respectively (Shrivastava & Gupta, 2011). 
LOD and LOQ were 0.5 ng/ml and 1.93 ng/ml for CUR and 73.10 ng/ml and 243.68 
ng/ml for SP, respectively. Other LOD and LOQ values from the literature are 27.99-
90.00 ng/ml and 2.50-84.84 ng/ml, respectively, for CUR (Heath et al., 2003a; Jadhav 
et al., 2007; Wichitnithad et al., 2009) and 50 ng/ml and 10-20 ng/ml, respectively, for 
SP (Kasprzyk-Hordern et al., 2007; Gu et al., 2011). The LOD and LOQ values 
obtained in this study are either comparable or better than those reported in the 
literature. A low LOQ indicates that very low concentrations of the analyte can be 
detected and therefore give more credence to the procedure compared to methods with 
higher LOQ. The LOQ values should be lower than the expected analyte concentration 
at the first and last blood sampling in oral pharmacokinetics studies. A search through 
the literature revealed that CUR concentrations between 10-80 ng/ml occurs at the first 
blood sampling of a 10-100 mg/kg oral dosing (Yang et al., 2007; Li et al., 2009; Wan 
et al., 2012; Khatik et al., 2013). Likewise, SP concentrations of 80-100 ng/ml is 
produced at 20 mg/ml oral doses of sulfasalazine (Sjödin et al., 2011; Zamek-
Gliszczynski et al., 2012). Based on the aforementioned studies, we may conclude that 
the LOQ values obtained in this study are suitable for the detection and quantification 
of CUR and SP following oral administration of 10 mg/kg for each. 
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Table 5.1 Summary of HPLC method validation parameters for CUR (MP: 
41:36:23:1 acetonitrile: water: methanol: glacial acetic acid, detected at 425 nm and 
262 nm for CUR and EST, respectively) 
Parameter 
 
Concentration (µg/ml) 
 
Intra-day Inter-day 
Precision (%CV) 
LC 0.03 1.63 1.05 
MC 0.30 1.29 9.66 
HC 10.00 1.80 2.41 
Accuracy (%) 
LC 0.03 11.07 10.87 
MC 0.30 15.34 8.35 
HC 10.00 5.44 2.82 
Recovery (%) 
LC 0.03 92.04 ± 5.20  
MC 0.30 96.54 ± 1.62 
HC 10.00 93.07 ± 1.44 
Sensitivity 
LOD 0.50 ng/ml 
LOQ 1.93 ng/ml 
Linearity Range 0.05-10.00 µg/ml 
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Table 5.2 Summary of HPLC method validation parameters for SP (MP: 80:20 
acetate buffer (pH 4): Acetonitrile, detected at 260 nm) 
Parameter 
 
Concentration (µg/ml) 
 
Intra-day Inter-day 
Precision (%CV) 
LC 0.10 10.51 9.81 
MC 0.50 2.29 2.95 
HC 20.00 1.58 1.16 
Accuracy (%) 
LC 0.10 2.65 3.76 
MC 0.50 7.70 8.86 
HC 20.00 1.91 1.36 
Recovery (%) 
LC 0.10 90.22 ± 15.85  
MC 0.50 105.48 ± 15.12 
HC 20.00 90.10 ± 7.80 
Sensitivity 
LOD 73 ng/ml 
LOQ 243 ng/ml 
Linearity Range 0.05-10.0 µg/ml 
 
5.3.5   In vivo Pharmacokinetics studies 
5.3.5.1   Selection of animal model 
Small animals such as mice, rats, guinea pigs, and rabbits are more suitable for 
conducting drug absorption and bioavailability studies of powder or solution 
formulations, whereas larger animals such as dogs, pigs, and monkeys are more suitable 
to assess other types of formulations (Kararli, 1995). Rats share remarkable expression 
of anatomical and physiological features of the GIT to that of humans (Kararli, 1995). 
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Using rats in biological studies possess numerous advantages such as their suitable size 
which is important during handling and blood sampling, feasible cost (Lannaccone & 
Jacob, 2009),  and a large volume of historical safety data in the use of rats for biological 
studies (Tometry, 2017). Thus, rats have been commonly used as animal model for 
determining drug absorption and bioavailability in various formulations, including 
nanoparticulate formulations (Girard et al., 1987; Srinivasan & Iversen, 1995; Poulin 
& Theil, 2002; Kalaria et al., 2009). A search through the literature has revealed that 
rats have been used in pharmacokinetics studies on CUR encapsulated in PLGA-NPs 
(Shaikh et al., 2009; Khalil et al., 2013), monomethoxy poly(ethyleneglycol)-poly(ε-
caprolactone) micelles (Gou et al., 2011), self-emulsifying liquid and pellet 
formulations (Setthacheewakul et al., 2010), and CS-poly(butyl cyanoacrylate) NPs 
(Duan et al., 2010). In the present study, male Sprague-Dawley rates were selected due 
to the fact that male rats are less prone to hormonal changes than female rats. Hormonal 
changes can affect physiological modalities that can affect pharmacokinetic profiles 
(Zhou et al., 2002; Roehr, 2007). 
5.3.5.2   Pharmacokinetics studies 
Despite the potent anti-proliferative activity of CUR and its low toxicity, its use 
as an anticancer agent has been restricted due to its poor absorption and poor 
bioavailability. Therefore, we have formulated a nanoparticulate delivery system with 
a resoluteness to improve the oral bioavailability and efficiently deliver CUR to the 
colon. CUR-CS-PEC-NPs and free CUR were orally administered at 10 mg/ml to 
monitor the pharmacokinetics properties for 24 hr. CUR is water insoluble and easily 
hydrolysed in the physiological conditions, thus, SSZ-CS-PEC-NPs were administered 
orally at the same dose as marker in estimating the drug for the orocaeceal transit time 
of CUR-CS-PEC-NPs. 
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Prior to administration, the SSZ-CS-PEC-NPs were characterized in terms of 
particle size and zeta potential and EE% as described in sections 2.1.4 and 3.2.5, 
respectively to ensure the parity between the physical characteristics of CUR-CS-PEC-
NPs and SSZ-CS-PEC-NPs. The particle size and zeta potential were 326.50 ± 5.6 and 
21.7 ± 0.8, respectively for SSZ-CS-PEC-NPs however, the EE% was 21.0 % ± 3.1%. 
A review of the literature revealed seldom encapsulation of SSZ in polymeric NPs due 
to its relatively good bioavailability following oral administration (Amekyeh et al., 
2015) and is reported to manifest low EE% (Lamprecht et al., 2000; Tavakol et al., 
2013) which could be attributed to its hydrophobic nature. In this study, no SP was 
detected at any time during the 24hr study period, which could be due to the low EE% 
of SSZ-CS-PEC-NPs. The SP detection and quantification in the plasma would have 
provided more information about the in vivo behaviour of the CS-PEC-NPs, but 
nonetheless, CUR was detected and statistically significant data were collected and 
discussed below for the proof of concept.  
One rat from the free CUR group was excluded after 2 hr of the study due to 
insufficient blood samples volume and discomfort observed in this rat. The relevant 
pharmacokinetic parameters including Cmax, Tmax, AUC0-∞, and t1/5 for CUR-CS-PEC-
NPs and free CUR are summarized in Table 5.3.  
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Table 5.3 Pharmacokinetic studies of CUR-CS-PEC-NPs and free CUR 
Pharmacokinetic 
parameters 
CUR-CS-PEC-NPs Free CUR 
Cmax (ng/ml) 1000.57 ±15.23 704.67 ± 73.17 
Tmax (hr) 5.65 ± 0.51 1.35 ± 0.21 
Ka (hr) 0.91 ± 0.12 0.45 ± 0.03 
Kel (hr) 0.04 ± 0.01 0.16 ± 0.001 
AUC0-t (ng hr/ml) 4479.50 ± 137.00 2181.91 ± 195.04 
AUC0-∞ (ng hr/ml) 10041.95 ±  
1859.78 
2397.97 ± 216.07 
t1/5 (hr) 17.65 ± 1.40 4.88 ± 0.19 
 
The mean CUR concentration in the serum after oral administration of both 
CUR-CS-PEC-NPs and free CUR are illustrated in Figure 5.14. Maximum serum 
availability of CUR is 704.677 ± 15.230 (ng/ml) and 1000.571 ± 73.176 (ng/ml) were 
observed after 30 min. and 6 hr of free CUR and CUR-CS-PEC-NPs administration, 
respectively. This short Cmax observed from CUR suspension is attributable to the 
readily availability of free CUR for immediate absorption from the upper digestive 
tract, whilst CUR encapsulated in CUR-CS-PEC-NPs was at most available for 
absorption in the later part of the GIT. A higher AUC0-∞ value was observed in CUR-
CS-PEC-NPs (10041.946 ± 1859.783) compared to free CUR (2397.974 ± 216.074) 
suggesting that the formulation aids in a better bioavailability of CUR than when 
administered alone. Unlike free CUR, higher concentration of CUR was detected at 24 
hr. 
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Figure 5.14 Plasma concentration profile of CUR in rats after the oral 
administration of equivalent doses of free CUR (n=3) and CUR-CS-PEC-NPs (n=4). 
(significant is identified with respect to free CUR *p<0.01, **p<0.001) 
Shaikh et al., (2009) encapsulated CUR in PLGA-NPs to enhance the oral 
bioavailability of CUR. After oral administration of 100mg/Kg of CUR-PLGA-NPs 
and 250 mg/Kg of CUR suspension, values of Cmax(ng/ml), Tmax(hr), and AUC0-
∞(ng/ml.hr) obtained from CUR-PLGA-NPs were 260.50 ± 26.40 ng/ml, 2.00 hr, and 
3224.00 ng/ml.hr ± 329.00 and from CUR suspension were 90.3 ± 15.50 ng/ml, 0.50 
hr, and 312.00 ng/ml.hr, respectively. Thus, as in the present study, improved oral 
bioavailability was observed when CUR was encapsulated in PLGA-NPs. In another 
study, Khalil et al., (2013) fabricated CUR-PLGA-NPs to enhance its oral 
bioavailability. After oral administration of the nanoparticulate system at 50mg/kg, 
enhanced absorption of CUR from CUR-PLGA-NPs was observed as the reported Cmax 
of the latter was 11.78 ± 0.454 ng/ml compared to 4.06 ± 0.564 ng/ml obtained from 
CUR suspension. In addition, Tmax values were increased up to four folds in CUR-
PLGA-NPs compared to CUR suspension. Khatik et al.,.  (2013) studied the 
pharmacokinetics behaviour of CUR-Eudragit-CS-NPs compared to free CUR. In the 
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study, significant enhancement in CUR absorption and oral bioavailability after its 
encapsulation was observed. Reported Cmax and AUC0-∞ values were 904.74 ± 38.46 
ng/ml and 16906.62 ± 103.87 ng/ml.hr of the NPs compared to 514.12 ± 14.09 ng/ml 
and 4722.55 ± 76.98 ng/ml.hr of free CUR, respectively. The pharmacokinetics data 
obtained from CUR-CS-PEC-NPs in this study were either comparable or even better 
than those reported in the literature which indicates enhanced oral bioavailability and 
successful delivery of CUR to the colon. In view of the fact that the CUR-CS-PEC-NP 
were designed to be delivered to the colon, we envisage that this is manifested in vivo 
and that absorption proper of CUR occurs at this site of the GIT. Therefore, in the event 
of a colorectal cancer therapy, we believe that this delivery system has a promising 
outlook for a favourable therapy. 
5.4 Conclusion 
In the first part of this chapter, simple, rapid, accurate, reproducible, and reliable 
HPLC methods for the determination and quantification of CUR and SP in plasma using 
EST and TP as IS, respectively, were developed and validated. The peaks for all of the 
analytes were well resolved in a relatively short run time (<10 min. for each). The 
volume of plasma used was appropriate for pharmacokinetic studies in rats. In the 
second part of this chapter, we discussed pharmacokinetics studies of CUR-CS-PEC-
NPs and free CUR after oral administration in rats. Our findings reflect a successful 
delivery of CUR to the colon with increased oral absorption and bioavailability of CUR 
with time as observed for 24 hr. In contrast, lower bioavailability of free CUR was 
observed, possibly as a result of rapid metabolism of free CUR. The CUR-CS-PEC-
NPs were developed to specifically deliver CUR to the colon without being degraded 
by the onslaught effects of the upper digestive tract and we believe that this is realised 
in vivo so that the high bioavailability observed from CUR-CS-PEC-NPs is due to 
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delivery to the colon followed by absorption. Thus, CUR-CS-PEC-NPs might serve as 
a suitable delivery system for CUR to the colon in which CUR will be available on site 
for its chemotherapeutic activity and induction of apoptosis in tumour cells. 
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6         Conclusion and future work 
6.1      Conclusion 
Despite the extensive research in trying to fully understand the manifestation of 
carcinogenesis as well as intensive research in the provision of a framework for the 
prevention and treatment of the disease, cancer remains one of the most challenging 
and complex causes of mortality around the world with ever increasing prevalence 
(Johnson & Mukhtar, 2007). The two major challenges in the management of cancer 
treatment are: (i) non-selectivity in the treatment whereby all tissues are a target for a 
viable formulation and (ii) the constraint of needing to overcome the biological barriers 
that hinders the effectiveness of the cancer therapeutic (Ferrari, 2005). In order to avoid 
the side effects that arise from (i) there is a move towards the use of natural 
chemotherapeutic agents derived from plant sources such as CUR, whose anticancer 
potential is unquestionable and has been extensively reviewed in Chapter 1 of this 
thesis. Despite this potential, the use of CUR as anticancer agent is somewhat curtailed 
due to its poor biopharmaceutical properties comprising of low water solubility, low 
oral bioavailability, extensive metabolism, and rapid elimination rates (Yallapu et al., 
2012; Naksuriya et al., 2014). In the present study, we have successfully fabricated 
CUR-containing mucoadhesive nanoparticulate delivery system with demonstrable 
potential for the treatment of colorectal cancer. In a further project from the present 
work, we aim to use biodegradable excipients so that reported toxicity of the “courier” 
system can be minimised.  
The use of a simple and non-toxic ionic gelation technique, CUR-CS-PEC-NPs 
were successfully prepared. The optimized formulation has mean particle size of 200.6 
nm (±6.6 nm) and zeta potential of +32.8 mV (±0.5 mV). The size of CUR-CS-PEC-
NPs was suitable for delivery to the colorectal tumour, whereas the zeta potential 
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reflected a considerably stable formulation. The SEM images showed spherical and 
well-separated NPs with sizes in agreement with those obtained from the photon 
correlation analysis. FT-IR, DSC, and XRD analyses confirmed the encapsulation of 
CUR onto the CS-PEC-NPs in its inactive, amorphous phase. 
The mucoadhesive propensities of CUR-CS-PEC-NPs were confirmed and 
mainly attributed to the ionic interaction between the positively charged CUR-CS-PEC-
NPs and negatively charged mucin. The EE% of the freshly prepared CUR-CS-PEC-
NPs was found to be 64% (±1.40 %) where cumulative release of 86% of CUR was 
observed after 7 hr of the study in gastrointestinal simulated fluids. Stability studies 
showed “fair” storage stability of CUR-CS-PEC-NPs as well as the protection of CUR 
against thermal- and photo-degradation. 
In vitro cellular studies confirmed that CUR retained its antiprofilerative 
properties against colorectal cancer cell line HT-29 after encapsulation in CUR-CS-
PEC-NPs. The safety and selectivity of the formulation as well as free CUR were 
confirmed. CUR-CS-PEC-NPs showed less than 65% and 12% cell viability at lowest 
and highest treatment doses, respectively, after three days of cell viability study. The 
cellular apoptosis effects of CUR-CS-PEC-NPs were confirmed via fluorescent nuclear 
images whereas quantitative and qualitative cellular uptake studies demonstrated 
considerable uptake of CUR-CS-PEC-NPs by colorectal cancer cell line HT-29. 
A simple, sensitive, accurate, and reproducible HPLC analytical procedure was 
developed for the quantitative determination of CUR and SP using suitable IS for each 
and validated in human plasma for subsequent in vivo analyses. The methods required 
a small volume of plasma, which makes them applicable for pharmacokinetics studies 
in rats. A proof of concept study was conducted to evaluate the pharmacokinetics of 
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CUR-CS-PEC-NPs. Enhanced oral absorption and bioavailability as well as decreased 
elimination rate of CUR-CS-PEC-NPs compared to free CUR. The concentration-time 
profile indicates successful delivery of CUR-CS-PEC-NPs to the colon.  
In conclusion, successful fabrication of CUR-CS-PEC-NPs with mucoadhesive 
propensities resulted in enhancing the oral bioavailability of CUR as well as its targeted 
delivery to the colon whilst retaining its antiproliferative efficiency. The formulation 
tends to be selective against tumour cells. Therefore, CUR-CS-PEC-NPs is a promising 
potential nanoformulation for the treatment of colorectal cancer. 
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6.2       Suggestions for future work 
The research on enhancing the oral bioavailability of CUR and its delivery to 
the target site using nanoparticulate delivery systems is winning growing interest. CUR-
CS-PEC-NPs developed in this study shows promising data for future clinical 
translation. To reach that point, a few suggestions for future work are discussed below. 
High EE% of a formulation provides higher payload of the drug using the same 
amount of the carrier. The EE% of the current formulation can be enhanced by 
increasing the initial concentration of the drug, this might require modification of the 
nanoparticulate system to attain higher drug loading while maintaining its physico-
chemical properties. Other approaches for increasing the EE% include increasing 
working pH, using pH-responsive excipients such as lauric acid, caprylic acid, and 
poly(methyl methacrylate-co-methacrylic acid) (PMMA-MAA) (Hans & Lowman, 
2002), and the addition of co-polymers such as pluronic F127 (Das et al., 2010). 
In general, the storage stability of the polymeric NPs is one of the major hurdles 
which might regressively effect its development, which is applicable to this formulation 
as well (Wu et al., 2011). Strategies for improving nanoparticulate shelf-life including 
the use of stabilizers such as polyethylene glycol (PEG), poly(vinylalcohol) (PVA), and 
poly(L-lysine) (PLL), however, using them might cause toxicity issues (Wu et al., 
2011). Safer strategies include freeze drying of the NPs with the use of suitable 
cryoprotectant such as sucrose and trehalose and the formulation of the nanoparticles 
with higher zeta potential (Shaikh et al., 2009).  
The in vivo studies have undoubtedly proven the enhanced oral bioavailability 
and pharmacokinetics behavior of CUR upon its encapsulation in CS-PEC-NPs. 
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However, other in vivo evaluation would help to better understand the fate of CUR-CS-
PEC-NPs such as Gamma Scintigraphy and histological analyses.  
Certainly, cellular studies confirmed the anticancer efficiency of both free CUR 
and CUR-CS-PEC-NPs against colorectal cancer cells. However, their effects were 
evaluated against one cell line only, HT-29, evaluation using other colorectal cancer 
cell lines such as SW1417, SW480, DLD-1, and HCT-15 would represent more 
information about CUR-CS-PEC-NPs efficiency against various colorectal cancer 
types with different gene expressions. Moreover, in vivo anticancer evaluation of CUR-
CS-PEC-NPs is necessary as the obtained in vitro data, although provides basic 
indication, does not necessarily represent the in vivo anticancer behavior of the 
formulation. In such evaluations, human cancer xenograft can be established in animal 
modules and the anticancer effects of the formulation can be subsequently assessed via 
in vivo imaging and measuring the change in the tumour volume.  
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